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Nothing in life is to be feared, it is only to be understood. Now 
is the time to understand more, so that we may fear less. 
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The work of this thesis is primarily based on the development of novel probes for 
peroxynitrite (ONOO-) detection and their applications in vitro.  
Chapter 1 introduces peroxyresorufin-1 (PR1) as an ONOO- sensitive and selective 
probe. Confocal imaging in J774.2 macrophages confirmed PR1’s ability to detect 
exogenous and endogenous ONOO-. Subsequent studies using a plate reader focused 
on validating PR1 as an effective tool to study pathways involved in generating 
ONOO-. Stimulation with LPS, IFN-γ, PMA and ATP, scavenging effects with O2
∙- 
and NOS inhibitors as well as hypoxic environments were investigated. 
Following on from validating PR1 as an effective fluorescent tool in macrophages, 
Chapter 2 discusses the synthesis and in vitro studies of PR1 derivatives. Two classes 
of PR1 derivatives are explored in this chapter: organelle targeting probes and alkyne 
and alkane based probes with increasing lipophilicity and in situ click chemistry 
applications. The organelle targeting PR1 derivatives showed poor cell permeability 
in contrast to the alkyne and alkane derived probes. The latter were shown to detect 
exogenous and endogenous ONOO- in RAW264.7 macrophages with one showing 
good applicability for in vivo studies. Subsequently, this led to the development of 
theranostics probes: detection of ONOO- and release of a drug in situ. 
Chapter 3 outlines the development of three ONOO- coumarin probes that target 
specific organelles in the cell: mitochondria, lysosome and endoplasmic reticulum. All 
three ratiometric probes displayed excellent selectivity and sensitivity towards ONOO- 
over other ROS. In vitro studies with RAW 264.7 macrophages were carried out using 
exogenous and endogenous ONOO- generation. The lysosome targeting coumarin 
probe was the only one found to be cell permeable and able to detect exogenous and 
endogenous ONOO-.  
Chapter 4 introduces a series of ONOO- probes based on fluorescein, rhodamine, and 
rhodol fluorophores with benzyl Bpin target groups for ONOO-. Rhodamine and 
rhodol should allow for targeting the mitochondria and endoplasmic reticulum 
respectively, whereas fluorescein is of interest since it has been approved by the FDA. 
vi 
All three probes were selective and sensitive for in situ detection of ONOO- but 
showed poor properties in vitro. 
Finally, Chapter 5 describes a rhodamine based probe for the selective and sensitive 
detection of glutathione (GSH). The unusual reactivity of the azide to preferentially 
detect GSH over hydrogen sulfide (H2S) led to comprehensive fluorescence studies to 
validate the GSH probe in situ. Azides are known to be reduced by H2S into the 
corresponding amine. To our surprise, the binding of GSH to the azide group is 
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Chapter 1 – Detection of ONOO- with Peroxyresorufin-1 in 




Our immune system has developed remarkably when it comes to the combat of 
extracellular and intracellular harmful pathogens.1-3 In the event of an extracellular 
pathogen, the immune system aims to eradicate the pathogen itself and neutralise its 
products. Intracellular pathogens are either destroyed by lymphocytes, which were 
previously activated by an antigen or other relevant cells are triggered to combat the 
pathogen. In fact, during inflammation three major events occur: blood supply to the 
infected area is increased, capillary permeability is enhanced and leucocytes migrate 
out of the venules into the surrounding tissues. A classification of different types of 
cells is illustrated in Figure 1. Immune responses towards harmful stimuli are 
primarily produced by leucocytes. Mature, circulating leucocytes differentiate from 
hematopoietic stem cells. There are three main types of leucocytes: phagocytes which 
are associated with innate immune responses, lymphocytes associated with adaptive 
immune responses and auxiliary cells such as basophils for example. Among these, 
different subtypes can be distinguished. Phagocytes can be classified into monocytes, 
macrophages and polymorphonuclear neutrophils. Essentially, a process called 
phagocytosis occurs where phagocytes bind to microorganisms, internalise them and 
subsequently kill the pathogen. This is achieved by a so called phagolysosome which 
acidic in nature, allows to digests the pathogen. Lymphocytes of which there are two 




Figure 1: Simplified overview of different types of cells involved in the inflammatory 
response towards a harmful pathogen. Pluripotent hematopoietic stem cells 
differentiate in bone marrow into common lymphoid or common myeloid progenitor 
cells. These two main cell types then give rise to a range of other cell lineages. 
Lymphoid stem cells can be differentiated into B lymphocytes, natural killer (NK) 
cells, NK T cells and T lymphocytes whereas myeloid stem cells first give rise to 
specific colony form units (CFU) which differentiate into granucolyte-macrophages 
(GM) including monocytes (which then give rise to either macrophages and dendritic 
cells), and neutrophils, eosinophils, basophils, mast cells, megakaryotes and 
erythrocytes. Dendritic cells (DC) can also derive from a Flt3 receptor DC precursor 
which in turn can either come from lymphoid or myeloid stem cells. The diagram has 
been adapted from Chaplin.4 
 
The interaction between lymphocytes and phagocytes is crucial in the effective 
recognition and combat of harmful internal and external stimuli. The innate immune 
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system heavily interacts with the adaptive immune system as illustrated in Figure 2. 
Hereby, one of the crucial signalling molecules between phagocytes and lymphocytes 
are cytokines of which one of the main classes of cytokines are interferons (IFN). 
These can limit the spread of certain viral infections. One type of interest is IFN-γ. 
IFN-γ is released by macrophages, activated CD8 T cells, NK T cells, and Th1 CD4 
T cells which in turn activate phagocytes.5 
 
 
Figure 2: Innate immunity towards a pathogen is mediated by a variety of different 
cell types: macrophages, NK cells, epithelial cells, immature DC, fibroblasts and mast 
cells. Immature DC can be polarised by a variety of factors: type 1, 2 and regulatory 
pathogen-associated molecular patterns (PAMPS) and tissue factors (TFs). This 
allows then to activate either mature or immature dendritic cells that will differentiate 
into T Helper 1, 2 or adaptive regulatory cells. If pathogens inhibit dendritic cell 
expression, other innate immune cells can generate the various polarization factors 





1.1. Macrophage Function and Polarization 
 
In recent years, growing evidence has linked non-communicable diseases (NCDs) 
such as cancer, autoimmune diseases, and arthritis with inflammation. Changes in 
mitochondrial function, oxidative stress and inflammation interchangeably determine 
disease progression of NCDs. It is not clear whether inflammation and oxidative stress 
are at the origin or constitute consequences of cellular pathology of NCDs. 
Nevertheless, they significantly contribute to the pathogenesis of NCDs.7 Detecting 
signs of infection or damage are mainly mediated by innate immune signalling 
receptors such as toll-like or NOD-like receptors.8 These monitor the extracellular and 
subcellular space and are able to detect changes.9 As shown in Figure 2, macrophages 
are part of the innate immune response towards a harmful pathogen. Macrophages 
respond to micro-environmental stimuli and signals from different tissues by 
undergoing specific phenotype changes.10 This process is known as macrophage 
polarization. Based on the expression of specific cytokines and cell surface markers, 
two major macrophage sub types can be generated: classically activated or 
inflammatory (M1) and alternatively activated or anti-inflammatory (M2) 
macrophages (Figure 3). 
M1 macrophages are typically activated by LPS, IFN-γ, or TNF-α. M1 macrophages 
produce and secrete high levels of pro-inflammatory cytokines IL-1β, IL-6, IL-12, 
TNF-α and MCP-1. M1 macrophages remove harmful pathogens through activation 
of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system, and 
subsequent generation of reactive oxygen species (ROS). Hence, M1 macrophages 
mediate ROS-induced tissue damage, and impair tissue regeneration.11 
M2 macrophages are mainly polarized by cytokines IL-4 and IL-13 but other cytokines 
such as IL-10 and TGFβ are also involved. Polarization of M2 macrophages is often 
associated with the up-regulation of arginase as well as the secretion of IL-10 and 
TGFβ and low levels of a few other cytokines. M2 macrophages are anti-inflammatory 
in nature in contrast to M1 macrophages which are pro-inflammatory. Additionally, 
depending on the stimulus, M2 macrophages can be divided into subsets M2a, M2b, 
M2c and M2d macrophages.12 
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Figure 3: Macrophages can polarise into two main subtypes – M1 and M2 
macrophages – with distinct properties. Activation of M1 and M2 macrophages occur 
by different intrinsic triggers and can also be selectively polarised for in vitro studies. 
Upon polarization into M1 or M2 macrophages, the secretion of different cytokines 
results. Additionally, M2 macrophages are polarised into different subsets: M2a, M2b, 
M2c, and M2d macrophages. The diagram was adapted from Laouini et al.13 and 
Sahebkar et al.11 
 
Among all these different types of cells involved in the inflammatory response, I am 
mostly interested in macrophages due to their versatile role. They recycle and clear 
cells during inflammation, participate in tissue repair and most importantly are 
involved in the host response towards infectious pathogens through secretion of 
cytokines, enzymes and ROS. In particular, the secretion of ONOO-, a strong ROS 
oxidant, allows to directly interact with harmful stimuli and induce their apoptosis. 
6 
1.2. Macrophages and Reactive Oxygen Species 
 
Free radical species or most commonly known as ROS are a vital part in many cellular 
processes (Figure 4). A balanced generation of ROS assures normal cell growth and 
metabolism. However, lower or higher ROS generation ultimately links to impaired 
physiological functioning. ROS can originate from three different sources: 
endogenous sources, antioxidant defences and exogenous sources. In particular, the 
mitochondria is one of the main intracellular ROS generator and has been linked to 
many diseases where high levels of ROS are generated.14 
 
 
Figure 4: Sources and cellular responses to ROS adapted from Finkel et al.15 
 
The term ROS is often used interchangeably with free radical species. However, free 
radical species can be actually divided into three categories: 
 Reactive oxygen species (ROS): superoxide anion (O2∙-), hydroxyl radical 
(HO∙), peroxyl radical (ROO∙), hydroperoxyl radical (HO2∙), hydrogen 
peroxide (H2O2), hypochlorite (ClO
-), ozone (O3), singlet oxygen (
1O2), 
peroxynitrite (ONOO-) 
 Reactive nitrogen species (RNS): nitric oxide (NO∙), nitrogen dioxide radical 
(NO2∙), nitrous acid (HNO2), nitrosyl cation (NO
+), nitrosyl anion (NO-) 
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 Reactive chlorine species (RCS): atomic chlorine (Cl-), hypochlorous acid 
(HClO), chlorine (Cl2), nitronium chloride (NO2Cl) 
Among these three, ROS have gained particular attention in the research 
community.15-17 ROS are short-lived species and produced in a variety of 
physiological processes (Figure 5). 
 
 
Figure 5: Physiologically relevant ROS – The diagram covers in a simplified way the 
generation of most ROS species within cells. The diagram has been adapted from 
Winterbourn and Krumova & Cosa.18,19 
 
ROS are involved in the functional and phenotypic regulation of macrophages and 
promote both M1 and M2 macrophages. M1 macrophages activate lipopolysaccharide 
(LPS) which triggers the generation of ROS upon contact with a harmful stimuli. ROS 
are generated from NADPH by NADPH oxidase (NOX), which is produced through 
the pentose phosphate pathway (PPP).20 In vitro generation of ROS is achieved by 
LPS stimulation. LPS-induced ROS generation is NOX-dependent and also induces 
TNF𝛼 production. At the same time, ROS can serve as a second messenger by 
activating NF-𝜅B which is a protein involved in the transcription of DNA, cytokine 
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production and cell survival. Given that ROS are closely related to the activation of 
NF-𝜅B, ROS may partially be involved in M1 macrophage polarization. Additionally, 
the inflammatory response is regulated by stimulation of mitochondrial complexes and 
adenosine triphosphate (ATP). Activating ATP triggers ROS generation which in turn 
activates inflammasome formation and, consequently, cytokine production such as IL-
1𝛽 and IL18 (Figure 6). 
 
 
Figure 6: Multiple pathways are involved concerning ROS and their regulatory 
activity in M1 macrophages phagocytic activity. Generation of NADPH is essential 
for the NOX to generate ROS. The high levels of ROS mediate enhanced phagocytic 
activity of M1 macrophages. Additionally, ATP can also enhance increased ROS 
generation. ROS can also serve as a second messenger through NF-𝜅B and 
inflammasome activation allowing to induce the inflammatory response of M1 
macrophages. The diagram was adapted from Feng et al.21 
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M1 macrophages express inflammasome genes. In fact, inflammasomes regulate 
immune responses. Most inflammasomes contain NOD-like receptor (NLR) sensor 
molecules such as NLRP1, NLRP3, NLRP6, NLRP7, NLRP12 and NLRC4. Their 
exact activation mechanism is still under investigation with certain factors emerging 
as potential therapeutic and diagnostic targets.22 
As part of the innate immune system, inflammasomes play a major role in the 
activation of the inflammatory response. Inflammasomes activate one or more 
caspases which trigger the secretion of pro-inflammatory cytokines. Inflammasomes 
were first identified by Tschopp et al. in 2002.23 The group went on to identify the role 
of the NLRP3 inflammasome in 2004.24 Activation of the NLRP3 inflammasome 
(Figure 7) contributes to the cellular mechanisms underlying infectious, metabolic, 
and neurodegenerative diseases.25-27 NLRP3 inflammasome expression has mostly 
been observed in macrophages and neutrophils since its expressions is primarily 
related to myeloid cell types.27 
An inflammasome is a cytoplasmic multi-protein complex composed of a sensor 
protein, an adaptor protein and pro-caspase-1: 
 Sensor protein: This is the main stimulus for the assembly of the 
inflammasome and hence its activity. Different stimuli include but are not 
limited to microbial products, and host-derived danger signals. One of the 
sensor molecules of interest in elucidating mitochondrial ROS production is 
the PYD domain containing protein 3 (NLRP3). 
 Adaptor protein: It can be defined as an apoptosis-associated speck-like 
protein. It contains a caspase recruitment domain (ASC). 
 Pro-caspase-1: It is a cysteine protease which is initially inactive. The 
autocatalysis of pro-caspase-1 to active capase-1 is controlled by the caspase-
1 inflammasome.28 
Prior to activation of NLRP3, the sensor protein must be primed. This involves in a 
first instance LPS binding to TLR4, a toll like receptor, which initiates increased 
expression of the NLRP3 protein and pro-IL-1β. Moreover, priming induces the 
deubiquitination of NLRP3, which is essential for further NLRP3 inflammasome 
assembly. Apart from the priming step, further activation signals are vital for 
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activation. The current literature suggests a range of factors contributing to the 
activation22, 29, 30: 
1. Translocation of NLRP3 to mitochondria 
2. Generation of mitochondrial reactive oxygen species (mROS) and release of 
mitochondrial DNA or cardiolipin 
3. Potassium efflux out of the cell 
4. Release of cathepsins into cytosol after lysosomal destabilisation 
Upon activation of the sensor molecule (NLRP3), the inflammasome assembles 
through the interaction of the pyrin domain (PYD) and caspase activation and 
recruitment domain (CARD). The assembly of this complex leads to processing pro-
caspase in proximity to caspase-1. Hence, this leads to cleavage of pro-IL-1β, which 
induces the pro-inflammatory process. 
Neurodegenerative diseases31, type 2 diabetes32, ageing33, cancer34 and other 
diseases35 have been associated with the dysregulation of NLRP3 inflammasome 
activation. Hence, the innate immune system is less capable to sense microbe-derived 








Figure 7: Simplified diagram of the mechanism of NLRP3 inflammasome activation 
adapted from Ting et al.37 Before activation of NLRP3, two events need to occur that 
form part of priming: LPS binds to TLR, stimulating NF-κB activation, followed by 
the expression of pro-IL-1β and the NLRP3 protein. At the same time priming allows 
to induce the deubiquitination of NLRP3. After priming, a range of activating stimuli 
are required to activate NLRP3 leading towards NLRP3 inflammasome assembly: 1) 
translocation of NLRP3 to mitochondria, 2) generation of mROS and release of 
mitochondrial DNA or cardiolipin, 3) potassium efflux out of the cell, and 4) release 
of cathepsins into cytosol after lysosomal destabilisation. In addition to the activated 
NLRP3 protein, activation of pro-caspase 1 and linearly ubiquitinated and 
phosphorylated adaptor protein ASC are required for assembly. 
 
In contrast to M1 macrophages, activation of M2 macrophages reduces ROS 
production. M2 macrophages’ main function is anti-inflammatory in nature and 
wound healing. Wound healing properties of M2 macrophages go hand in hand with 
a reduction of NOX activity and an increase in disulphide protein degradation. The 
programming of the M2 phenotype is linked to an increase of arginase-1 (Arg-1), YM1 
and FIZZ1 which promote anti-inflammatory properties of M2 macrophages. 
Interestingly, these are regulated by the redox dependant gene STAT6’s translocation 
which is activated by H2O2.
38 Moreover, in contrast to M1 macrophages, extracellular 
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ATP associated with P2X7 receptors blocks IL-1𝛽 in M2 macrophages, which impacts 
ROS generation (Figure 8). 
 
 
Figure 8: The involvement of ROS in regulating M2 macrophages governs anti-
inflammatory and wound healing activities. Multiple pathways are involved in 
reducing NOX which consequently lowers ROS levels. The low ROS level reduces 
inflammatory mediators (IL-1β) and increases M2-regulated genes (FIZZ-1, Arg-1, 
YM-1). The diagram was adapted from Feng et al.21 
 
ROS are involved in the functional and phenotypic regulation of M1 and M2 
macrophages. Hence, ROS are implicated in cell death, proliferation, motility, and the 
phagocytic ability of macrophages. Essentially, ROS play an important role in 
maintaining the homeostatic functions of macrophages. 
 
1.3. Detectors of Reactive Oxygen Species 
 
Detection of cellular ROS in physiological and pathological processes requires 
sophisticated methods. Current analysis of ROS is challenging due to the complexity 
of the biological environment. Harrison et al. and Yuan et al. have reviewed recent 
advancements in methodology development for ROS detection.39, 40 The main 
challenges of current methods include specificity issues and lack of subcellular 
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localisation. Overcoming these deficiencies in the following available techniques 
remains a great challenge: 
 Spin trapping: Spin traps allow to quantify and identify radicals. These form 
covalent bonds with the radical by addition reaction. Spin traps are used in conjunction 
with electron paramagnetic resonance (EPR) spectroscopy. Spin traps have been 
mostly used for O2
∙- and ∙OH identification and quantification with DMPO, DPPO and 
DEPMPO have been popular choices.41 However, these spin traps together with O2
∙- 
can easily form adducts in the presence of reducing agents e.g. ascorbate resulting in 
EPR silent compounds. 
 
 Chemiluminescent probes: These probes are mainly used for the detection of 
O2
∙-. Common probes for biological studies include lucigenin, luminol, MCLA, and 
coelenterazine. Lucigenin has been extensively used but is limited by redox cycling: 
the lucigenin radical can readily react with oxygen to generate O2
∙-.42 Consequently, 
identification and quantification of cellular produced ROS is biased. 
 
 Fluorescent probes: Most notable examples of fluorescent probes in biological 
systems include dihydroethidium, mitoSOX, dichlorodihydrofluorescein, 
dihydrorhodamine and Amplex red.43 All these fluorescent probes are oxidant 
sensitive: they only become fluorescent upon reaction with ROS. These have 
traditionally mostly focused on H2O2 detection. Despite new emerging fluorescent 
probes, specificity for ROS and intracellular vs extracellular detection are challenges 
to be overcome. 
 
Table 1 summarises the various detection methods currently available to study ROS 
and shows their main advantages and disadvantages. Some have been briefly discussed 
above but Table 1 nicely illustrates the vast range of additional methods available. As 
part of my thesis, I am interested in the identification of new fluorescent probes due 
to their stability, quantifiable nature and signal intensity. The current drawbacks can 
be synthetically addressed to assure high specificity and precise localisation.  
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Table 1: Advantages and disadvantages of different ROS detection methods adapted 
from Yuan et al.40 
Detection method Specificity Advantages Disadvantages 
Spin traps ROS, RNS Specific, sensitive Expensive 
Electrochemical 
biosensors 


























time, low toxicity, 
good permeability 






















Designing highly specific and sensitive fluorescent probes for ROS is challenging. 
The choice of fluorophore (Figure 9) is essential to establish a scaffold that can be 
synthetically easily modified. Fluorophores can be combined with a variety of 
different sensing motifs which respond to ROS, proteins, metals, or other relevant 
biological species. In addition to the choice of fluorophore, a good ROS probe 
requires44: 
 Good sensitivity 
 High selectivity 
 Fast and reversible kinetics 
 Good signal-to-background and signal-to-noise contrast 
 Good intracellular loading and uptake of the probe 
 Excitation at visible wavelength 
 Non toxic 
 
 





I decided to identify a simple fluorescent probe for ONOO- detection which upon 
validation as a biological tool, could be synthetically modified to introduce further 
functionalities. Due to the short half-life of ONOO-, its detection can be challenging. 
Therefore, there is a need to find new effective and reliable ONOO- probes. This led 
to identifying peroxyresorufin-1 by Chang et al.45 as an ideal candidate for ONOO- 
detection and its applicability as a biological tool. 
 
2. Peroxyresorufin-1: Background  
 
In 2005, Chang et al. developed the boronate based fluorescent probe peroxyresorufin-
1 (PR1) for the detection of H2O2.
45 PR1 was achieved in a two-step synthesis 
(Scheme 1). Bromination of phenoxazine 1.1 gave dibromophenoxazine 1.2 in a poor 
10 % yield. Subsequent Miyaura borylation gave target probe PR1 in 69 % yield.  
 
 
Scheme 1: Synthesis of PR1 by Chang et al.45  
 
High selectivity towards H2O2 compared to other competing ROS was achieved with 
PR1: recognition of H2O2 enhanced the fluorescence > 1000-fold. PR1 has been of 
particular interest since it highlights the usage of boronate deprotection as an effective 
mechanism to probe H2O2 in biological systems.
46 Upon reaction with H2O2, a well-
known fluorescent probe is generated: resorufin. Previous cell studies of PR1 in the 
Chang group only focused on the use of HEK 293T cells with exogenous addition of 
H2O2.
45 This system does not truly reflect the ability of PR1 to detect ROS in vitro. 
Stimulation of macrophages is required for ROS generation to mimic a situation where 
overexpression of ROS is achieved to simulate an inflammatory environment. 
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3.  Project Aim 
 
The aim of this chapter is to investigate PR1 as an effective ONOO- sensing tool.  
Previously used as an H2O2 probe by Chang and co-workers
45, the aim is to show that 
the boronate groups of PR1 are more sensitive towards ONOO-. Subsequently, 
following in situ validation, in vitro studies will be performed to undermine PR1’s 
potential as an effective ONOO- evaluating tool. Hereby, J774.2 macrophages have 
been chosen as the cell line model system. A cell protocol for ONOO- stimulation in 
J774.2 macrophages will be developed in order to adequately test PR1. Subsequently, 
this protocol should form the basis for the evaluation of PR1 analogues with improved 
functionalities that I have developed in Chapter 2. 
 
4. Peroxyresorufin-1: Synthesis and Fluorescence 
 
I realised that PR1 could be a useful tool for ONOO- detection in vitro. To validate 
this, initially the synthesis of PR1 was revisited and its fluorescence ability upon 
reaction with ONOO- was evaluated. The initial synthesis involved a low yielding 
bromination step with HBr generating a large amount of side products (Scheme 1). 
The subsequent Miyaura borylation reaction gave PR1. The overall yield of the two 
step process is 7 %. NBS was identified as a brominating agent for phenoxazine 1.1 
which affords dibromophenoxazine 1.2 in an 80 % yield, followed by the Miyaura 
borylation to obtain PR1, allowing to increase the overall yield to 56 % (Scheme 2). 
 
 
Scheme 2: Synthesis of PR1 developed in the James group. 
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Boronic esters are also effective sensing groups for ONOO-. In fact, their reactivity 
towards ONOO- is a million times faster than with H2O2.
47 The boronate deprotection 
is the underlying mechanism of PR1 with ONOO-. ONOO- attaches to the boronate, 
generating an intermediate, allowing the boronate group to easily fall off which gives 
the corresponding alcohol. Then, the other boronate group is cleaved in the same way. 
The alcohol group then rearranges to the ketone due to keto-enol tautomerism, 
generating resorufin (Scheme 3). 
 
 
Scheme 3: When reacting with ONOO-, PR1 undergoes boronate deprotection to give 
the fluorophore resorufin. 
 
Initial UV studies were carried out to confirm the formation of resorufin: a maximum 
absorbance close to 573 nm was observed (Figure 10). ROS selectivity studies 
confirmed PR1’s ability to detect ONOO- whereby an enhanced selectivity over other 
ROS was achieved (Figure 11). The low activating concentrations and fast reaction 
time of ONOO- confirm PR1’s superiority over other ROS species. Subsequent 
screening of different ONOO- concentrations reveals that PR1 turns on at 
concentrations as low as 1 μM and saturates at 50 μM (Figure 13) in contrast to H2O2 
(Figure 12). Initial studies of Chang et al. only tested PR1 with H2O2 at a concentration 
of 100 μM to show the turn-on response of the probe. The limit of detection (LoD) for 





Figure 10: UV spectra of PR1 without and with ONOO- (excess) in PBS buffer 52 % 




Figure 11: Selectivity data for PR1 (500 nM): a) emission spectrum and b) relative 
intensity ratios (I/I0) in the presence of ONOO
- (50 µM), OH· (500 µM), O2
∙- (500 
µM), 1O2 (500 µM) after 5 min. H2O2 (1 mM), ROO· (500 µM) and ClO
- (500 µM) 
were measured after 30 min. The data was obtained in PBS buffer 52 % MeOH : H2O, 
pH = 8.2 at 25 °C with λex = 550 (bandwith: 15) nm and max λem = 590 nm on a BMG 




Figure 12: a) Emission spectra and b) dose dependence curve (I/Imax) for PR1 (500 
nM) in the presence of H2O2 (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 2 mM) in PBS buffer 52 % 
MeOH : H2O, pH = 8.2 at 25 °C. Fluorescence intensities were measured with λex = 




Figure 13: a) Emission spectra and b) dose dependence curve (I/Imax) for PR1 (500 
nM) in the presence of ONOO- (0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 μM) in PBS 
buffer 52 % MeOH : H2O , pH = 8.2 at 25 °C. Fluorescence intensities were measured 
with λex = 550 (bandwith: 15) nm and max λem = 590 nm on a BMG Labtech 
CLARIOstar® plate reader. 
 
5. Validating PR1 in J774.2 Macrophages 
 
Having established the selectivity and sensitivity of PR1 towards ONOO- in situ, the 
probe was next evaluated in vitro. Generation of ONOO- in J774.2 macrophages under 
different pro-inflammatory conditions using PR1 as a detection tool was evaluated. 
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5.1. Visualising PR1 in J774.2 Macrophages 
 
To my knowledge, PR1 has not been studied in J774.2 macrophages beforehand, only 
in HEK 293T cells.45 Macrophages respond to endogenous and exogenous signals by 
undergoing a phenotypic change called polarization.48 They respond to an array of 
stimuli under conditions of injury and infection that lead to M1 polarization.48 Factors 
that trigger M1 polarization include LPS and IFN-γ. A combination of LPS and IFN-
γ has previously been used to enhance the production of ONOO-.46, 49 All recordings 
were performed in the presence of 1 mM probenecid to reduce the cellular efflux of 
PR1.50 Further details about how probenicid regulates the efflux is outlined in Section 
5.2.4. 
First, PR1’s sensitivity and sub-cellular localisation in J774.2 macrophages was 
evaluated (Figure 14). In a subset of experiments, 3-morpholino-sydnonimine (SIN-
1) was added as a positive control. PR1 should display cytosolic localisation without 
targeting an organelle such as the mitochondria. To probe this hypothesis, PR1 was 
co-loaded with a mitochondria fluorescent probe, MitoView Green. PR1 was 
permeable in J774.2 macrophages and showed an increase in PR1 fluorescence upon 
stimulation with LPS and IFN-γ, as shown by confocal microscopy. As anticipated, 
PR1 does not co-localise with MitoView Green. Since PR1 stains no particular 
organelle and shows no specificity in localisation, the subsequent chapter looks at 







Figure 14: Confocal microscopy images of J774.2 macrophages incubated in 
probenecid (1 mM): 1a – e: PR1 (15 μM, 30 min); 2a – e: PR1 (15 μM, 30 min), LPS 
(1 μg/ml, 4 h) and IFN-γ (50 ng/ml, 4 h); 3a – e: PR1 (15 μM, 30 min), LPS (1 μg/ml, 
4 h), IFN-γ (50 ng/ml, 4 h) and SIN-1 (15 μM, 5 min); 4a – e: MitoView Green (200 
nM, 30 min); 5a – e: MitoView Green (200 nM, 30 min), PR1 (15 μM, 30 min), LPS 
(1 μg/ml, 4 h) and IFN-γ (50 ng/ml, 4 h); 6a – e: MitoView Green (200 nM, 30 min), 
PR1 (15 μM, 30 min), LPS (1 μg/ml, 4 h), IFN-γ (50 ng/ml, 4 h) and SIN-1 (15 μM, 
5 min). Channel (a): brightfield, channel (b): ex = 490 nm, em = 523 nm, channel (c): 
ex = 572 nm, em = 583 nm, channel (d): channel (b) and (c) combined, channel (e): 
channel (a), (b) and (c) combined. Magnification: x63. Scale bar: 10 μM. N = 3. 
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5.2. Evaluating PR1 as a Fluorescent Tool for ONOO- Generating 
Pathways 
 
The permeability of PR1 in J774.2 macrophages to detect exogenous and endogenous 
ONOO-, led me to evaluate PR1 as a fluorescent tool for the study of ONOO- 
generating pathways. PR1’s applicability to be used for assays studying ONOO- 
linked pathways was evaluated. Hereby, PR1 fluorescence in M1 polarized 
macrophages was quantified using a fluorescence plate reader. 
 
5.2.1. Cell Distribution for in vitro Studies 
 
Next, I performed plate reader experiments to screen PR1 responses in J774.2 murine 
macrophages. First, the cell number/well was evaluated to ensure optimal coverage of 
the well in a 96-well plate format. This allows to ensure the detection of cell-localised 
PR1 fluorescence using a plate reader approach. Using an EVOS microscope, pictures 
were taken for 10 000, 50 000 and 100 000 cells/well (Figure 15). Poor surface 
coverage is observed at a cell density of 10 000 cells/well with large areas without 
adherent cells. On the other hand, 100 000 cells/well lead to densely packed adherent 
cells at the base of the well. Hence, a cell density of 50 000 cells/well gave the most 
uniform cell adherence across the base of the well and was selected as the most suitable 
cell density for further characterisation studies with PR1. 
 
 
Figure 15: Pictures of different cell densities a) 10 000 cells/well, b) 50 000 cells/well, 
c) 100 000 cells/well using an EVOS microscope. Pictures were captured from the 
middle of the well. Magnification: x20. N = 3. 
24 
Having shown how densely J774.2 macrophages grow with increasing cell numbers, 
the aim was to evaluate how cell density affects the fluorescence signal once PR1 
reacts with ONOO- (generated by SIN-1) in J774.2 macrophages.  
SIN-1 is a positive control for ONOO- and should validate PR1’s ability to detect 
exogenous ONOO- within J774.2 macrophages. SIN-1 generates NO∙ and O2
∙-. These 
two precursors rapidly react with each other to generate ONOO-. In the first instance, 
through base catalysis, the sydonimine ring is opened giving 4.1. SIN-1 reduces O2 to 
O2
∙- giving a cation radical species 4.2 which decomposes to 4.3 generating NO∙ as a 
by-product (Scheme 4).51 
 
 
Scheme 4: Generation of O2
∙- and NO∙ through SIN-1, a positive control for ONOO- 
detection in J774.2 macrophages. The scheme was adapted from Kalyanaraman et al.51 
 
Cells were plated at the stated cell number and incubated for 16 h at 37 °C, 5 % CO2 
prior to incubation with PR1 for 30 min (Figure 16). Subsequent measurements of 
fluorescence intensities were performed on a BMG Labtech ClarioStar plate reader 
through which SIN-1 was injected after 5 min (Figure 16 – 17). Figure 16 illustrates 
the fluorescent response to SIN-1 at different cell numbers. No variation of the 
fluorescence signal is observed in the negative controls with no PR1 or SIN-1 as 
expected. With increasing cell numbers, the rate of fluorescence intensity increases, 
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though the increase in response is not significantly different. This indicates that despite 
a constant concentration of PR1 (15 μM), there is a trend towards an increased PR1 
response with an increase in cell number. I concluded from this data that a higher cell 
number resulted in improved ONOO- detection. Figure 17 shows an example response 
when 50 000 cells/well are evaluated. As can be seen at this cell number, reaction of 
PR1 and SIN-1 is instantaneous and a significant increase in fluorescence intensity of 
PR1 can be observed. PR1 shows a small fluorescent response when untreated with 




Figure 16: A PR1 fluorescence rate increase with increasing J774.2 macrophages cell 
number. After SIN-1 injection, the fluorescence intensity rate of PR1 increases at all 
cell distributions. Increasing cell numbers show increased rates of fluorescence 
intensity signal of PR1 detecting ONOO-. The control conditions show no change in 
rate of fluorescence intensity. Data show mean values (n = 3) ± SEM, no statistical 
significance. Fluorescence intensities were measured with λex = 550 (bandwith: 15) 




Figure 17: An increase in fluorescence intensity of PR1 upon reaction with SIN-1 at 
a cell density of 50 000 cells/well. Upon injection of SIN-1, an increase of 
fluorescence intensity of PR1 is observed, validating its ability to detect exogenous 
ONOO-. Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm 
and max λem = 590 nm on a BMG Labtech CLARIOstar® plate reader. 
 
5.2.2. SIN-1, a Positive Control for ONOO- Detection 
 
Different SIN-1 concentrations were investigated with PR1 to probe the sensitivity of 
ONOO- detection in J774.2 macrophages (Figure 18). The initial results with different 
cell numbers showed that PR1 detects ONOO- in vitro. Hence, the study of different 
SIN-1 concentrations should allow for optimised concentrations for the validation of 
PR1. 
Increasing concentrations of SIN-1 respectively produce higher concentrations of 
ONOO-. As reported by Feelisch & Kelm in 1991, 1 mM of SIN-1 generates 10 μM 
of ONOO-/min.52 This can be extrapolated to the investigated SIN-1 concentrations: 2 
μM of SIN-1 generate 20 nM ONOO-/min and 40 μM of SIN-1 generate 400 nM of 
ONOO-/min. Considering that PR1’s LoD is 32 nM, sufficient amounts of ONOO- 
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should be present to release resorufin. After SIN-1 injection, the fluorescence signal 
of PR1 was recorded for a further 15 min. Within this time frame, I was able to look 
at two extremes of ONOO- production: 300 nM and 6 μM of ONOO- respectively. The 
results validate a) sensitivity of the probe (loaded at 15 μM) at low concentrations of 
ONOO- produced in the nanomolar range and b) the ability of the probe to detect 
ONOO- intracellularly in J774.2 macrophages. 15 μM of SIN-1 was selected as the 
optimal concentration for further studies where using SIN-1 as a positive control for 
ONOO- (Figure 18). This allows sufficient production of ONOO- and avoids 
overproduction of ONOO- which could lead to apoptosis of J774.2 macrophages. 
 
 
Figure 18: A SIN-1 concentration dependent increase in PR1 fluorescence in J774.2 
macrophages. Fluorescence intensity was measured after SIN-1 injection. The control 
conditions show no change in rate of fluorescence intensity. In the presence of PR1, 
increasing SIN-1 concentrations show increasing rates of fluorescence intensity of 
PR1. Data show mean values (n = 3) ± SEM, ***p  0.001, **p  0.01with respect to 
the PR1 only treated group. Fluorescence intensities were measured with λex = 550 





5.2.3. LPS Stimulation to Induce Endogenous ONOO- Production 
 
LPS (Figure 19) is an agonist that binds to toll-like receptors and consequently, 
induces enhanced production of NO∙53, which upon reaction with O2
∙- generates 
ONOO-. LPS also primes NOX, which is linked to increasing O2
∙- production. 
Inducing enhanced expression of ONOO- allows to simulate a biological environment 
where the inflammatory system is exposed to a harmful stimuli. Herein, enhanced 
ROS and consequently ONOO- production is observed. 
 
 
Figure 19: Schematic representation of the general structure of LPS. 
 
Examples in the literature have used LPS to stimulate RAW264.7 macrophages.54 
Hereby, LPS was incubated for 4 h at a concentration of 1 μg/ml. Taking these 
conditions as an initial starting point, different concentrations of LPS (0.1, 1, 100, and 
1000 ng/ml) and times of LPS incubation (4 and 24 h) were investigated. This should 
allow to a) induce endogenous ONOO- production within J774.2 macrophages and b) 
establish favourable detection conditions. Achieving a fine balance of sufficient 
ONOO- production is challenging as apoptosis can be easily induced by high 
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concentrations of LPS stimulation. ONOO- was successfully detected by PR1 at all 
investigated concentrations and incubation times (Figure 20). As seen previously, PR1 
exhibits initial fluorescence in J774.2 macrophages which can be attributed to low 
levels of ONOO- present within normal cell metabolism.55 In comparison to this 
baseline fluorescence signal, increasing LPS concentration at both 4 h and 24 h 
incubation times respectively increased the fluorescence signal of PR1. However, 
comparing 4 h and 24 h incubation of LPS in J774.2 macrophages, slight differences 
between the two can be observed. The fluorescence signal of PR1 at 4 h LPS 
incubation does not change substantially between the different LPS concentrations. In 
contrast, for 24 h of LPS incubation, a substantial increase in PR1 fluorescence is 
observed when using LPS concentration from 0.1 ng/ml to 100 ng/ml. This validates 
the role of LPS as an O2
∙- inducer where high levels of O2
∙- can react more readily with 
NO∙ to form ONOO-. 
 
 
Figure 20: LPS concentration and incubation time dependant increase in PR1 
fluorescence in J774.2 macrophages. Different LPS concentration (0.1, 1, 100, and 
1000 ng/ml) and incubation times (4 and 24 h) were evaluated at 1 min of fluorescence 
signal recording. The histogram indicates that PR1 successfully detects ONOO- 
induced via LPS stimulation in J774.2 macrophages. Increasing times of LPS 
incubation do not alter fluorescence intensity significantly. Data show mean values (n 
= 3) ± SEM, no statistical significance. Fluorescence intensities were measured with 




5.2.4. Stimulation of ONOO- Production with PMA 
 
Phorbol 12-myristate 13-acetate (PMA, Figure 21) stimulates the production of O2
∙-. 
O2
∙- was identified as the major ROS species induced by PMA.56 PMA activates 
protein kinase C which stimulates NOX. NOX are a family of enzyme complexes that 
generate O2
∙- from molecular oxygen at the expense of NADPH.57 Hence, PMA can 
induce enhanced O2
∙- production via this pathway. In conjunction with LPS, high 
levels of ONOO- should be favoured. 
 
 
Figure 21: General structure of phorbol 12-myristate 13-acetate (PMA) and 
probenecid. 
 
J774.2 macrophages have the ability to transport probes out of the cell via organic 
anion transporters.58 This can impact ROS signalling studies since the probe is only 
partially or not present in J774.2 macrophages. Probenecid (Figure 21) inhibits organic 
anion transporters, enhancing hereby the retention of probes within macrophages.59 
To test whether this impacts the loading of macrophages with probe PR1, probenecid 
was incubated in one set of experiments together with PR1. This should indicate a) 
whether PR1 is being removed by J774.2 macrophages through transporters, b) how 
probenecid prevents PR1 from being pumped out by J774.2 macrophages and c) 
investigate the ability of PMA to induce O2
∙-. However, using probenicid could also 
have a direct inhibitory effect on the P2X7 receptors.60  
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The fluorescence intensity after PMA injection increases with increasing PMA 
concentrations when compared to PR1 (15 μM, 30 min) and LPS incubation (100 
ng/ml, 4 h) in J774.2 macrophages (Figure 22). This is true with and without 
probenecid incubation. However, the rate of increase is minimal and variation within 
certain PMA concentrations is prominent. No significant difference with and without 
probenecid incubation can be observed in terms of fluorescence signal of PR1. 
 
 
Figure 22: PMA stimulation of J774.2 macrophages shows no significant increase of 
ONOO- production. Different PMA concentrations (5, 10, 50, and 100 nM) and 
incubation with and without probenecid were investigated. The histogram indicates 
that PR1 successfully detects ONOO- induced via PMA and LPS stimulation in J774.2 
macrophages. The usage of probenecid does not alter the fluorescence response of 
PR1 and hence, its ability of ONOO- detection. Data show mean values (n = 3) ± SEM, 
no statistical significance. Fluorescence intensities were measured with λex = 550 







5.2.5. IFN-γ: Activation of Nitric Oxide Synthase 
 
IFN-γ is a cytokine that is involved in innate and adaptive immunity. One of its key 
roles is the activation of inducible nitric oxide synthase (NOS), therefore, increasing 
the concentration of NO∙ produced. In addition to LPS, priming of macrophages with 
IFN-γ enhances ONOO- production.61 Recent literature reveals that a combination of 
LPS and IFN-γ can be used for ONOO- production for evaluating newly developed 
probes.46 
Most commonly, IFN-γ is used at a concentration of 50 ng/ml and incubated for 4 h.62 
Using these conditions, 50 ng/ml IFN-γ was added with 100 ng/ml LPS  and incubated 
together for 4 h to enhance ONOO- production (Figure 23). A combination of IFN-γ 
and LPS triggered an increase in PR1 fluorescence compared to untreated 
macrophages (***p  0.001, n = 3). Over a time period of 20 min, an increase in the 
macrophages’ availability to produce enhanced levels of ONOO- was observed. Lower 
fluorescent responses were observed with LPS or IFN-γ alone compared to using both 
factors. Also, a basal response was observed in the absence of LPS and IFN-γ which 
could reflect a low level of endogenous ROS production converting PR1 into 
fluorescent resorufin during the loading period. Hence, enhanced O2
∙- production 
through LPS and NO∙ production through IFN-γ allowed for larger amounts of ONOO- 





Figure 23: A rate increase in PR1 fluorescence in J774.2 macrophages when using 
both LPS and IFN-γ. Fluorescence intensity measured over a time period of 20 min 
whereby the slope of fluorescence intensity increase is evaluated. The control 
conditions show no change in rate of fluorescence intensity. LPS and IFN-γ alone 
induce increased rates of ONOO-. When used together, the rate of ONOO- produced 
increases more substantially. Data show mean values (n = 3) ± SEM, ***p  0.001, 
*p  0.05 with respect to PR1. Fluorescence intensities were measured with λex = 550 
(bandwith: 15) nm and max λem = 590 nm on a BMG Labtech CLARIOstar® plate 
reader. 
 
5.2.6. Scavenging ONOO- Production 
 
As mentioned earlier, ONOO- is generated by the reaction of O2
∙- and NO∙. Therefore, 
by inhibiting the production of one of the precursors, ONOO- concentrations should 
decrease. The ability of PR1 to detect changes in ONOO- generation was studied. First, 
only LPS stimulation and scavenger effects were evaluated. Then, IFN- γ stimulation 
is introduced to revaluate scavenging effects. 
The generation of O2
∙- within biological processes is a particularly fundamental one. 
The reaction of oxygen with NADPH rapidly generates O2
∙- and NADP+ (Equation 1). 
This process is mediated by the NOX. As part of the NOX enzyme family, there are 



















































structure. All these enzymes are able to transfer electrons from NADPH from oxygen 
to generate O2
∙-.63 Together with mitochondrial respiration, they are at the origin of 
ROS generation. 
 
2O2 + NADPH 
(oxidase)
→       2O2
∙− + NADP+ + H+   (Equation 1) 
 
Subsequently O2
∙- reacts with a variety of other ROS such as NO∙ for example to 
generate ONOO-. Hence by inhibiting the production of O2
∙-, this should allow for a 
decrease in ONOO- production. It is anticipated that PR1 should be able to detect the 
change in ONOO- production in J774.2 macrophages. 
First, three O2
∙- scavengers and one ONOO- scavenger were investigated (Figure 24). 
The rational for their usage and involvement in scavenging is given below: 
 
 
Figure 24: Investigation of different scavengers: ebselen, uric acid, N-acetyl-L-







 Ebselen  
2-phenyl-1,2-benzisoselenazol-3(2H)-one most commonly known as ebselen (EBS) is 
a GSH peroxidase mimic. Therefore, EBS-Se is readily oxidised by ROS to EBS-
SeOH at the active Se site. It is then reduced by GSH to the intermediate EBS-SeSG 
followed by a further reduction to its original form (Figure 25). It is a well-known O2
∙- 
scavenger illustrated by numerous examples in the literature.64-66 
 
 
Figure 25: Simplified catalytic mechanism of action of ebselen (EBS) adapted from 
Azad and Tomar.67 
 
 Uric acid 
Uric acid is an ONOO- scavenger. It requires ascorbic acid and thiols for its full 






N-acetyl-L-cysteine (NAC) is an antioxidant that can increase intracellular reduced 
GSH. This in turn allows to minimise oxidative stress. 
 
 Mn-cpx3 
This manganese complex containing 7-hydroxflavonones (flavones act as 
antioxidants) acts as a superoxide dismutase (SOD) mimetic. SODs are the major 
antioxidant defence systems against O2
∙-.69 Additionally, SODs are able to inactivate 
NO∙ production and are involved in the regulation of mitochondrial O2
∙- production.  
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J774.2 macrophages were treated with LPS (100 ng/ml) for 4 h, followed by 
incubation with scavengers (1 mM) for 1 h and incubation with PR1 (15 μM) for 30 
min. The fluorescence response of PR1 was studied over a 20 min timeframe. Figure 
26 displays PR1’s fluorescence intensity at a time point of 10 min. All scavengers 
display a significant decrease in PR1’s fluorescence compared to control conditions: 
LPS stimulation without probe incubation (Figure 26). Each scavenger seems to 
operate along the suggested mechanism of action of either directly inhibiting O2
∙- 
formation, ONOO- formation or enzymatic pathways that are linked to oxidative 
stress. The results are statistically significant with respect to the control conditions 
(**p  0.01) in the case of ebselen, uric acid and N-acetyl-L-cysteine. The 
fluorescence intensity of PR1 does not decrease significantly in the case of Mn-cpx3. 




Figure 26: Effectiveness of scavengers in J774.2 macrophages. Different scavengers 
(ebselen, uric acid, N-acetyl cysteine, and Mn-cpx3 – final concentration: 1 mM) were 
investigated. The histogram shows the fluorescence response of PR1 at the time point 
of 10 min of recording. The ability of PR1 to detect changes in ONOO- generation 
was validated with each scavenger, whereby uric acid showed the most significant 
decrease. Data show mean values (n = 3) ± SEM, **p  0.01 with respect to control 
conditions. Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm 
and max λem = 590 nm on a BMG Labtech CLARIOstar® plate reader. 
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The initial screening of scavengers was to determine a saturated inhibition response 
and maintain cell viability. Ebselen was chosen to be evaluated at different 
concentrations since PR1’s ability to indirectly detect the inhibition of O2
∙- was of 
main interest. Different concentrations of ebselen were incubated for 1 h: 0.1, 0.25, 
0.5, 0.75, 1 mM (Figure 27). From 0.25 mM upwards, a decrease in PR1 fluorescence 
can be observed which is statistically significant from 0.5 mM upwards when 
compared to the control group. Interestingly, when comparing the fluorescence 
intensity of PR1 when J774.2 macrophages are exposed to ebselen (0.5 mM) and to 
LPS and ebselen (100 ng/ml and 0.5 mM respectively), the same level is achieved. 
The stimulation of J774.2 macrophages with LPS is cancelled out by the introduction 
of ebselen at 0.5 mM. Hence, ebselen allows to validate the inhibition of O2
∙- 
production. Also, background PR1 fluorescence in untreated J774.2 macrophages was 
also partially reduced by 0.5 mM ebselen indicating detection of basal ONOO- 
formation by PR1. In the presence or absence of LPS, 0.5 mM ebselen reduces PR1 
fluorescence to a comparable baseline level. Consequently, this impacts ONOO- 









Figure 27: Effect of ebselen concentration on the scavenging of O2
∙- consequently, 
limiting the ability of ONOO- production. Different ebselen concentrations (0.1, 0.25, 
0.5, 0.75, 1 mM) were investigated. Increasing concentrations of ebselen impact the 
production of O2
∙-: less O2
∙- is readily available, as a consequence less ONOO- is 
produced. Hence, the ability of PR1 to detect ONOO- diminishes in fluorescence 
signal due to less ONOO- being produced in J774.2 macrophages. Data show mean 
values (n = 3) ± SEM, ***p  0.001 with respect to the PR1 and LPS treated group. 
Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm and max 
λem = 590 nm on a BMG Labtech CLARIOstar® plate reader. 
 
Having shown that O2
∙- production in J774.2 macrophages can be impacted and hence, 
limit ONOO- formation, this should allow evaluation of NO∙ production. As NO∙ is 
the other key component for ONOO- formation, inhibiting NOS, a family of enzymes 
(NOS 1-3) that produces NO∙ from L-arginine, should also limit ONOO- formation. In 
the same manner as O2
∙-, if less NO∙ is readily available, less ONOO- can be produced 
when J774.2 macrophages are subjected to stress conditions. This led to the 




Figure 28: NOS inhibitors: non-competitive NG-methyl-L-arginine-acetate and 
competitive Nw-nitro-L-arginine inhibitors. 
 
 NG-methyl-L-arginine-acetate: Initially reported as an inhibitor of macrophage 
nitrite generation, it is also a competitive inhibitor for NOS established through 
studies in RAW264.7 macrophages.70, 71 
 Nw-nitro-L-arginine: It mostly acts as a competitive inhibitor for NO∙ 
formation. Numerous examples in the literature have shown that Nw-nitro-L-
arginine is effective in a variety of biological systems as a NOS inhibitor.72-74 
A range of different concentration of NG-methyl-L-arginine-acetate and Nw-nitro-L-
arginine were incubated for 1 h: 0.1, 0.25, 0.5, 0.75, 1 and 2 mM. Comparing the 
inhibitor and LPS treated groups towards the control group of PR1 and LPS only, in 
both cases a decrease of fluorescent intensity of PR1 was observed. Similarly, a 
decrease in PR1 fluorescence is observed for both competitive inhibitors. Comparing 
the inhibitor only with the inhibitor and LPS treated group, the fluorescence intensity 
of PR1 achieves the same level as the inhibitor only with concentrations of LPS > 0.5 
mM onwards. Since LPS also induces NOS activity next to enhanced production of 
O2
∙-, this suggests that both inhibitors are successful in diminishing NO∙ levels. 
Overall, the inhibition of NOS is not as significant as O2




Figure 29: Effect of a) NG-methyl-L-arginine-acetate and b) Nw-nitro-L-arginine, 
competitive inhibitors of NOS, on the inhibition of the catalytic production of NO∙ 
from L-arginine in J774.2 macrophages. Different NG-methyl-L-arginine-acetate and 
Nw-nitro-L-arginine concentrations (0.1, 0.25, 0.5, 0.75, 1, 2 mM) were investigated. 
Increasing concentrations of both NOS inhibitors impact towards a greater extent the 
catalytic production of NO∙. Less NO∙ is readily available to react with O2
∙- to form 
ONOO-. Consequently, PR1 detects less ONOO- due to the diminishing fluorescence 
signal. Data show mean values (n = 3) ± SEM, ***p  0.001, * p  0.05 with respect 
to the PR1 and LPS treated group. Fluorescence intensities were measured with λex = 
550 (bandwith: 15) nm and max λem = 590 nm on a BMG Labtech CLARIOstar® plate 
reader. 
 
With the introduction of IFN-γ, a screen of NOS inhibitors, O2
∙- scavenger, and 
ONOO- scavenger was repeated to see how these results compare to the previous ones 
where only LPS was used to induce NO∙ and O2
∙- production.  
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J774.2 macrophages were stimulated with LPS (100 ng/ml) and IFN-y (50 ng/ml) for 
4 h. NOS inhibitors (500 μM, 1 h) - NG-methyl-L-arginine-acetate (NO1) and Nw-
nitro-L-arginine (NO2) – ebselen (500 μM, 1 h) and uric acid (500 μM, 1 h) were 
incubated after LPS and IFN-γ treatment. After PR1 (15 μM, 30 min) incubation, the 
fluorescence intensity was recorded. At a time point of 4 min of recording, the ability 
of PR1 to detect ONOO- was evaluated (Figure 30). Upon treatment with LPS and 
IFN-γ, a high fluorescence response of PR1 was observed as expected through the 
induced ONOO- stimulation, compared to the control conditions. By introducing NOS 
inhibitors, O2




Figure 30: LPS and IFN-γ induced ONOO- production quenched by inhibitors and 
scavengers. The fluorescence signal of PR1 is quenched with the introduction of NOS 
inhibitors (NG-methyl-L-arginine-acetate (NO1) and Nw-nitro-L-arginine (NO2)) and 
scavengers (ebselen and uric acid (UA)), which impact O2
∙- and NO production. Data 
show mean values (n = 3) ± SEM, ***p  0.001 with respect to the PR1, LPS and 
IFN-γ treated group. Fluorescence intensities were measured with λex = 550 (bandwith: 






5.2.7. Activation and Inhibition of P2X7 Receptors 
 
By definition, ATP (Figure 31) transports (bio)chemical energy within cells for 
metabolism. However, extracellular ATP also plays a pivotal role in inflammation. In 
the late 1980s, evidence emerged that ATP generates O2
∙-.75, 76  
 
 
Figure 31: Adenosine-5’-triphosphate (ATP) is involved in inflammation. 
 
Under inflammatory conditions, cells are able to release ATP that is being recognised 
by purinergic receptors.77 In fact, ATP, its metabolites (adenosine diphosphate , AMP 
and adenosine), uridine triphosphate and uridine diphosphate, all stimulate the 
activation of purinergic receptors. There are two types of purinergic receptors: P1 
adenosine receptors and P2 receptors which are subdivided into P2Y GPCRs and P2X 
ligand gated ion channels whereby I will focus on the latter one. P2X receptors mediate 
many of the extracellular actions of ATP.78 There are seven different subtypes: P2X1, 
P2X2, P2X3, P2X4, P2X5, P2X6 and P2X7 (Table 2). ATP acts as an agonist for all 
subtypes, however different types of antagonists are able to block these receptors. 
Each subtype is associated with a variety of diseases and constitute essential 
therapeutic targets for thrombosis (P2X1), chronic neuropathic and inflammatory pain 
(P2X3, P2X2/3, P2X4, P2X7), dysfunctional urinary bladder (P2X1, P2X2, P2X3), 





Table 2: A summary of the role of the different subtypes of P2X receptors and selective 
antagonists of P2X receptors is presented. The table was summarized using data from 
Kennedy et al.78 
P2X receptor Role Antagonists 
any various Suramin, PPADS 
P2X1 
expression in smooth 
muscle, mediation of 




expression in central and peripheral 
neurones, mediation of neuro-




expression in sensory neurones, also 




expression in central and peripheral 
neurones, and glandular tissues 
5-BDBD 
P2X5 
expression in central neurones, eye, 








Expressed in glial cells of the CNS, 
peripheral nervous system, and in 
cells of the immune system, 
including macrophages, monocytes, 






I am mainly interested in the sub-type P2X7 since it has been associated with 
inflammasome assembly and is believed to play a major role in NLRP3 inflammasome 
activation, thus, initiating the release of IL-1β. Hence, I decided to look at their 
activation with ATP and consequently whether inhibition with one of the 
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commercially available antagonists would go in line with changes in ONOO- 
stimulation. 
No or minimal increase of ONOO- generation was detected by PR1 during ATP 
stimulation with concentrations up to 1 mM of ATP (Figure 32). This could indicate 
that the P2X7 receptors were not activated at this concentration and hence, no 
enhanced ONOO- production is induced. However, upon injection of ATP at a 
concentration of 5 mM, the rate of fluorescence intensity of PR1 increased above 
control conditions (no ATP added following LPS priming). The change in rate was 
not statistically significant. This is true for and without the use of probenecid. Though, 
the usage of probenecid (1 mM) reduced variation of the samples within each ATP 
concentration used. 5 mM of ATP with probenecid incubation hints at the activation 
of P2X7 receptors and their involvement in inflammasome assembly. Subsequent 
investigation of a P2X7 antagonist could validate my hypothesis. 
 
 
Figure 32: Concentration dependant ATP stimulation of J774.2 macrophages shows 
an increase in PR1 fluorescence. Different ATP concentrations (0.1, 0.5, 1, 5 mM) 
and incubation with and without probenicid (1 mM) were investigated. The histogram 
indicates that PR1 successfully detects ONOO- induced via ATP and LPS stimulation 
in J774.2 macrophages. Using probenecid allows for less variation for ATP 
stimulation. This allows for reproducibility of ONOO- detection via PR1. Data show 
mean values (n = 3) ± SEM, no statistical significance of the results was observed. 
Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm and max 
λem = 590 nm on a BMG Labtech CLARIOstar® plate reader. 
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The same conditions were then used to evaluate how ATP could overcome scavenging 
ONOO- behaviour. After injection of ATP (5 mM), the rate of ONOO- production was 
monitored by the change of fluorescence signal of PR1. Comparing the PR1, LPS and 
IFN-γ group with the PR1, LPS, IFN-γ and ATP, a decrease in the fluorescence signal 
can be observed. As such, the response to 5 mM ATP is changed with the co-addition 
of IFN-γ with LPS in the priming stage. It seems that when in addition to LPS, IFN- γ 
is present, it takes a more dominant role: NOS expression is increased and ATP has 
an inhibitory effect (Figure 33).79 In contrast, when LPS is used alone (Figure 32), the 
signal increases after ATP injection suggesting that the activation of P2X7 could be 
the prominent response. Evaluating the rate of ONOO- production through PR1 in the 
case of the NOS inhibitors and ROS scavengers when ATP is introduced, shows in all 
cases an increase in ONOO- production compared to when no ATP is present. It seems 
interesting that there could be an ATP-dependant increase in the presence of inhibitors 
and scavengers (Figure 33). 
 
 
Figure 33: ATP induces O2
∙- production, overcoming inhibitor and scavenger effects. 
The rate of ONOO- production is quenched by NOS inhibitors (NG-methyl-L-arginine-
acetate (NO1) and Nw-nitro-L-arginine (NO2)) and scavengers (ebselen and uric acid 
(UA)). Introduction of ATP (5 mM) allows to overcome this effect. Increased O2
∙- 
production is stimulated via ATP, suggesting also the activation of purinergic 
receptors. Data show mean values (n = 3) ± SEM, ***p  0.001, * p 0.05 with respect 
to the PR1, LPS and IFN-γ treated group and ###p  0.001, # p  0.05 with respect to 
the PR1, LPS, IFN-γ and ATP treated group. Fluorescence intensities were measured 
with λex = 550 (bandwith: 15) nm and max λem = 590 nm on a BMG Labtech 
CLARIOstar® plate reader. 
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When stimulating J774.2 macrophages with high levels of ATP, P2X7 receptors 
should be activated. This leads to subsequent cell signalling events including the 
formation of ROS.80 Oxidative stress increases adenosine release (partly through ATP 
degradation into adenosine) by activating adenosine receptors which can also play a 
key part in the immune response. In this study, I looked at two specific receptor 
antagonists: A-438079 and CGS 15943 (Figure 34). A-438079 is a competitive P2X7 
antagonist, which inhibits small cation flux (such as calcium and potassium) and IL-
1β release.81 On the other hand, CGS 15943 is a competitive, non-selective adenosine 
receptor antagonist.82 Under oxidative stress, increased amounts of adenosine are 
released, activating adenosine receptors (a class of purinergic G protein-coupled 
receptors) which through a cascade of other signalling events activate NF-κB. NF-κB 
plays a key role in the regulation of the immune response towards an infection.  
 
 
Figure 34: P2X7 receptor inhibitor: 3-[[5-(2,3-Dichlorophenyl)-1H-tetrazol-1-
yl]methyl]pyridine hydrochloride (A438079) and adenosine receptor inhibitor: 9-
Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine (CGS 15943). 
 
Different concentrations of ATP were investigated while keeping the concentration of 
the respective antagonist constant at 100 μM (Figure 35). Control conditions with no 
antagonist present were also evaluated in order to correctly attribute inhibition to the 
relevant receptors. The rate of ONOO- formation after ATP injection detectable by 
PR1 was evaluated. In the case of the P2X7 inhibitor A-438079, no clear trend was 
established other than an ATP-dependant increase in PR1 fluorescence was not 
observed at 5 mM ATP in the presence of antagonists. At 1 mM ATP when LPS is 
present, it seems to stimulate higher ROS generation. However, the antagonist should 
show a decline in ROS generation detectable for PR1. No clear conclusion can be 
drawn in terms of the ability to inhibit the P2X7 receptor. As for the adenosine receptor 
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inhibitor CGS 15943, the same conditions were employed as with A-438079. The 
anticipated effect of adenosine receptor inhibition was not fulfilled: significant 
reduction of ROS. On the contrary, it seems that high concentrations of ATP seem to 
overcome CGS 15943 inhibitory effects. Nevertheless, it seems that ATP increases 
ONOO- formation with no limiting effect by CGS 15943. 
 
 
Figure 35: Effect of using a) A-438079, a P2X7 inhibitor, and b) CGS 15943, an 
adenosine receptor inhibitor and how this alters ATP’s ability to open the receptors. 
Different ATP concentrations (1, 2, 3, 4, 5 mM) were investigated when exposed to a 
receptor inhibitor and compared to control conditions when no antagonist was present. 
No clear effect was observed on the usage of the antagonist when exposed to different 
ATP concentrations, suggesting in comparison to the no antagonist data that it has no 
effect on this receptor due to the continuous increase in rate of PR1’s ability to detect 
ONOO-. Data show mean values (n = 3) ± SEM, no statistical significance of the 
results was observed. Fluorescence intensities were measured with λex = 550 
(bandwith: 15) nm and max λem = 590 nm on a BMG Labtech CLARIOstar® plate 
reader. 
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5.2.8. Comparing Hypoxic and Normoxic Environments 
 
A common feature of tumours such as cancer cells for example, is a low availability 
of oxygen. This state is called hypoxia where oxygenation of the tumour tissue is poor 
and usually at levels of 1 – 2 % O2. In contrast, normoxia is the healthy state of tissues 
where oxygenation is assured. Depending on the tissue, these oxygen levels can vary 
(Table 3).83 
 
Table 3: Comparison of oxygen levels in healthy and diseased tissues adapted from 
Azab et al.83 
Tissue Normoxia (% O2) Hypoxia (% O2) 
Breast 8.5 1.5 
Liver 4.0 – 7.3 0.8 
Cervix 5.5 1.2 
Kidney 9.5 1.3 
 
The tumour microenvironement is composed of blood vessels, lymphatic vessels, 
fibroblasts, immune cells and chemico-physical components. During tumour 
development and progression, access to oxygen is restricted. This low oxygen state is 
mainly linked to hypoxida-inducible factors (HIFs) which contain an oxygen-sensitive 
HIF-α subunit.84 Under hypoxic conditions, increased levels of ROS are generated, 
particularly in the mitochondria. This is mainly due to the effects of ROS on the 
mitochondria electron transport chain whereby the exact mechanisms are still not 
clear.85 In order to stimulate J774.2 macrophages towards a hypoxic environment, a 
limited supply of O2 was induced using a hypoxic chamber. J774.2 macrophages were 
cultured at 1 % O2. These were then compared to normoxic J774.2 macrophages. 
Hypoxia influences key macrophage functions, such as energy metabolism and 
different immune responses.86 The fluorescence intensity of PR1 varies significantly 
when comparing normoxic to hypoxic conditions (Figure 36). PR1 will detect basal 
levels of ONOO-, which are naturally produced by J774.2 macrophages as well as by 
LPS stimulation. Under hypoxic conditions, I hypothesize that less O2
∙- is produced by 
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J774.2 macrophages, limiting the availability of ONOO- produced as shown by PR1’s 
ability to detect those decreased levels. One would expect increased amounts of 
ONOO- under hypoxic conditions in J774.2 macrophages.  
 
 
Figure 36: Comparing the ability of PR1 to detect ONOO- under normoxic and 
hypoxic conditions. J774.2 macrophages were stimulated with LPS under normoxic 
and hypoxic conditions. The fluorescence intensity of PR1 was measured allowing to 
evaluate the ability of PR1 to detect ONOO-. A clear decrease of ONOO- production 
can be observed under hypoxic conditions in comparison to normoxic conditions. Data 
show mean values (n = 3) ± SEM, ***p  0.001 with respect to the relevant 
normoxic/hypoxic control conditions, #p  0.05 with respect to the PR1 treated group 
under normoxic conditions, and +p  0.05 with respect to the PR1 and LPS treated 
group under normoxic conditions. Fluorescence intensities were measured with λex = 





I have successfully identified a new fluorescent tool to study ONOO- mediated 
pathways. I have taken a known H2O2 probe, PR1, and evaluated it as an ONOO
- 
selective and sensitive probe. PR1 showed excellent permeability in J774.2 
macrophages and was able to detect endogenous ONOO- as confirmed by confocal 
imaging. Subsequently, by using a plate reader, PR1 was evaluated as a fluorescent 
tool for assays. Using SIN-1, exogenous ONOO- was evaluated followed by an 
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investigation of LPS, IFN-γ, PMA and ATP as endogenous stimulants to increase O2
∙- 
and NO∙ generation, both essential precursors to form ONOO-. At the same time O2
∙-, 
NOS and ONOO- scavengers were introduced to evaluate the impact on inhibition of 
ONOO- precursors as well as ONOO- itself. Additionally, the inhibition of P2X7 and 
adenosine receptors was evaluated, which are essential receptors in the activation of 
ROS related mechanisms. Finally, I also looked at comparing the hypoxic and 
normoxic environment and PR1’s ability to detect changes in ONOO- generation. The 
established protocol allowed to evaluate some of the PR1 derived probes (Chapter 2). 
Evaluating all these factors, allows us to draw a picture about some of the cellular 
processes and how PR1 is able to detect these (Figure 37). 
 
 
Figure 37: A range of factors have been successful in stimulating and inhibiting 
ONOO- generation. These changes were detected by PR1 which upon reaction with 
ONOO- generates resorufin. The fluorescence output of resorufin was closely 




7. Future Work 
 
Until this point, PR1 has only been used as a fluorescent tool for the detection of 
ONOO- in M1 polarized macrophages. ROS are also implicated in M2 polarization as 
outlined in Section 1.2. Whereby in M1 macrophages an increase in ROS is observed, 
for M2 polarized macrophages, the generation of ROS should decline. To validate M2 
polarization, stimulation with cytokines IL-4 and IL-13 should activate this phagocytic 
change. 
Additionally, the introduction of chemotherapy agents would be interesting to evaluate 
in macrophages. Chemotherapeutics drive an increase in ROS generation, including 
ONOO- and also alter redox homeostasis. For example, doxorubicin and daunorubicin 
are common anti-cancer drugs used in combination with other chemotherapy agents 
(Figure 38). Both drugs are made biosynthetically whereby daunorubicin is a precursor 
for doxorubicin. A previous study demonstrated that both doxorubicin and 
daunorubicin stimulate an increase in IL-1β production and other inflammatory 
cytokines in conjunction with LPS in murine bone marrow derived macrophages.87 
IL-1β is generated from pro IL-1β and caspase-1 whereby the latter is activated by the 
NLRP3 inflammasome.88 However, it is important to note that both doxorubicin and 
daunorubicin are inherently fluorescent and this needs to be accounted for when using 
PR1 to evaluate ONOO- levels. 
 
 
Figure 38: Anti-cancer drugs doxorubicin and daunorubicin stimulate an increase in 
ROS production.  
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As outlined in Chapter 1, PR1 is based on resorufin. Resorufin is an attractive 
fluorophore since it is water soluble and emits red light. The most prominent example 
of using resorufin in immunoassays is Amplex Red 1.1. The commercial probe 1.1 is 
mainly utilised for the quantitative study of H2O2 (Scheme 1).
89 The amine of resorufin 
is masked which upon reaction with H2O2 releases resorufin. 
 
 
Scheme 1: Amplex Red 1.1, a commercially available probe for the quantitative study 
of H2O2. 
 
Resorufin is a fairly underexploited fluorophore in contrast to fluorescein or coumarin 
where many ROS probes exist. I have reviewed the literature and was able to mainly 
identify probes for the detection of sulphur and nitrogen species, with few examples 
of ROS species. A small overview of the current literature is herein provided.  
Resorufin based probes 2.1 and 2.2 for reactive sulphur species were developed by 
Chang et al.90 and Tian et al.91 (Scheme 2). Resorufin was masked with relevant 
sensing groups for thiols. Upon reaction of the probe with the thiol, resorufin is 
released. Tian and co-workers even went a step further and designed a dual analyte 
probe 2.2 for simultaneous thiol and redox sensing. Using macrophages, the probe was 
successfully validated to detect both analytes. 
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Scheme 2: Resorufin-based probes 2.1 and 2.2 for RSS sensing: a) sulphite sensor and 
b) dual analyte sensor for thiol and redox homeostasis. 
 
Chemical probes based on a resorufin core for hydrazine and nitroxyl have been 
developed by Zhu et al.92 and Bhuniya et al.93 (Scheme 3). Exposure to increased 
levels of hydrazine can damage the liver, lungs, kidneys and nervous system either 
through inhalation or oral absorption.94 The resorufin probe 3.1 is activated by the 
deprotection of the bromo-butyric ester. Selectivity studies were carried out with a 
range of metal ions and halides. However, the probe could also potentially be cleaved 
by ONOO- since this strong nucleophile can easily attack the ester group and generate 
free resorufin. The reaction based probe 3.2 by Bhuniya and co-workers uses a 
phosphine unit that selectively reacts with nitroxyl. The selectivity study looked at a 
variety of ROS and RNS. ONOO- was not included but could lead to cleavage of the 
ester group, impacting the claims of nitroxyl sensitivity and selectivity. Only 
exogenous nitroxyl was evaluated in Chinese hamster ovary cells. Endogenous 
nitroxyl generation could potentially give a false positive if the probe selectively reacts 




Scheme 3: Resorufin-based molecular probes 3.1 and 3.2 for the detection of a) 
hydrazine and b) nitroxyl. 
 
Zhang et al. developed a resorufin based probe 4.1 with a benzyl Bpin group attached 
for tyrosinase detection.95 The authors also evaluated H2O2 as part of their study, 
acknowledging that it could interfere and compete with tyrosine. It would have been 
interesting to see what effect ONOO- has on the probe 4.1 since similar to H2O2 it can 
easily oxidise the boronic ester. A similar probe 4.2 was developed by Ma and co-
workers96 whereby the boronic ester was placed at the ortho position instead of the 
meta one (Scheme 4). Their probe has been developed for benzoyl peroxide (BPO) 
detection with a selectivity study plainly looking at inorganic salts and amino acids. 
Ma et al. realised that probe 4.2 shows good turn on responses with H2O2. For the 
purpose of their application, the probe seems suitable for selective BPO detection. 
Nevertheless, probe 4.2 could be also a ROS probe for ONOO- and H2O2 in vitro.  
 
 
Scheme 4: Resorufin-based probes 4.1 and 4.2 with a benzyl Bpin motif for the 
detection of a) tyrosinase and b) benzoyl peroxidase (BPO) respectively. 
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The functionalisation of resorufin has mainly focused on the masking of the alcohol 
group of resorufin with relevant sensing groups for a variety of analytes. I wanted to 
explore the functionalisation at the amine position in the hope to access a new class of 
reaction based fluorophores for the sensitive and selective detection of ONOO- by 
ideally incorporating an organelle targeting aspect i.e. direct selective sensing. 
 
1.1. Project Aim 
 
As seen in Chapter 1, PR1 shows good selectivity and sensitivity for ONOO- and is a 
useful tool in understanding ONOO- mediated pathways in J774.2 macrophages. 
Functionalisation at the amine position of PR1 should allow the development of 
(organelle) targeted ONOO- molecular sensors. Previous work in the group led to the 
development of 5.8, a useful intermediate for further functionalisation at the alcohol 
position (Scheme 5). The incorporation of the 4-hydroxyphenyl moiety at the amine 
position has been previously shown by Guo et al. to increase sensitivity towards 
ONOO- in addition to the boronic esters.49 5.8 was afforded in a six step synthesis with 
an overall yield of 13.7 %. First, selective protection of the alcohol in the 1 position 
of 4-hydroxybenzyl alcohol 5.1 was achieved using pivaloyl chloride. Subsequent 
bromination of the alcohol in the 4-position of 5.2 afforded 5.3 in 76 %. Alkylation of 
phenoxazine 5.4 with 5.3 gave 5.5 followed by a NBS bromination to yield 5.6. 
Following the deprotection of the pivalate group of 5.6 with DIBAL-H, Miyaura 




Scheme 5: Synthesis of resorufin-based intermediate 5.8. 
 
Fluorescence studies confirmed 5.8’s ability to be an affective ONOO- probe. Titration 
studies of 5.8 with ONOO- showed that towards 10 μM, the fluorescence response is 
starting to saturate (Figure 1). A subsequent ROS selectivity study showed that 5.8 
preferentially detects ONOO- over other ROS species (Figure 2). The fluorescence 
response of 5.8 with H2O2 is expected due to the ability of boronic esters to also act as 
targeting group for H2O2. However, the reactivity with ONOO
- is instantaneous and 




Figure 1: Emission spectra for probe 5.8 (500 nM) in the presence of ONOO- (1, 2, 3, 
4, 5, 6, 7, 8, 9, 10 μM) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. 
Fluorescence intensities were measured with λex = 550 (bandwith 15) nm on a BMG 
Labtech CLARIOstar® plate reader. 
 
 
Figure 2: Selectivity data for 5.8 (500 nM) in the presence of ONOO- (50 µM), 
OH·(500 µM), O2
∙- (500 µM), 1O2 (500 µM) after 5 min. H2O2 (1 mM), ROO· (500 
µM) and ClO- (500 µM) were measured after 30 min. (a) Bar chart of relative 
fluorescence intensities. (b) Emission spectra. The data was obtained in PBS buffer 52 
% MeOH : H2O, pH = 8.2 at 25 °C  at λex = 550 (bandwith 15) nm and max λem = 590 
nm on a BMG Labtech CLARIOstar® plate reader. 
 
Given this useful intermediate, it was decided to explore the scope further by 
developing a series of analogues (Appendix). For the purpose of this thesis, only a 
selection of these PR1 derivatives will be discussed. 
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2. Organelle Targeting Fluorescent Probes 
2.1. Synthesis of Organelle Targeting ONOO- Resorufin Based 
Probes 
 
The development of probes that preferentially localise in a certain type of organelle 
are highly preferable to understand cellular pathways in more depth as outlined in 
Chapter 1. The mitochondria is one of the main sources of ROS. To this end, two 
mitochondrial targeting probes and one endoplasmic reticulum targeting probe were 
developed. The two mitochondrial targeting probes use the core structure of 5.8 and 
include a lipophilic cation such as triphenylphosphonium (TPP) and quaternised 
pyridine. These cations allow for easier passage through the mitochondrial 
membrane.97, 98 Targeted delivery of molecular sensors towards the endoplasmic 
reticulum can be achieved for example through the attachment of a short alkane chain 
with a Cl atom at the end.99, 100 Hence, three structures were proposed that should be 
synthetically easily accessible (Scheme 6). 
 
 
Scheme 6: Organelle targeting ONOO- probes based on a resorufin scaffold. 
 
To achieve final target probe 6.1, intermediate 5.8 was reacted with acyl chloride 7.2, 
which was previously synthesised from carboxylic acid 7.1. The addition elimination 




Scheme 7: Synthetic route towards a mitochondrial targeting probe 6.1. 
 
Following the successful synthesis of 6.1, a peptide coupling approach was 
investigated for the conversion of the alcohol into the ester (Scheme 8). Peptide 
coupling reagents such as HATU for example are also used for alcohol acylation 
reactions with carboxylic acids whereby the corresponding ester is generated. Using 
HATU as a coupling reagent, 6.1 was obtained in 38 % yield, similar to the previous 
synthetic strategy. The peptide coupling reaction allowed the overall synthesis of 6.1 
to be shortened by one step. 
 
 
Scheme 8: Alternative route towards a mitochondrial targeting probe 6.1. 
 
The postulated mechanism for the conversion of 6.1 into resorufin, a well-known 
fluorescent probe, is illustrated in Scheme 9. Essentially, ONOO- allows for the 
cleavage of the boronic esters as well as the attached phenyl moiety at the amine 




Scheme 9: Postulated mechanism for the conversion of 6.1 into resorufin. 
 
A second mitochondrial targeting probe was developed whereby pyridinium was 
incorporated as the mitochondrial targeting group (Scheme 10). Reaction of 5.8 with 
2-chloroacetyl chloride 11.1 gave 6.3 in a very low yield of 12 %. Further 
functionalisation with pyridine then gave the mitochondrial target probe 6.2 in 90 
%.101 Coincidentally, it was realised that the intermediate leading towards 6.2 could 
be used as an endoplasmic reticulum targeted probe 6.3. The short alkane chain with 
a Cl atom at the end has previously been shown to be an effective group to localise 
probes within the endoplasmic reticulum.99, 100 
 
 
Scheme 10: Synthesis of mitochondrial targeting probe 6.2 and endoplasmic reticulum 




2.2. Fluorescence Studies 
 
Due to the inherent nature of boronic esters to act as sensing groups for ONOO- and 
H2O2, fluorescence titration studies were carried out for both ROS in order to validate 
the faster reaction time and sensitivity with ONOO-. ROS selectivity studies were 
carried out to confirm this hypothesis. 
In a first instance, UV spectra were collected for 6.1, 6.2, and 6.3 in order to validate 
the change in absorbance in the presence of ONOO-. The formation of a new species 
was observed upon addition of ONOO- (Figure 3). The new absorption peak matches 
with resorufin, validating the release of the fluorophore after reaction with ONOO-. 
 
 
Figure 3: UV spectra of a) 6.1 (50 µM), b) 6.2 (50 µM), and c) 6.3 (50 µM), with and 
without ONOO- (excess) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C 
measured on a BMG Labtech CLARIOstar® plate reader. 
 
ROS selectivity studies were carried out for 6.1, 6.2, and 6.3 to assure selectivity 
towards ONOO- over other ROS (Figure 4). As expected preferential detection for 
ONOO- was seen for all probes. At the same time, H2O2 was also detected. 
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Nevertheless, in a biological environment, boronic esters would be more quickly and 
easily oxidised by ONOO- rather than H2O2. 
 
 
Figure 4: Selectivity data for a) probe 6.1 (500 nM), b) probe 6.2 (500 nM), and c) 
probe 6.3 (500 nM) in the presence of ONOO- (50 µM), OH· (500 µM), O2
∙- (500 µM), 
1O2 (500 µM) after 5 min. H2O2 (1 mM), ROO· (500 µM) and ClO
- (500 µM) were 
measured after 30 min. The data was obtained in PBS buffer 52 % MeOH : H2O, pH 
= 8.2 at 25 °C with λex = 550 (bandwith: 15) nm and max λem = 590 nm on a BMG 
Labtech CLARIOstar® plate reader.  
 
Following these selectivity results, H2O2 was investigated with concentrations ranging 
from 100 μM – 2 mM over 1 h. For a significant fluorescence signal, H2O2 needs to 
be incubated for at least 30 min to react. No fluorescence is initially observed with 
H2O2 alone. Upon addition of the probe, the fluorescence signal increases relative to 




Figure 5: Fluorescence intensity changes over time of a) probe 6.1 (500 nM), b) probe 
6.2 (500 nM) and c) probe 6.3 (500 nM) in the presence of H2O2 (0.1, 0.2, 0.4, 0.6, 
0.8, 1, 1.5, 2 mM) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. Fluorescence 
intensities were measured with λex = 550 (bandwith: 15) nm and max λem = 590 nm on 
a BMG Labtech CLARIOstar® plate reader. 
 
H2O2 titrations (100 μM – 2 mM) of 6.1, 6.2, and 6.3, all show no saturation of the 
fluorescence signal (Figure 6). Higher H2O2 concentrations are not biologically 
relevant and were therefore, not investigated. Lower H2O2 concentrations than 100 μM 
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did not activate 6.1, 6.2, and 6.3 limiting the detection of H2O2 at small biologically 




Figure 6: Emission spectra and dose dependence curve (I/Imax) for a) & b) probe 6.1 
(500 nM), c) & d) probe 6.2 (500 nM) and e) & f) probe 6.3 (500 nM) in the presence 
of H2O2 (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 2 mM) after 1 h in PBS buffer 52 % MeOH : 
H2O, pH = 8.2 at 25 °C. Fluorescence intensities were measured with λex = 550 
(bandwith: 15) nm and max λem = 590 nm on a BMG Labtech CLARIOstar® plate 
reader. 
 
Subsequent evaluation of 6.1, 6.2, and 6.3 with ONOO- gave insights into sensitivity 
towards a different ROS. The time frame of reacting probes with H2O2 and ONOO
- 
differs significantly with ONOO- being a stronger oxidant and hence, a faster reacting 
species. Titration of 6.1, 6.2, and 6.3 with ONOO- (1 – 50 μM) confirmed that much 
65 
lower concentrations of ONOO- are required for a turn-on response compared to H2O2 
(Figure 7). All react almost instantaneously with ONOO-, indicating their potential for 
ONOO- detection. LoDs for 6.1, 6.2, and 6.3 are 3 μM, 0.8 μM and 0.2 μM 
respectively. Therefore, all three probes are highly applicable for low concentration 
detection of ONOO- in biological systems. 
 
 
Figure 7: Emission spectra and dose dependence curve (I/Imax) for a) & b) probe 6.1 
(500 nM), c) & d) probe 6.2 (500 nM) and e) & f) probe 6.3 (500 nM) in the presence 
of ONOO- (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 μM) after 5 min in PBS buffer 
52 % MeOH : H2O, pH = 8.2 at 25 °C. Fluorescence intensities were measured with 





2.3. Cell Studies 
 
The cell protocol established in Chapter 1 was used to assess the ability of probes 6.1, 
6.2 and 6.3 to detect endogenously produced ONOO-. J774.2 macrophages were 
stimulated with LPS and IFN-γ. At the same time, ebselen and Nω-nitro-L-arginine 
were used to assess the ability to suppress ONOO- production and if this could be 
detected by 6.1, 6.2 and 6.3. PR1 was used as a positive control. Unfortunately, all 
three organelle targeting probes 6.1, 6.2, and 6.3 showed negligible activity in 
detecting endogenous ONOO- and subsequent suppression of its production by 
inhibitors (Figure 8). Strangely enough, for 6.3, a higher fluorescence signal was 
observed upon usage of ONOO- inhibitors then stimulation with LPS and IFN- γ alone. 
Hence, the organelle targeting ONOO- probes seem to have cell permeability issues. 
 
 
Figure 8: LPS and IFN-γ induced ONOO- production quenched by ebselen (ebs) and 
Nω-nitro-L-arginine (NOS inh.) with respective incubation of a) probe 6.1, b) probe 
6.2, and c) probe 6.3. Fluorescence intensities were measured with λex = 550 
(bandwith: 15) nm and max λem = 590 nm on a BMG Labtech CLARIOstar® plate 
reader. Data show mean values (n = 3) ± SEM. No statistical significance.  
 
67 
Despite these results, 6.1 was evaluated using confocal microscopy. It was anticipated 
that 6.1 would be able to penetrate the mitochondria and detect ONOO- inside the 
organelle. To be able to rationalise whether localisation occurs in the mitochondria, 
MitoView Green was used as a complimentary commercially available mitochondrial 
stain. Unfortunately, poor penetration of the mitochondrial targeting probe 6.1 was 
observed (Figure 9). It also seems that it is competing to a certain extent with 
MitoView Green, which seems to weaken the signal in the presence of 6.1 compared 
to when used alone. This suggest that the use of 6.1 for mitochondria targeting is 




Figure 9: Confocal microscopy images of J774.2 macrophages incubated in 
probenecid (1 mM): 1a – e: 6.1 (15 μM, 30 min); 2a – e: LPS (1 μg/ml, 4 h), IFN-γ 
(50 ng/ml, 4 h) and 6.1 (15 μM, 30 min); 3a – e: LPS (1 μg/ml, 4 h), IFN-γ (50 ng/ml, 
4 h), 6.1 (15 μM, 30 min) and SIN-1 (15 μM, 5 min); 4a – e: MitoView Green (200 
nM, 30 min); 5a – e: LPS (1 μg/ml, 4 h), IFN-γ (50 ng/ml, 4 h), MitoView Green (200 
nM, 30 min), and 6.1 (15 μM, 30 min); 6a – e: LPS (1 μg/ml, 4 h), IFN-γ (50 ng/ml, 4 
h), MitoView Green (200 nM, 30 min), 6.1 (15 μM, 30 min),  and SIN-1 (15 μM, 5 
min). Channel (a): brightfield, channel (b): ex = 490 nm, em = 523 nm, channel (c): 
ex = 572 nm, em = 583 nm, channel (d): channel (b) and (c) combined, channel (e): 
channel (a), (b) and (c) combined. Magnification: x63. Scale bar: 10 μM. N = 3. 
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Since the organelle targeting ONOO- probe 6.1 showed poor cell permeability, the 
focus was shifted towards more soluble and cell permeable PR1 derivatives. 
 
3. Alkyne and Alkane Chain Functionalised Resorufin Probes 
3.1. Synthesis of Alkyne and Alkane Chain Functionalised ONOO- 
Fluorescent Probes 
 
A series of ONOO- probes were developed containing ester or ether groups connected 
to either an alkyne chain or alkane chain (Figure 10). It was postulated that these 
functionalities would on the one hand improve cell permeability (alkane chain to 
improve lipophilicity) or allow for the development of future theranostic systems 
(alkyne group allows for in situ click chemistry). 
 
 
Figure 10: A series of ONOO- probes incorporating alkyne and alkane chain 
functionalities: 10.1, 10.2, 10.3 and 10.4. 
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10.1 and 10.2 were easily accessible from 5.8. Coupling the relevant acyl chlorides 
11.2 (previously accessed from 11.1) and 11.3 to 5.8, yielded final target compounds 
10.1 and 10.2 in 47 % and 51% yield respectively (Scheme 11). 
 
 
Scheme 11: Synthesis of ONOO- probes 10.1 and 10.2. 
 
Ether functionalised probes were also easily accessible in a one-step synthesis from 
5.8. Nucleophilic substitution between bromide 12.1 and 12.2 respectively and alcohol 
5.8 allowed for the ether version of 10.1 and 10.2. 10.3 and 10.4 were obtained in 




Scheme 12: Synthesis of target probes 10.3 and 10.4. 
 
We were interested to evaluate how the structural variation of ester and ether groups 
with corresponding alkyne and alkane groups would impact the fluorescence ability 
of the resorufin derived probes as well as their cell permeation ability. 
 
3.2. Fluorescence Studies 
 
UV spectra confirmed the formation of resorufin as expected when probes 10.1, 10.2, 




Figure 11: UV spectra of a) probe 10.1, b) probe 10.2, c) probe 10.3 and d) probe 10.4 
with and without ONOO- (excess) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 
°C measured on a BMG Labtech CLARIOstar® plate reader. 
 
ROS selectivity studies allowed to confirm selectivity and sensitivity towards ONOO- 





Figure 12: Selectivity data for a) probe 10.1 (500 nM), b) probe 10.2 (500 nM), c) 
probe 10.3 (500 nM) and d) probe 10.4 in the presence of ONOO- (50 µM), OH· (500 
µM), O2
∙- (500 µM), 1O2 (500 µM) after 5 min. H2O2 (1 mM), ROO· (500 µM) and 
ClO- (500 µM) were measured after 30 min. The data was obtained in PBS buffer 52 
% MeOH : H2O, pH = 8.2 at 25 °C at λex = 550 (bandwith: 15) nm and max λem = 590 
nm on a BMG Labtech CLARIOstar® plate reader.  
 
In the same manner as in Section 2.2, fluorescence of the probes was evaluated over 
time with different concentrations of H2O2, followed by titration studies with H2O2. 
These were carried out for probes 10.1, 10.2, 10.3 and 10.4 (Figure 13 and Figure 14). 
Good turn-on responses were observed with H2O2. LoDs were determined as 24 μM, 




Figure 13: Fluorescence intensity changes over time for probes a) 10.1 (500 nM), b) 
10.2 (500 nM), c) 10.3 (500 nM) and d) 10.4 (500 nM) in the presence of H2O2 (0.1, 
0.2, 0.4, 0.6, 0.8, 1, 1.5, 2 mM) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. 
Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm and max 
λem = 590 nm on a BMG Labtech CLARIOstar® plate reader. 
 
 
Figure 14: Emission spectra for probes a) 10.1 (500 nM), b) 10.2 (500 nM), c) 10.3 
(500 nM) and d) 10.4 (500 nM) in the presence of H2O2 (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 
2 mM) after 1 h in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. Fluorescence 
intensities were measured with λex = 550 (bandwith: 15) nm on a BMG Labtech 
CLARIOstar® plate reader. 
75 
 
Figure 15: Dose dependence curve (I/Imax) for probes a) 10.1 (500 nM), b) 10.2 (500 
nM), c) 10.3 (500 nM) and d) 10.4 (500 nM) in the presence of H2O2 (0.1, 0.2, 0.4, 
0.6, 0.8, 1, 1.5, 2 mM) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. 
Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm and max 
λem = 590 nm on a BMG Labtech CLARIOstar® plate reader. 
 
Following H2O2 studies, 10.1, 10.2, 10.3 and 10.4’s ability to detect ONOO
- was 
evaluated. As expected, the probes show much higher sensitivity towards ONOO- 
requiring concentrations in the low micromalor range for turn-on effects. Titration 
studies (Figure 16) allowed to establish dose dependence curves (Figure 17) giving 





Figure 16: Emission spectra for probes a) 10.1 (500 nM), b) 10.2 (500 nM), c) 10.3 
(500 nM) and d) 10.4 (500 nM) in the presence of ONOO- (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
20, 30, 40, 50 μM) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. Fluorescence 
intensities were measured with λex = 550 (bandwith: 15) nm and max λem = 590 nm on 
a BMG Labtech CLARIOstar® plate reader. 
 
 
Figure 17: Dose dependence curve (I/Imax) for probes a) 10.1 (500 nM), b) 10.2 (500 
nM), c) 10.3 (500 nM) and d) 10.4 (500 nM) in the presence of ONOO- ( 1, 2, 3, 4, 5, 
6, 7, 8, 9, 10, 20, 30, 40,50 μM) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. 
Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm and max 
λem = 590 nm on a BMG Labtech CLARIOstar® plate reader. 
77 
3.3. Cell Studies 
 
In collaboration with Xiao-Peng He from ECUST, probes 10.1, 10.2, 10.3 and 10.4 
were assessed in HeLa and RAW264.7 macrophages.  
All four probes were evaluated in terms of their toxicity in murine RAW264.7 
macrophages. Using a MTS proliferation assay, probes 10.1, 10.2, 10.3 and 10.4 were 
incubated at different concentrations ranging from 5 to 40 μM for 24 h (Figure 18). 
Probes 10.1, 10.3 and 10.4 were shown to be non-toxic. Probe 10.2 decreases the 
viability of RAW264.7 macrophages by 40 % at a concentration of 40 μM. This limits 
the usage of probe 10.2 since high concentrations might be required for in vivo studies. 
 
 
Figure 18: Viability of RAW264.7 macrophages upon incubation of probes 10.1, 10.2, 
10.3 and 10.4 at different probe concentrations (0, 5, 10, 20, and 40 μM) determined 
by a MTS proliferation assay. Error bars represent s. d. (n = 3). 
 
Given the slight toxic nature of probe 10.2, a simple evaluation in RAW264.7 
macrophages allowed to show that the probe is cell permeable and can detect 
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exogenous ONOO- generated from SIN-1 (Figure 19). At this point, probe 10.2 was 
not taken for further cell studies but was shown to be cell-permeable. 
 
 
Figure 19: Fluorescence imaging of RAW264.7 macrophages with probe 10.2 (20 μM, 
30 min) without or with addition of SIN-1 (500 μM, 30 min) with probe fluorescence 
collected at ex = 520 – 550 nm and em = 580 – 650 nm. Scale bar = 100 μm. N = 3. 
Cell experiments were kindly carried out by Xiao-Peng He’s research group. 
 
Since probes 10.1, 10.3 and 10.4 were shown to be non-toxic in RAW264.7 
macrophages, these were evaluated with exogenous ONOO- (Figure 20). All three 
probes were cell permeable and increased in fluorescence with the addition of SIN-1. 
Using uric acid as a scavenger for O2
∙- generation, the fluorescent signal detected by 
all probes was sensitive to uric acid loading demonstrating a requirement of O2
∙- anion 
in the signal detected. Simultaneously, a Hoechst33342 dye was used, which stains 
the nuclei of the cell and confirms the presence of cells in each experiment. 
Furthermore, as expected, the fluorescent probes do not localise in the nuclei and 
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hence, are good tools to detect ONOO- produced by various organelles located in the 
cytoplasm. 
 
Figure 20: Confocal imaging of RAW264.7 macrophages were loaded with probes 
10.1 (20 μM, 30 min), 10.3 (20 μM, 30 min) or 10.4 (20 μM, 30 min) and treated with 
SIN-1 (500 μM, 30 min) or uric acid (100 μM, 2 h) and SIN-1 (500 μM, 30 min), as 
indicated. Probe fluorescence was collected at ex = 559 nm and em = 580 – 650 nm, 
respectively. The cell nuclei was stained by Hoechst 33342 and fluorescence collected 
at ex = 405 nm and em = 470 – 520 nm. Scale bar = 20 μm. N = 3. Cell experiments 
were kindly carried out by Xiao-Peng He’s research group. 
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Probes 10.1, 10.3 and 10.4 were also evaluated in HeLa cells with exogenous ONOO- 
generation (Figure 21). The cervical cancer cell line is a useful model system to 
evaluate fluorescent probes as it allows to simulate a scenario of high amounts of ROS 
present to kill a harmful pathogen. This means that the immune system will be under 
oxidative stress and generating vast amounts of ROS in order to fight and kill the 
cancer cells.102 Hence, exogenous ROS generation allows to simulate this scenario 
with the fluorescent probes. All three probes showed good fluorescent responses upon 
stimulation with SIN-1 of HeLa cells. Uric acid attenuated the SIN-1 mediated 
fluorescent signal of probes 10.1, 10.3, and 10.4 confirming the detection of ONOO- 
in HeLa cells. The probes showed a very low level of localisation in the nuclei as 
confirmed by the usage of the Hoechst staining probe. 
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Figure 21: Confocal imaging of HeLa cells loaded with probes 10.1 (20 μM, 30 min), 
10.3 (20 μM, 30 min) or 10.4 (20 μM, 30 min) then treated with SIN-1 (500 μM, 30 
min) or uric acid (100 μM, 2 h) and SIN-1 (500 μM, 30 min), as indicated. Probe 
fluorescence was collected at ex = 559 nm and em = 580 – 650 nm, respectively. The 
cell nuclei was stained by Hoechst33342 and fluorescence collected at ex = 405 nm 
and em = 470 – 520 nm. Scale bar = 20 μm. N = 3. Cell experiments were kindly 
carried out by Xiao-Peng He’s research group. 
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Having confirmed the ability of probes 10.1, 10.3, and 10.4 to detect exogenous 
ONOO-, these were evaluated in RAW264.7 macrophages for endogenous ONOO- 
generation. Endogenous ONOO- production allows to simulate in a more accurate way 
how the immune system would behave towards a pathogen. Exogenous ONOO- can 
give insights into permeability and how the probe will eventually behave in a real 
system. Exposing the cells under oxidative stress to increase their ONOO- production 
gives more accurate insights into the ability of the probes to detect physiological and 
pathophysiological responses. Probes 10.1, 10.3, and 10.4 successfully detected 
endogenously produced ONOO- in RAW264.7 macrophages (Figure 22). The cells 
were stimulated with LPS for 24 h which enhances indirectly O2
∙- production, a key 
precursor of ONOO-. The localisation of the probes showed little penetration into the 
nuclei as confirmed by using a Hoechst staining probe. ROS species can be generated 
by the mitochondria but also other organelles such as lysosomes. Future cell studies 
would need to focus on determining the specific localisation of the probes. This can 
be easily achieved by using relevant commercial organelle specific staining probes 
e.g. MitoTracker for the mitochondria, LysoTracker for the lysosome, and 
EndoTracker for the endoplasmic reticulum. 
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Figure 22: Confocal imaging of RAW264.7 macrophages primed with LPS (1 μg/ml, 
24 h) and then loaded with probe 10.1 (20 μM, 30 min), 10.3 (20 μM, 30 min) or 10.4 
(20 μM, 30 min) as indicated. Probe fluorescence was collected at ex = 559 nm and 
em = 580 – 650 nm, respectively. The cell nuclei was stained by Hoechst33342 and 
fluorescence collected at ex = 405 nm and em = 470 – 520 nm. Scale bar = 20 μm. N 
= 3. Cell experiments were kindly carried out by Xiao-Peng He’s research group. 
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Additionally, probe 10.1 was evaluated in A549 cells, a cancerous lung tissue cell line 
(Figure 23). The probe was able to detect exogenous ONOO-. Using various cell lines 
while simulating oxidative stress scenarios allows to validate the versatility of the 
probes. In the future, it would be also useful to assess the other probes of this series to 
validate them as useful ONOO- tools in a variety of cell lines. 
 
 
Figure 23: Confocal imaging of A549 cells were loaded with probe 10.1 (20 μM, 30 
min) without and with SIN-1 (500 μM, 30 min) as indicated. Probe fluorescence was 
collected at ex = 559 nm and em = 580 – 650 nm, respectively. The cell nuclei was 
stained by Hoechst33342 and fluorescence collected at ex = 405 nm and em = 470 – 
520 nm. Scale bar = 20 μm. N = 3. Cell experiments were kindly carried out by Xiao-
Peng He’s research group. 
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Overall, all four probes 10.1, 10.2, 10.3 and 10.4 were validated as cell permeable 
ONOO- detection tools. Some showed more promise than others in terms of their 
toxicity profile but overall all had the same applicability to detect exogenous and 
endogenous ONOO- in a range of cell lines. 
 
3.4. In vivo Studies 
 
Since probes 10.1, 10.2, 10.3 and 10.4 showed good cell permeability and were able 
to detect exogenous and endogenous ONOO-, probe 10.1 was evaluated in vivo in 
collaboration with Jingya Li from the Chinese Academy of Sciences, China. A LPS-
induced acute inflammation mouse model C57BL/6J103 was used to evaluate 10.1’s 
ability to detect endogenous ONOO- (Figure 24). As expected, the probe by itself 
shows no fluorescence even after subcutaneous injection with saline as a control 
group. Control experiments with saline and LPS alone were conducted to rule out any 
autofluorescence. Upon treatement of the mice with LPS, the probe was activated in 
the abdomindal region of the mice. A peak emission of 2.8 x 107 p s-1 cm-2 sr-1 was 
observed compared to negligible peak emission in saline treated mice (n = 3) (Figure 
24). These observations were quantified in Figure 25. The quantified fluorescence 
intensity in the probe (+) / LPS (+) group was significantly larger than that in the probe 
(+) / LPS (-) group, suggesting the potential of the probe to be used in monitoring 




Figure 24: Intraperitoneal injection of male C57BL/6J mice with probe 10.1 (200 μM) 
or saline in the absence and presence of LPS (2 mg/ml in saline) with ex = 535 nm 




Figure 25: Quantification of Figure 24 – C57BL/6J male mice treated with probe 10.1 
(200 μM) or saline in the absence and presence of LPS (2 mg/ml in saline) with ex = 
535 nm and em = 600 nm. Error bars represent s. d. with **p  0.01. N = 3.   
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4. Moving towards Theranostic Systems 
 
With these encouraging in vitro and in vivo results outlined in Section 3.3 and 3.4, I 
decided to explore the possibility of designing theranostic systems. A theranostics 
combines the terms therapy and diagnosis and aims to incorporate these two units into 
one system. One of the pioneers in this field is Jong Seung Kim who has published 
numerous examples in the literature of which two of his theranostic systems will be 
birefly reviewed. This should guide the design of my theranostic resorufin probes. 
Kim and co-workers designed a H2O2 coumarin specific probe 13.1 incorporating the 
anticancer drug SN-38 (Scheme 13).104 The coumarin unit was masked with a boronic 
ester as the sensing unit for H2O2, which would then allow to access the drug via 
cleavage at the carbonate group. The theranostic probe 13.1 was evaluated in HeLa 
cells with exogenous H2O2 and co-localisation studies showed that the probe mainly 
localises in lysosomes. The release of the drug was also studied in HeLa cells and 
showed similar activity to the drug alone. In vivo studies with mice induced with lung 
metastasis confirmed the applicability of probe 13.1 in a living system. 
 
 
Scheme 13: Theranostic probe 13.1 gives upon reaction with H2O2 fluorescent 
coumarin and anticancer drug SN-38. 
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Following the development of this system, a closely releated theranostic probe 14.1 
was prepared using rhodol as a fluorophore, the anticancer drug SN-38 and biotin as 
a targeting unit to direct the theranostic towards cancer cells (Scheme 14).105 In vitro 
studies with HeLa, A549, and NIH3T3 cells were carried out in conjunction with the 
drug release profile. In vivo studies with HeLa tumour-bearing mice were carried out 
including comparison of tumours when untreated and treated with the theranostic. The 
drug is released in vivo and results in an observed reduction in size of the tumour. 
 
 
Scheme 14: Theranostic probe 14.1 relasing the active fluorophore, and anticancer 
drug SN-38 upon reaction with thiols.  
 
These two examples using two different fluorophore systems incorporating anticancer 






4.1.  Synthesis of Theranostic Resorufin Based Systems 
 
Our aim was to synthesise two theranostic probes incorporating different drug motifs: 
chlorambucil and indomethacin (Figure 26). Chlorambucil is mainly used for chronic 
lympothatic leukemia and indomethacin as a non-steroidal anti-inflammatory drug. 
Both conditions, the drugs are respectively used for, are largely associated with 
oxidative stress and hence, an increased release of ROS species. 
 
 
Figure 26: Theranostic probes 26.1 and 26.2. 
 
Both 26.1 and 26.2 were easily accessible from 5.8 through coupling of the alcohol 
with the carboxylic acid 16.1/16.2 to create the corresponding ester (Scheme 15). 26.1 




Scheme 15: Synthesis of theranostic probes 26.1 and 26.2. 
 
26.1 and 26.2 were evaluated with mass spectrometry (MS) to assure the release of 
resorufin and more importantly the drug fragment (chlorambucil and indomethacin 
respectively) upon reaction of the probes with ONOO-. As expected, both 26.1 and 
26.2 were able to release the fluorophore and the drug, hence, validating the 




Figure 27: MS data revealed that probe 26.1 upon reaction with ONOO- releases (a) 




Figure 28: MS data revealed that probe 26.2 upon reaction with ONOO- releases (a) 
resorufin and (b) indomethacin. 
 
4.2.  Fluorescence Studies 
 
Theranostic probes 26.1 and 26.2 were initially evaluated with UV to confirm the 
formation of resorufin (Figure 29). Upon reaction with ONOO-, both 26.1 and 26.2 





Figure 29: UV spectra of a) probe 26.1 and b) probe 26.2 with and without ONOO- 
(excess) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C measured on a BMG 
Labtech CLARIOstar® plate reader. 
 
The standard fluorescence studies were carried out including ROS selectivity studies 
(Figure 30), H2O2 fluorescence intensity changes over time and titration studies 
(Figure 31 – 32) and ONOO- titration studies (Figure 33). This allowed on the one 
hand to establish LoDs – for H2O2: 17 μM for probe 26.1 and 6 μM for probe 26.2; for 
ONOO-: 5 nM for both probes 26.1 and 26.2 – and on the other hand confirm 
sensitivity and selectivity towards ONOO-. 
 
 
Figure 30: Selectivity data for a) probe 26.1 (500 nM) and b) probe 26.2 (500 nM) in 
the presence of ONOO- (50 µM), OH· (500 µM), O2
∙- (500 µM), 1O2 (500 µM) after 5 
min. H2O2 (1 mM), ROO· (500 µM) and ClO
- (500 µM) were measured after 30 min. 
The data was obtained in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C at λex = 





Figure 31: Fluorescence intensity changes over time for a) probe 26.1 (500 nM) and 
b) probe 26.2 (500 nM) in the presence of H2O2 (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 2 mM) 
in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. Fluorescence intensities were 
measured with λex = 550 (bandwith: 15) nm and max λem = 590 nm on a BMG Labtech 




Figure 32: Emission spectra and dose dependence curve (I/Imax) for a) & b) probe 26.1 
(500 nM) and c) & d) probe 26.2 (500 nM) in the presence of H2O2 (0.1, 0.2, 0.4, 0.6, 
0.8, 1, 1.5, 2 mM) after 1 h in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. 
Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm and max 




Figure 33: Emission spectra and dose dependence curve (I/Imax) for a) & b) probe 26.1 
(500 nM) and c) & d) probe 26.2 (500 nM) in the presence of ONOO- (1, 2, 3, 4, 5, 6, 
7, 8, 9, 10, 20, 30, 40, 50 μM) in PBS buffer 52 % MeOH : H2O, pH = 8.2 at 25 °C. 
Fluorescence intensities were measured with λex = 550 (bandwith: 15) nm and max 
λem = 590 nm on a BMG Labtech CLARIOstar® plate reader. 
 
4.3. Cell Studies 
 
Cell studies are currently being carried out by our collaborator Xiao-Peng He at 




I have successfully expanded the scope of PR1 based probes. In particular, the 
introduction of alkyne and alkane groups allowed us to overcome the initial cell 
permeability issues. All probes evaluated displayed excellent selectivity and 
sensitivity for ONOO- in solution. This was confirmed in vitro with the detection of 
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exogenous and endogenous ONOO- in RAW264.7 macrophages. Probe 10.1 was also 
evaluated in vivo confirming the applicability of the probe to detect the induced 
inflammatory state of the mouse. Following these positive results, two theranostic 
probes that would be able to detect ONOO- and release an inflammatory related 
disease drug were developed. The resorufin analogue series developed as part of this 
PhD constitutes a new class of resorufin functionalised probes for ONOO- detection. 
The unique tunability of the scaffold has opened up new red fluorescent probes, which 
are underexploited as demonstrated in the introduction of this chapter. 
 
6. Future Work  
 
The alkyne functionalised probes 10.1 and 10.3 allow for the exploration of in situ 
click chemistry. Test reactions have been carried out confirming the feasibility of click 
chemistry for these probes: a mitochondrial targeting group to achieve 34.1 and 34.2 
was introduced (Figure 34). This can be expanded with the introduction of other 
organelle targeting groups (for lysosome or endoplasmic reticulum) or drug molecules 




Figure 34: Proposed ONOO- probes for diagnostic and/or therapeutic applications. 
 
Additionally, the evaluation of all developed probes in vivo would help determine 
which structural motifs are the most biocompatible. Consequently, this raises the 
question whether the C57BL/6J mouse model is the most applicable one. A large 
number of commonly used mouse models for inflammation and arthritis has been 
reviewed by Webb outlining advantages and disadvantages of each.106 This could be 
taken into consideration for probe evaluation if a particular animal model is more 
suited than the C57BL/6J mouse model. The intraperitoneal injection of LPS into 
C57BL/6J mice does not necessarily accurately simulate endogenous ONOO- 
production. The next step would be to initiate the translation of the in vivo studies to 
clinical studies to enhance current efforts in fluorescence guided surgery. In a first 
instance, it would be beneficial to evaluate the probes in human macrophages which 
should allow for comparison to the murine equivalent cell line. Additionally, further 
mice experiments could focus on tumour containing mice where the inherent immune 
system should produce large amounts of ONOO-, detectable by the probes. A 
continuous evaluation of the fluorescent response over a longer time period would be 
beneficial in understanding the kinetics of the probes in vivo. 
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Chapter 3 – Targeting Different Organelles Using 




Coumarins are widely employed in a variety of applications, notably as fluorescent 
tools for the detection of biologically relevant analytes, with coumarin scaffolds 
having been used as fluorescent tools for the selective and sensitive detection of 
ROS.107 Coumarin fluorophores exhibit good photostability, large Stokes shift and 
high quantum yields, and so, a brief review of coumarin fluorescent probes that have 
been developed for ROS detection are now described. 
Lo and Chu developed a selective and sensitive H2O2 probe in 2003 that combined a 
coumarin unit and a benzyl Bpin based sensing group (Scheme 1).108 The coumarin 
unit reacts with H2O2 to afford fluorescent 7-amino-4-methylcoumarin. This probe 
works through H2O2 mediated oxidative cleavage of its arylboronate group to afford 
an unstable phenol that decomposes via elimination of a quinomethane unit and CO2 
(from the carbamate group) to afford the 7-amino-4-methylcoumarin fluorophore. 
This probe is quite a simplistic example since no ROS selectivity test was carried out 
to determine the selectivity of the probe towards H2O2 and it is likely that the boronic 
ester would show greater reactivity towards ONOO-. Nevertheless, this probe 
illustrates effectively the tunability of boronic acid containing coumarins to act as 
efficient fluorescent reporters for the detection of ROS. 
 
 
Scheme 1: H2O2 selective probe containing a 7-amino-4-methylcoumarin fluorophore. 
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Kim et al. then reported a boronic ester reaction based probe containing an 
iminocoumarin unit (Scheme 2),109 which undergoes oxidative cleavage of its 
arylboronate group when exposed to ONOO- . This results in formation of an unstable 
phenol intermediate that eliminates a quinomethane unit to generate a new phenolate 
unit that undergoes rapid cyclisation to generate a fluorescent aminocoumarin. The 
probe was able to detect endogenously produced ONOO- in J774A.1 macrophages as 
well as detect changes in ONOO- production when ROS scavengers were introduced, 
although no in vivo studies were carried out.  
Yu et al. and Yang et al developed ROS selective fluorescent probes containing  an 
iminocoumarin scaffold for ONOO- and ClO- detection respectively (Scheme 2),46, 110 
which exhibited better fluorescent properties because iminocoumarins emit at longer 
wavelengths when compared to simple coumarin scaffolds. Yu’s probe incorporated a 
pyridinium moiety to increase water solubility which could potentially also function 
as a targeting unit for the mitochondria (not demonstrated).  
 
 
Scheme 2: Iminocoumarin scaffolds containing reactive targeting groups for ROS 
based on: a) ONOO- mediated cleavage of a benzyl Bpin group (Kim et al.); b) ONOO- 
mediated cleavage of the conjugated alkene of a pyridinium unit (Yu et al.); c) ClO- 
mediated cleavage of a diaminomaleonitrile group (ICT probe by Yang et al.). 
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Imato and co-workers were interested in designing probes to detect ROS in specific 
parts of the cell and so designed a coumarin probe which could effectively detect 
hydroxyl radicals in lipid membranes.111 The design of this probe is based on an off-
on strategy. The probe reacts with hydroxyl radicals to produce a highly fluorescent 
7-hydroxy-coumarin unit (Scheme 3). Incorporation of a phospholipid moiety assured 




Scheme 3: A coumarin based probe for hydroxyl radicals that is preferentially 
localised in lipid membranes in cells. 
 
Coumarins have increasingly been used for the development of ratiometric probes, 
which have the potential to closely monitor intracellular ROS concentrations as a 
function of time (Scheme 4).112, 113 Yoon and co-workers developed a coumarin-
hemicyanine system to detect ONOO-,112 that exhibits a red emission in the absence 
of any analyte due to the presence of its extended conjugation system that results in an 
intramolecular charge transfer process. Oxidation of the probe by ONOO- results in 
cleavage of the alkene bond which in turn results in the formation of a coumarin unit 
that exhibits green emission. Stimulation of RAW264.7 macrophages with ONOO- 
resulted in this coumarin probe undergoing a shift from red to green emission in vivo.  
A slightly different strategy was employed by Zhou et al.112 who developed a 
ratiometric dual emission probe containing conjoined rhodamine and coumarin 
fragments that exhibits a green emission in its unreacted form (Scheme 4). Reaction 
with ClO– results in hydrolysis of the hydrazinyl fragment to afford separated 
rhodamine and coumarin units with the release of N2 gas. This results in rhodamine 
which gives a red emission profile and coumarin which affords a blue emission profile 
(coumarin’s emission profile has slightly shifted) enabling ratiometric determination 
of ClO– concentrations in biological environments. 
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Scheme 4: Ratiometric fluorescent probes for the detection of ROS: a) a coumarin-
hemicyanine scaffold for the detection of ONOO-, and b) a coumarin-rhodamine 
scaffold to detect ClO-.112, 113 
 
1.1. Project Aim 
 
The aim of this chapter was to synthesise a series of coumarin-based ONOO- 
molecular probes which would target different organelles, such as the mitochondria, 
the lysosome and the endoplasmic reticulum. I was particularly interested in gaining 
an understanding of ONOO- formation in different organelles, since this could provide 
information on the prevalence and importance of ONOO- in different biological 
processes. This required the attachment of organelle-specific targeting groups to the 





Figure 1: Targeting groups that have been used to localise probes in the mitochondria, 
lysosome and endoplasmic reticulum of cells.114 
 
I choose to develop coumarin probes containing an oxidatively cleavable benzyl Bpin 
group to allow for the selective and sensitive sensing of ONOO-, which contained 
specific targeting group for each organelle. This would include probes containing a 
triphenylphosphonium unit for targeting the mitochondria; a morpholine unit for 
targeting the lysosome; and a sulphanilamide unit for targeting the endoplasmic 
reticulum. (Figure 2). 
 
 
Figure 2: A series of coumarin based fluorescent probes for ONOO- detection that 
target different organelles. Key: red – ONOO- targeting group, blue – coumarin 
fluorophore, green - organelle targeting unit. 
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2. Results & Discussion 
2.1. Synthesis of Coumarin Organelle Targeting Fluorescent 
Probes for ONOO- 
 
The synthesis of Cou-Bpin 5.5 has previously been reported by Zhang115, Borbas116 
and Zhu117 (Scheme 5), and an adaptation of these protocols was used for its synthesis. 
The alcohol at position 2 of 2,4-dihydrobenzaldehyde 5.1 was selectively substituted 
using 4-(bromomethyl) benzeneboronic acid pinacol ester 5.2 to afford intermediate 
5.3 containing the desired benzyl Bpin sensing group in 49 % yield. This was followed 
by addition of Meldrum’s acid 5.4, piperidine and acetic acid in ethanol to afford Cou-
Bpin 5.5 in 55 % yield. Amide bond forming reactions were then used to functionalise 
the free carboxylic acid unit of Cou-Bpin 5.5 with different targeting units to afford 
the three organelle targeting probes 2.1, 2.2 and 2.3. 
 
 
Scheme 5: Synthetic route for the synthesis of the key intermediate Cou-Bpin 5.5. 
 
In the first instance, (4-bromobutyl) triphenylphosphonium bromide 6.1 was 
converted into its corresponding amine 6.2 via treatment with ammonia (7M solution 
in methanol), giving an excellent 76 % yield after a long reaction time of 72 h. Amine 
6.2 was subsequently used in a peptide coupling with coumarin acid 6.5 to afford Cou-




Scheme 6: Synthesis of mitochondrial targeting ONOO- probe Cou-mito 2.1. 
 
The same coupling conditions were then used to couple the commercially available 
morpholine amine 7.1 with coumarin acid 5.5 to form the lysosome targeting probe 
Cou-lys 2.2 in an unoptimized 28 % yield (Scheme 7).  
 
 
Scheme 7: Synthesis of lysosomal targeting ONOO- probe Cou-lys 2.2. 
 
The mono-tosyl-diamine 8.3 coupling partner required to prepare Cou-endo 2.3 was 
synthesised in 63 % yield through treatment of ethylenediamine 8.1 with one 
equivalent of p-toluenesulfonyl chloride 8.2, and Et3N in DCM. Finally, the 
endoplasmic reticulum based probe for ONOO- was prepared (Scheme 8). Mono-
tosyl-diamine was then coupled with coumarin acid 5.5 using HATU as a coupling 




Scheme 8: Synthesis of endoplasmic targeting ONOO- probe Cou-endo 2.3. 
 
2.2. Fluorescence Studies  
 
Initial UV studies allowed the excitation wavelengths of Cou-mito 2.1, Cou-lys 2.2 
and Cou-endo 2.3 to be determined. 7-hydroxycoumarin-3-carboxylic acid (referred 
to as Cou-acid 9.1) is a widely commercially used fluorophore with an excitation 
wavelength of ex = 342 nm (Figure 3a). Cou-mito 2.1 and Cou-endo 2.3 both showed 
maximum absorbances at 350 nm, whilst Cou-lys 2.2 had a maximum absorption at 
375 nm. Cou-Bpin 5.5 was used as a reference compound and exhibited the same UV 
behaviour as Cou-acid 9.1, with a maximal ex = 342 nm. Figure 3b – d illustrate the 
UV spectra of Cou-mito 2.1, Cou-lys 2.2 and Cou-endo 2.3 in the absence and 
presence of ONOO-, with a clear shift in the absorbance maxima observed in all three 
cases upon addition of ONOO-. Interestingly, relative to Cou-acid 9.1, a red shift was 
observed for the absorbance profiles of Cou-mito 2.1 and Cou-endo 2.3 whereas a 




Figure 3: UV spectra of: a) Cou-acid 9.1, Cou-Bpin 5.5, Cou-mito 2.1, Cou-lys 2.2 
and Cou-endo 2.3, b) Cou-mito 2.1 without and with ONOO- (excess), c) Cou-lys 2.2 
without and with ONOO- (excess), and d) Cou-endo 2.3 without and with ONOO- 
(excess) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C measured on a BMG 
Labtech CLARIOstar® plate reader. 
 
Figure 4a shows the emission spectrum of Cou-mito 2.1, Cou-lys 2.2 and Cou-endo 
2.3 without ONOO-, which gave maximum fluorescent emission values at max = 400 
nm, max = 395 nm and max = 405 nm, respectively (cf max = 447 nm for Cou-acid 
9.1 and max = 395 nm for Cou-Bpin 2.5). Addition of ONOO
- to probes 2.1, 2.2 and 
2.3 resulted in a change in their emission spectra, which resembled the emission 
spectra observed for Cou-acid 9.1 (Figure 4b). This suggests that the generated species 
must be structurally linked to Cou-acid 9.1, whose presence was confirmed by MS 
analysis. Therefore, it was postulated that addition of ONOO- to the probes results in 
oxidative cleavage of their benzyl Bpin groups to afford a phenolic intermediate whose 




Figure 4: a) Emission spectra for Cou-acid 9.1 (5 μM), Cou-Bpin 5.5 (5 μM), Cou-
mito 2.1 (5 μM), Cou-lys 2.2 (5 μM), Cou-endo 2.3 (5 μM) and b) Emission spectra 
for Cou-acid 9.1 (5 μM), Cou-Bpin 5.5 (5 μM), Cou-mito 2.1 (5 μM), Cou-lys 2.2 (5 
μM), Cou-endo 2.3 (5 μM) in the presence of ONOO- (50 μM) in PBS buffer 52 % 
MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities were measured with λex = 
340 (bandwith: 20) nm on a BMG Labtech CLARIOstar® plate reader. 
 
 
Scheme 9: Postulated mechanism upon reaction of Cou-mito 2.1, Cou-lys 2.2, Cou-
endo 2.3 with ONOO- to give Cou-acid 9.1. 
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Having established these initial findings, ROS selectivity and titration studies were 
carried out, with the aim of confirming preferential selectivity and sensitivity of Cou-
mito 2.1, Cou-lys 2.2 and Cou-endo 2.3 for ONOO- over H2O2. ROS selectivity studies 
were carried out for Cou-mito 2.1, Cou-lys 2.2 and Cou-endo 2.3 as illustrated in 
Figure 5 – 7. All three probes exhibited the same behaviour, only showing a significant 
change in their emission spectrum when exposed to the stronger oxidant ONOO-, with 
essentially no changes in the presence of H2O2, and other ROS. 
 
 
Figure 5: Selectivity data for Cou-mito 2.1 (5 μM): a) emission spectrum and b) 
relative intensity ratios (I450/I400) in the presence of ONOO
- (50 µM), OH· (500 µM), 
O2
·- (500 µM), 1O2 (500 µM) after 5 min. H2O2 (1 mM), ROO· (500 µM) and ClO
- 
(500 µM) were measured after 30 min. The data was obtained in PBS buffer 52 % 
MeOH : H2O, pH = 7.4 at 25 °C at λex = 340 (bandwith: 20) nm on a BMG Labtech 
CLARIOstar® plate reader. 
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Figure 6: Selectivity data for Cou-lys 2.2 (5 μM): a) emission spectrum and b) relative 
intensity ratio (I450/I400) in the presence of ONOO
- (50 µM), OH· (500 µM), O2
·- (500 
µM), 1O2 (500 µM) after 5 min. H2O2 (1 mM), ROO· (500 µM) and ClO
- (500 µM) 
were measured after 30 min. The data was obtained in PBS buffer 52 % MeOH : H2O, 





Figure 7: Selectivity data for Cou-endo 2.3 (5 μM): a) emission spectrum and b) 
relative intensity ratio (I450/I400) in the presence of ONOO
- (50 µM), OH· (500 µM), 
O2
·- (500 µM), 1O2 (500 µM) after 5 min. H2O2 (1 mM), ROO· (500 µM) and ClO
- 
(500 µM) were measured after 30 min. The data was obtained in PBS buffer 52 % 
MeOH : H2O, pH = 7.4 at 25 °C at λex = 340 (bandwith: 20) nm on a BMG Labtech 
CLARIOstar® plate reader. 
 
Titration studies for Cou-mito 2.1, Cou-lys 2.2 and Cou-endo 2.3 with ONOO- showed 
similar reaction profiles (Figure 8 – 10). These three probes 2.1, 2.2 and 2.3 (in the 
absence of ONOO-) exhibit emission profiles at max ≈ 400 nm, which decrease with 
increasing ONOO- concentrations with the appearance of new strong emission profiles 
at max ≈ 450 nm. Consequently, it was concluded that Cou-mito 2.1, Cou-lys 2.2, and 
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Cou-endo 2.3 could be used to sense ONOO- in a ratiometric manner. LoDs were 
determined to be 0.28 μM, 0.26 μM and 0.36 μM for 2.1, 2.2 and 2.3 respectively. 
 
 
Figure 8: a) Dose dependence curve (I450/I400) and b) Emission spectra for Cou-mito 
2.1 (5 μM) in the presence of ONOO- (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 
50 μM) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities 




Figure 9: a) Dose dependence curve (I450/I400) and b) Emission spectra for Cou-lys 2.2 
(5 μM) in the presence of ONOO- (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 
μM) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities 




Figure 10: a) Dose dependence curve (I450/I400) and b) Emission spectra for Cou-endo 
2.3 (5 μM) in the presence of ONOO- (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 
50 μM) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities 
were measured with λex = 340 (bandwith: 20) nm on a BMG Labtech CLARIOstar® 
plate reader. 
 
As the ROS selectivity studies revealed, all three probes show little sensitivity towards 
H2O2, which was confirmed through a series of H2O2 titrations (Figure 11a – c), which 
revealed that their emission at max = 400 nm only diminished slightly, with no new 
emission peaks appearing at max = 450 nm, even when very high concentrations of 
H2O2 (2 mM) were used. Therefore, it can be concluded that the oxidising strength of 
H2O2 is insufficient to oxidatively cleave the boronate ester and organelle targeting 
fragments of the probes to generate Cou-acid 9.1, thus, accounting for its selectivity 




Figure 11: Emission spectra for a) Cou-mito 2.1 (5 μM), b) Cou-lys 2.2 (5 μM), c) 
Cou-endo 2.3 (5 μM) in the presence of H2O2 (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 
1, 1.5, 2 mM) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence 
intensities were measured with λex = 340 (bandwith: 20) nm on a BMG Labtech 




2.3. Cell Studies 
 
Since Cou-mito 2.1, Cou-lys 2.2 and Cou-endo 2.3 showed great promise for 
selectively detecting ONOO- in situ over other ROS species, it was decided to study 
these organelle targeting ONOO- probes in vitro. Consequently, the three coumarin 
ONOO- sensitive probes 2.1, 2.2, and 2.3 were evaluated in RAW264.7 macrophages 
during a research stay in the group of Professor Kazuya Kikuchi at Osaka University. 
First, exogenous generation of ONOO- was used to validate whether the probes were 
cell permeable. SIN-1 was used to generate and deliver ONOO- to the cells. Cells were 
first incubated with a 100 μM solution of SIN-1 for 1 h, followed by addition of the 
relevant probes Cou-mito 2.1, Cou-lys 2.2 and Cou-endo 2.2 for 30 min at a 
concentration of 20 μM (Figure 12). Lack of fluorescent response revealed that Cou-
mito 2.1 and Cou-endo 2.3 were unable to permeate inside RAW264.7 macrophages. 
However, Cou-lys 2.2 showed decent solubility and cell permeability levels and so, 
was taken forward for further cell studies. 
 
 
Figure 12: RAW264.7 macrophages were stimulated for 1 h with SIN-1 (100 μM, 1 
h). Cou-mito 2.1 (20 μM), Cou-lys 2.2 (20 μM) and Cou-endo 2.3 (20 μM) were then 
incubated for 30 min, respectively. Blue channel: ex = 405 nm, em = 420 – 460 nm. 
Scale bar: 20 μm. Magnification x60. N = 3. 
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Next, we investigated whether Cou-lys 2.2 could be used to detect endogenous 
generation of ONOO- in RAW264.7 macrophages (Figure 13), which was produced 
by stimulating the cells with LPS (1 μg/ml) and IFN-γ (50 ng/ml) for 4 h. The cells 
were then incubated with Cou-lys 2.2 (20 μM) for 30 min, with ebselen added as a O2
∙- 
scavenger to ensure that the Cou-lys 2.2 probe can selectively detect changes in 
ONOO- production. Cou-lys 2.2 was shown to exhibit the ability to act as a probe for 
detecting endogenously produced ONOO-, with a decrease in its fluorescence 
observed when the scavenging agent was present. However, the relatively low 
intensity of the fluorescence signal suggested that Cou-lys 2.2 has some cell 
permeability issues.  
 
 
Figure 13: RAW264.7 macrophages were stimulated with LPS (1 μg/ml, 4 h) and IFN-
γ (50 ng/ml, 4 h) and where indicated treated with ebselen (50 μM, 1 h). Cou-lys 2.2 
(20 μM), was incubated for 30 min. Blue channel: ex = 405 nm, em = 420 – 460 nm. 
Scale bar: 20 μm. Magnification x60. N = 3. 
 
Lastly, I decided to evaluate the performance of Cou-lys 2.2 in RAW264.7 
macrophages upon stimulation with PMA, which induces high levels of O2
∙- (Figure 
14) and hence, activates intracellular ONOO- production in a different way to LPS and 
IFN-γ. As before with LPS and IFN-γ stimulation, the induced fluorescence signal of 
the Cou-lys probe 2.2 was relatively weak, thus confirming that the probe was not 
fully permeating into the cells. Unfortunately, the weak signal produced by Cou-lys 
2.2 generated under the various ONOO- cell stimulation conditions, meant that co-
localisation studies with LysoTracker were inconclusive.  
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Figure 14: RAW264.7 macrophages were stimulated with PMA (1 μg/ml) for 1 h. 
Cou-lys 2.2 (20 μM), was incubated for 30 min. Blue channel: ex = 405 nm, em = 
420 – 460 nm. Scale bar: 20 μm. Magnification x60. N = 3. 
 
3. Preliminary Work on a FRET Dual Analyte Probe 
 
The Cou-Bpin 5.5 unit offers great potential for functionalising its acid fragment, as 
demonstrated by previous coumarin and naphthalimide based FRET systems that have 
been used for ratiometric sensing of analytes.118-120 Ratiometric sensing allows an 
isobestic point to be identified helping to quantify analyte concentrations. It would be 
useful to construct a probe that could detect two analytes, hence, the synthesis of a 
proof of concept compound 10.6 was explored (Scheme 10). One of the amines of 
ethylenediamine 10.1 was N-Boc-protected to afford mono-protected diamine 10.2 in 
89 % yield. Subsequently, 10.2 was reacted with 4-bromo-1,8-naphthalic anhydride 
10.3 to give N-Boc-naphthalimide 10.4 in 85 % yield that was then deprotected via 
treatment with TFA to afford amino-naphthalimide 10.5 in 96 % yield. This amine 
10.5 was then coupled with Cou-Bpin 5.5 to achieve the core structure of the FRET 
probe 10.6 in 26 % yield. This precursor is designed to allow the detection of ONOO- 
(through the boronic ester unit) with its aryl bromide unit being functionalised with 
other sensing groups allowing for the simultaneous detection of a range of other 
analytes.   
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Scheme 10: Synthesis of an advanced FRET sensing precursor 10.6. 
 
Some preliminary analytical data was collected for the sensing precursor 10.6, whose 
UV spectrum and ONOO- titration data are reported in Figure 15 and Figure 16, 
respectively. As expected, the coumarin fragment of the probe was found to be 
fluorescent (λem = 400 nm) which shifted its emission profile to λem = 450 nm upon 
addition of ONOO-, as expected for formation of the 7-hydroxycoumarin-3-carboxylic 
acid cleavage product. As anticipated, no FRET response (around max ≈ 550 nm) was 
observed because the naphthalimide unit is not activated for this type of emission 





Figure 15: UV spectrum of probe 10.6 without and with ONOO- (excess) in PBS buffer 




Figure 16: a) Dose dependence curve (I450/I400) and b) emission spectrum of 10.6 (5 
μM) in the presence of ONOO- (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 μM) 
in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities were 





To conclude, a series of organelle targeting ONOO- probes has been successfully 
synthesized, with each probe designed to target a different organelle (mitochondria, 
lysosome, and endoplasmic reticulum) to allow for the selective and sensitive 
detection of ONOO- in cellular systems. The ratiometric fluorescent response of all 
three probes made them interesting candidates for in vitro studies. Cell studies with 
RAW264.7 macrophages revealed poor cell permeability of Cou-mito 2.1 and Cou-
endo 2.3. However, Cou-lys 2.2 was able to detect exogenously and endogenously 
produced ONOO- in RAW264.7 macrophages. The strength of the fluorescence signal 
of Cou-lys 2.2 was relatively weak, which indicated that further synthetic 
modifications are required to the scaffold to increase its permeability to allow for co-
localisation studies. Still, the development of 2.1, 2.2 and 2.3 allowed to introduce a 
new series of ratiometric probes with potential for organelle targeting. These initial 
findings led to the preliminary work on a FRET probe 10.6 which has potential for the 
development of dual analyte FRET probes and orgnalle targeting motifs.  
 
5. Future Work 
 
Future work will now focus on converting the bromine of the naphthalimide unit of 
the FRET probe with relevant sensing groups to demonstrate the potential of the FRET 
design strategy for sensing different types of bioanalytes (Figure 17). FRET probe 
11.1 allows the targeting of ONOO- and β-glucosidase (β-glc). The introduced glucose 
unit at the naphthalimide would be enzymatically cleaved by β-glc, giving the free 
phenol. Probe 11.2 allows for the simultaneous detection of ONOO- and H2S. Azides 
are excellent sensing groups for H2S since they are reduced to amines by H2S, 
consequently, activating the naphthalimide unit. Studying the interplay between 
ONOO- and H2S should allow for a more in depth understanding of redox homeostasis 
in cells. Finally, probe 11.3 could be used as a dual analyte FRET theranostics probe. 
11.3 is activated by ONOO- and thiols in which the latter cleaves the disulfide bond 
allowing for the release of chlorambucil and activation of the FRET probe. 
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Figure 17: Probe 10.6 can be easily functionalised at the Br of naphthalimide allowing 
for the development of dual analyte FRET probes sensing ONOO- and β-glc (11.1), 
ONOO- and H2S (11.2) and ONOO

















Chapter 4 – Targeting Organelles with Specific 
Fluorophores: Fluorescein, Rhodamine and Rhodol 
 
1.  Introduction 
 
Fluorescein, rhodamine 110 and rhodol are structurally highly similar fluorophores 
with the same tetracyclic core structure, only differing by the attachment of alcohol 
and amine groups (Figure 1). Functionalisation of these commonly used fluorophores 
is possible: at the alcohol or amine positions respectively as well as the phthalic 
anhydride moiety. This has led to the development of commercially available probes 
based on these fluorophores which are essential tools in biological research. Prominent 
examples include FITC (fluorescein isothiocyanate) or TRITC 
(tetramethylrhodamine), which can also be easily conjugated to antibodies and 
proteins, particularly useful for highly specific imaging applications. 
 
 
Figure 1: Core structures of fluorescein, rhodamine 110 and rhodol. 
 
Each fluorophore offers different advantages in terms of potential clinical usage as 
well as targeting of different organelles. In the following, examples from the literature 
of ONOO- or other ROS species specific fluorescent probes will be discussed. 
Fluorescein in contrast to rhodamine and rhodol is one of the few U.S. Food and Drug 
Administration (FDA) approved fluorophores, making it particularly attractive for 
clinical applications. Chang and co-workers have developed a range of boronate 
probes using fluorescein (and rhodol) scaffolds (Figure 2).45, 121-124 All boronate based 
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probes were developed for the detection of H2O2 whereas these could also show great 
promise for ONOO- sensing due to their inherent reactivity with boronic esters.  
In 2004, a water soluble turn-on optical probe 2.1 was developed, which was able to 
detect changes of intracellular H2O2 within living mammalian cells.
122 Fluorescent 
probe 2.4 was able to detect endogenous intracellular H2O2 generated by EGF/Nox 
activation as well as detecting H2O2 in live hippocampal neurons.
123 Following this, 
2.8 was developed for imaging mitochondrial H2O2 in HeLa cells.
124 Elevated levels 
of H2O2 were detected, originating from an oxidative stress system associated with 
Parkinson’s disease. These examples and many more from the Chang group illustrate 
the effectiveness of detection and monitoring of H2O2 in different oxidative stress 
conditions associated with cancer and other diseases.121 Synthetic modification of 
these scaffolds allows for selectivity and specific reactivity. 
 
 
Figure 2: Boronate based probes with fluorescein or rhodol scaffolds for the 
detection of H2O2. 
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Another interesting series of ONOO- probes based on fluorescein, rhodamine or rhodol 
scaffolds was developed by Yang and co-workers: HKGreen fluorescent probes 
(Figure 3). The initial focus centred upon the development of green fluorescent probes 
which later on moved towards yellow fluorescent probes. The first probe HKGreen-1 
3.1 based on a fluorescein scaffold incorporated an anisol derived ketone unit.125 The 
group previously showed that ONOO- reacts with activated ketones to form 
dioxiranes.126 This motif enhances preferential detection of ONOO- as demonstrated 
by fluorescence studies. Nevertheless, considerable amounts of other ROS were also 
detected, which could pose selectivity issues for in vivo studies. In vitro studies with 
primary cultured neuronal cells confirmed the initial concerns: HKGreen-1 detects 
ONOO- but the reaction between the two is fairly poor. 
The next generation of HKGreen replaced the fluorescein with a BODIPY scaffold 
and employed a PET mechanism.62 High sensitivity and selectivity towards ONOO- 
over other ROS was more substantial with HKGreen-2 3.2 compared to HKGreen-1 
3.1. In vitro studies with J774.2 macrophages showed enhanced localisation of the 
probe in the mitochondria. ONOO- generation in cells was achieved via stimulation 
with LPS, IFN-y and PMA. 
HKGreen-3 incorporated a different fluorescent scaffold compared to the last two 
generations: rhodol. Upon reaction of the trifluoromethyl ketone with ONOO-, 
subsequent N-dearylation generates the fluorescent moiety.127 Fluorescence studies 
indicated preferential sensing of ONOO-. However, as in HKGreen-1 3.1, significant 
amounts of other ROS such as OH∙ and ClO- were also detected. HKGreen-3 3.3 was 
changed to 3.4 in order to improve cell membrane permeability. In vitro studies with 
RAW264.7 and J774.2 macrophages confirmed intracellular ONOO- detection with 
3.4. No apparent cytotoxicity of 3.4 was displayed in the MTT assay, enhancing the 
probe’s suitability for in vivo studies. 
The rhodol scaffold was used for the development of the fourth generation of probes 
by the Yang group. The five synthesised probes 3.5 – 3.9 include phenol and aniline 
moieties. These were designed with the strong oxidising ability of ONOO- in mind to 
generate, via oxidative N-dearylation, the fluorescent N-methylrhodol. Yang et al. also 
suggested that the nitrogen atom linking towards the phenyl ring increases electron 
density of the phenyl and hence, facilitates increased reactivity towards ONOO-.128 
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Fluorescence studies of 3.5 – 3.9 showed that 3.6 is highly selective towards ONOO- 
whereas the other scaffolds show preferential detection of ClO-. High selectivity 
towards ONOO- over ClO- is required since the analytes could easily interfere in 
cellular processes and consequently, produce false results. The acetate derivative of 
3.6 was taken forward for RAW264.7 macropgaes studies since the acetate favours 
cell membrane permeability. 3.6 in conjunction with MitoTrackerRed confirmed the 
probe’s ability to detect mitochondrial produced ONOO-. In vivo studies with live 
tissues from a mouse model of atherosclerosis provided significant evidence for 
linking high ONOO- production with the atherosclerotic condition. The apolipoprotein 
E knockout mouse model readily develops atherosclerosis. The mice were fed on a 
normal diet for 20 weeks prior to investigation of the probe on the mouse’s heart. In 
comparison to the wild type mice, a two-fold increase in fluorescent intensity of the 
probe was observed at the smooth muscle of the aortic root of the apolipoprotein E 
knockout mouse. 
Following the investigation of multiple green fluorescent probes, the focus was shifted 
towards yellow and red fluorescent probes.129 These are more desirable for biological 
applications since probes in the yellow and red region show low intracellular auto-
fluorescence, deeper tissue penetration, low photo-induced damage and are more 
compatible for multicolour imaging.130 HKYellow 3.10 incorporated previous 
developed synthetic strategies: acetate moiety for cell membrane permeability and a 
phenol scaffold for targeted ONOO- sensing. The yellow fluorescent dye based on a 
rhodamine scaffold detected exogenously and endogenously produced ONOO- in SH-
SY5Y human neuroblastoma cells. In vivo studies on mouse livers with endogenous 
ONOO- stimulation showed that HKYellow 3.10 is a promising molecular imaging 




Figure 3: Different generations of ONOO- probes: HKGreen 1 – 4 and HKYellow. 
 
Yu and co-workers have developed various mitochondrial targeting probes for ClO- 
based on a rhodamine scaffold. In a first instance, rhodamine based probes 4.1 and 4.2 
with two different mitochondrial targeting units (TPP and pyridinium units) were 
successfully synthesised (Figure 4).101 The mitochondrial targeting units as well as the 
rhodamine scaffold enhance the lipophilicity of the probe which facilitates passage 
into the mitochondria. 4.1 and 4.2 are selective and sensitive towards ClO-: 
fluorescence intensity of both remained constant once the probes reacted with ClO-. 
In vivo studies with a nude mouse model successfully detected the exogenous ClO-, 
which was added in the form of NaOCl. The nude mouse model is particularly 
applicable since the mouse has been genetically modified in a way that fewer T cells 
are produced resulting in an inhibited immune system. 
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Based on this initial scaffold, 4.1 and 4.2 were extended by a coumarin unit that would 
allow for ratiometric detection of ClO-. 4.3 and 4.4 were successfully used for exo- 
and endogenous ClO- detection in RAW264.7 macrophages and HEK293 cells. 
Interestingly, 4.3 showed better cell membrane penetration since the TPP unit 
increased lipophilicity more substantially compared to the pyridinium one.131  
Due to the lipophilic nature of 4.3, the probe was taken forward for additional tumour 
specific targeting through a biotin unit. Probe 4.5 showed excellent cell membrane and 
mitochondria permeability. Cell studies with RAW264.7 macrophages, HEK293, and 
HeLa cells validated endogenous and exogenous ClO- detection as well as its tumour 
specificity due to the choice of cell lines investigated.132 Yu et al. claim to have 
synthesised the first mitochondrial targeted and tumour specific probe. Further in vitro 
and in vivo studies are required to fully validate the initial results. 
 
 
Figure 4: Yu et al. developed three generations of ClO- probes. In a first instance, a 
rhodamine (red) based scaffold with mitochondrial targeting units 1) TPP (blue) 4.1 
and 2) pyridinium (blue) 4.2 was prepared. Following on from the promising animal 
studies, the scaffold was extended by a coumarin unit (green) to give ratiometric ClO- 
probes 4.3 and 4.4. The highly lipophilic TPP probe 4.3 was further extended towards 
tumor targeting with the introduction of a biotin unit (orange) to give probe 4.5. 
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In addition to the introduction of organelle specific targeting groups, rhodamine and 
rhodol scaffolds are also used solely for targeting the mitochondria133 and endoplasmic 
reticulum134 respectively. 
Guo and co-workers introduced a methyl(4-hydroxyphenyl)amino group into the 
rhodamine scaffold, allowing them to specifically target ONOO- in the mitochondria 
through the combination of these two structural motifs (Scheme 1).49 In vitro studies 
with RAW264.7 macrophages allowed validation of the probe’s ability to detect 
exogenous and endogenous ONOO-. To confirm the localisation of the rhodamine 
probe in the mitochondria in BIU-87 cells, MitoTracker Red was used to compare its 
overlap with the probe. Pearson’s coefficient was 0.86 confirming an excellent overlap 
of both probes. Additionally, LysoTracker and ERTracker were used to examine 
lysosome and endoplasmic reticulum localisation. As expected, the probe solely 
localised in the mitochondria. 
 
 
Scheme 1: A mitochondria targeted rhodamine probe for ONOO-. 
 
Yoon et al. developed a ONOO- selective near-infrared (NIR) probe (Scheme 2).135 
They decided to extend rhodamine’s tricyclic core structure to create a semi-
naphthalene rhodamine core and incorporate hydrazine as an ONOO- sensing group in 
order to achieve a mitochondrial NIR probe for the detection of ONOO-. Selective and 
sensitive detection of ONOO- was achieved in situ, in vitro and ex vivo. Initially, 
exogenous ONOO- was evaluated in HeLa cells, followed by endogenous ONOO- in 
RAW264.7 macrophages and mouse bone marrow-derived neutrophils from a PAO1 
infested mouse model. They also compared the mice with a NOX2 deficient mouse 
model to ensure that ONOO- production is caused by the primary neutrophils in the 
wild type mice and that the probe is able to detect these changes under biological 
conditions. Additional in vitro studies could have centered on the specific localisation 
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of the probe in organelles. One would assume for the probe to localise in the 
mitochondria due to the rhodamine related core structure. 
 
 
Scheme 2: A NIR probe to detect endogenous ONOO-. 
 
Similarly, Zhu and co-workers developed a highly similar probe to Yoon et al. but 
with the ability to localise in the mitochondria (Scheme 3).136 The development of NIR 
probes allows for the minimisation of photo-damage to biological samples and 
achieves deeper tissue penetration. In vitro studies with MitoTracker allowed to 
confirm the localisation of the NIR probe in the mitochondria. Despite these positive 
results, the authors failed to evaluate endogenous ONOO-. HeLa cells are used with 
SIN-1 accounting only for the evaluation of exogenous ONOO-. 
 
 
Scheme 3: A NIR probe for ONOO- localising in the mitochondria. 
 
Peterson et al. used rhodol’s inherent ability to localise in the endoplasmic reticulum 
to develop a series of probes for selective and sensitive ONOO- detection.137 Their 
most promising candidate (Scheme 4) was taken forward for in vitro studies with 
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RAW264.7 macrophages. Interestingly, the group employed a different approach to 
stimulate RAW264.7 macrophages to produce endogenous ONOO- compared to 
standard procedures where LPS and IFN-γ are used. DNP-modified amino tentagel 
beads bound to anti-DNP IgG were used to stimulate phagocytosis resulting in the 
production of ONOO-. Essentially the bead bound antibodies are recognised by Fc 
receptors which then are engulfed by receptor mediated phagocytosis triggering the 
production of cellular ONOO-. The rhodol probe was able to detect endogenous 




Scheme 4: An ONOO- sensitive and selective rhodol based fluorescent probe 
localising in the endoplasmic reticulum. 
 
In summary, fluorescein, rhodamine and rhodol fluorophores have all been used in the 
development of ROS probes. Using rhodamine or rhodol as the core structure allows 
for targeted localisation of the probe in the mitochondria or the endoplasmic reticulum 
respectively. Studying ROS production in organelles allows for more accurate studies 
of ROS diffusion and its implications in physiological processes. While organelle 
targeted probes might be more useful for imaging applications, they can still be 
valuable tools for clinical studies. 
 
1.1. Project Aim 
 
The aim of this chapter was to synthesise a small series of ONOO- probes 
incorporating a benzyl boronate unit as a sensing unit. Hereby, this unit was introduced 
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into fluorescein, rhodamine and rhodol with the aim to develop targeted organelle 
probes. Upon reaction of 5.1, 5.2 and 5.3 with ONOO-, the benzyl Bpin unit is cleaved 
giving the respective fluorescent fluorophores (Scheme 5). 
 
 
Scheme 5: A series of ONOO- probes based on fluorescein, rhodamine and rhodol. 
 
2.  Results & Discussion 
2.1. Synthesis of a Series of ONOO- Fluorescent Probes  
 
Fluorescein based probe 5.1 has previously been synthesised by Cohen et al. validating 
it as a H2O2 probe.
138 However, due to the inherent nature of boronic esters, it seemed 
to be an excellent opportunity to study its ability to detect ONOO-. The bis(benzyl 
boronic ester) moiety has previously been used in the literature as a scaffold to mask 
fluorophores. Additionally, a further literature search revealed that Strongin et al. 
designed a highly similar probe to 5.2 for saccharide sensing (Figure 5).139, 140 Hence, 
targets 5.1, 5.2 and 5.3 should be synthetically achievable. 
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Figure 5: A rhodamine based probe for saccharide sensing. 
 
Target probe 5.1 was synthetically easily accessible as previously reported.138 Briefly, 
fluorescein 6.1 was substituted with 4-bromomethylphenylboronic acid pinacol ester 
6.2 to give 5.1 in 30 % yield (Scheme 6). 
 
 
Scheme 6: Synthesis of fluorescein based probe 5.1. 
 
Next, the synthesis of rhodamine based probe 5.2 was accessed (Scheme 7). 
Rhodamine 110 is commercially available but 1g of rhodamine 110 costs £263 on 
Sigma Aldrich. Hence, in contrast to fluorescein, the core structure of the fluorophore 
had to be developed. Rhodamine 110 7.3 was achieved in 35 % yield by refluxing 3-
aminophenol 7.1 and phthalic anhydride 7.2 in methanesulfonic acid. This was 
followed by a reductive amination with 7.5 which was previously synthesised from 4-
bromobenzaldehyde 7.4 via a Miyaura borylation. This gave 5.2 in 27 % yield. 
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Scheme 7: Synthesis of rhodamine based probe 5.2. 
 
Similarly, rhodol based probe 5.3 was accessed. 3-aminophenol 7.1, resorcinol 8.1 and 
phthalic anhydride 7.2 were refluxed in methanesulfonic acid. This gave rhodol 8.2 in 
33 % yield. Target probe 5.3 was successfully achieved in 33 % from rhodol 8.2 and 
4-bromomethylphenylboronic acid pinacol ester 6.2 (Scheme 8). 
 
 
Scheme 8: Synthesis of rhodol based probe 5.3. 
 
It was postulated that all three probe 5.1, 5.2, 5.3 upon reaction with ONOO- will be 
activated in the same fashion as outlined in Scheme 9. The benzyl Bpin moieties are 




Scheme 9: Probe 5.1, 5.2 and 5.3 reacting with ONOO- to generate fluorescent 
fluorescein, rhodamine and rhodol respectively. 
 
2.2. Fluorescence Studies 
 
Prior to fluorescence studies, initial UV spectra were recorded to observe changes in 
absorbance of the masked fluorescein 5.1, rhodamine 5.2 and rhodol 5.3 alone and 
upon addition of ONOO- (Figure 6). Maximum absorption peaks at  = 493, 510, 495 
nm for 5.1, 5.2 and 5.3 with ONOO- respectively were observed which mostly 
correlate with known absorption maxima of these fluorophores. Additionally, the 




Figure 6: UV spectra of probes a) 5.1, b) 5.2 and c) 5.3 without and with ONOO- 
(excess) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C measured on a BMG 
Labtech CLARIOstar® plate reader. 
 
First, a ROS selectivity study was carried out for each probe to validate its selectivity 
towards ONOO- over other ROS (Figure 7). Probes 5.1, 5.2 and 5.3 preferentially 
detected ONOO- over a range of other ROS which were used at maximum biological 




Figure 7: Selectivity data for probes a) 5.1 (500 nM), b) 5.2 (1 μM), and c) 5.3 (500 
nM) in the presence of ONOO- (50 µM), OH· (500 µM), O2
∙- (500 µM), 1O2 (500 µM) 
after 5 min. H2O2 (1 mM), ROO· (500 µM) and ClO
- (500 µM) were measured after 
30 min. The data was obtained in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C at 
λex = 475 (bandwith: 10) nm and max λem = 515 nm on a BMG Labtech CLARIOstar® 
plate reader. 
 
5.1, 5.2 and 5.3 were initially evaluated with H2O2 by evaluating the change of 
fluorescence intensity over time (Figure 8). Hereby, it was noticed that all three probes 




Figure 8: Fluorescence intensity changes over time for probes a) 5.1 (500 nM), b) 5.2 
(500 nM) and c) 5.3 (500 nM) in the presence of H2O2 (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 2 
mM) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities 
were measured with λex = 475 (bandwith: 10) nm and max λem = 515 nm on a BMG 
Labtech CLARIOstar® plate reader. 
 
Fluorescence titrations with H2O2 were carried out for 5.1, 5.2 and 5.3 (Figure 9) with 
LoDs identified to be 6.5 μM, 103.7 μM, 126.3 μM respectively. Both 5.2 and 5.3 
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Figure 9: Emission spectra and dose dependence curve (I/Imax) a) 5.1 (500 nM), b) 5.2 
(1 μM) and c) 5.3 (500 nM) in the presence of H2O2 (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, 2 
mM) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities 
were measured with λex = 475 (bandwith: 10) nm and max λem = 515 nm on a BMG 
Labtech CLARIOstar® plate reader. 
 
Following on from these results, ONOO- titrations confirmed better sensitivity 
towards ONOO- over H2O2 for all probes (Figure 10). Lower concentrations compared 
to H2O2 were used to achieve good turn-on responses for 5.1 and 5.3. 5.2 required 
similar concentrations to H2O2 which might limit its ability to detect ONOO
- in vitro. 
LoDs were determined: 0.89 μM, 27 μM and 0.49 μM for 5.1, 5.2 and 5.3 respectively. 
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Figure 10: Emission spectra and dose dependence curve (I/Imax) for a) 5.1 (500 nM), 
and c) 5.3 (500 nM) in the presence of ONOO- (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50 
μM) and b) 5.2 (1 μM) in the presence of ONOO- (0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 
1 mM) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities 
were measured with λex = 475 (bandwith: 10) nm and max λem = 515 nm on a BMG 
Labtech CLARIOstar® plate reader. 
 
2.3. Cell Studies 
 
All three probes 5.1, 5.2 and 5.3 were evaluated in collaboration with the research 
group of Juyoung Yoon at Ewha Woman’s University in Seoul, Korea. As an initial 
starting point, probes 5.1, 5.2, and 5.3 were tested in HeLa cells for their ability to 
detect exogenously generated ONOO- inside cells. HeLa cells were stimulated with 
exogenous ONOO- for 20 min followed by incubation of the probe for 20 min. 
Confocal imaging revealed that 5.1, 5.2 and 5.3 are all cell permeable (Figure 11). 
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However, in the absence of ONOO-, all three probes show significant background 
fluorescence. Upon addition of ONOO- (50 or 100 μM), the intensity of the 
fluorescence signal seems to stay the same when the probes 5.1, 5.2 and 5.3 are 
incubated alone. This suggests that probes 5.1, 5.2 and 5.3 might quickly decompose 
to fluorescein, rhodamine and rhodol respectively with the benzyl Bpin groups being 
labile enough in vitro prior to the presence of ONOO-. Hence, no further cell studies 
were undertaken. Looking back to the cell studies carried out by Cohen et al. on 5.1141, 
a similar behaviour was observed when the probe was incubated alone compared to 
the presence of H2O2. The group looked into the mean fluorescence and was able to 
show a statistical significant difference in the fluorescence output. While this is not 
ideal, this could be looked into with all three probes 5.1, 5.2 and 5.3 when exposed to 
ONOO-. Nevertheless, further synthetic modifications are required to allow 5.1, 5.2 





Figure 11: HeLa cells were stimulated with ONOO- (50 or 100 μM) for 20 min. Probe 
5.1 (200 nM), 5.2 (500 nM) or 5.3 (500 nM) was incubated for 20 min. Green channel: 
ex = 473 nm, em = 490 – 590 nm. Scale bar: 20 μm. Magnification x60. N = 3. Cell 




We have successfully synthesised three ONOO- sensitive and selective probes based 
on different fluorophores: fluorescein for 5.1, rhodamine for 5.2 and rhodol for 5.3. 
While ROS selectivity studies revealed preferential detection of ONOO- for 5.1, 5.2, 
and 5.3, it also showed that all three probes 5.1, 5.2, 5.3 exhibit some inherent 
fluorescence by themselves. Nevertheless, good turn-on responses were observed with 
both H2O2 and ONOO
- titration studies, confirming the applicability of these probes. 
Cell studies with HeLa cells revealed that 5.1, 5.2 and 5.3 showed inherent 
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fluorescence and no change in fluorescence signal upon the addition of ONOO- was 
observed. 
 
4. Future Work 
 
Despite probes 5.1, 5.2 and 5.3 being inherently fluorescent in cells, further synthetic 
modifications could overcome this issue. To support the targeting aspect of 5.1, 5.2 
and 5.3, additional relevant organelle targeting groups could be introduced into the 
scaffold (Figure 12). 
 
 
Figure 12: Enhanced targeting motifs incorporated into fluorescein, rhodamine and 
rhodol scaffolds. 
 
The development of dual analyte sensing probes (ONOO- and esterase or other 
enzymatic triggers) or theranostic probes (Figure 13) could also offer further insights 
in cellular processes as well as combine diagnosis with therapy in an effort to move 




Figure 13: Suggested probes for theranostics applications. 
 
If the benzyl Bpin structural motif and the additional synthetic modification will not 
suppress the fluorescence, another strategy could be to use already developed dual 
analyte probes in the James group142, 143 and integrate the organelle targeting motifs 
(Figure 14). The tunability of the fluorophore scaffolds should allow to identify new 
organelle targeting probes for dual analyte detection. 
 
 
Figure 14: Dual analyte probes for a) H2O2 and β-glucosidase
143 and b) ONOO- and 





Chapter 5 – A Rhodamine Based Probe for the Selective 




Glutathione (GSH) serves as an antioxidant, hence, playing a key role in oxidative 
stress. As the most abundant thiol based compound in cells, it is key to a variety of 
cellular functions. The interconversion of GSH to its oxidised form GSSG is the basis 
for some key metabolic processes (Scheme 1): GSSG is involved in protein 
modification and consequently, signal transduction.144 
 
 
Scheme 1: Simplified diagram of the interconversion of GSH and GSSG. 
 
Abnormal levels of GSH have been linked to cancer, liver and lung damage as well as 
Parkinson’s disease.145 Hence, the development of fluorescent probes would benefit 
understanding GSH’s involvement in disease progression.146 Yoon and co-workers 
have reviewed the main strategies for reaction based fluorescent probes for GSH147, 
which include but are not limited to (Scheme 2): 
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a. Cleavage of sulphonamide, sulfonate ester, and related functional groups 
b. Se–N bond cleavage 
c. Aryl substitution reactions 
d. Disulfide bond cleavage and cyclization 
e. Michael addition  
 
 
Scheme 2: Reaction based strategies for probes detecting GSH: black – non 
fluorescent, red or green: fluorescent. 
 
Herein, an overview of the current literature for GSH probes will be discussed, which 
include some the above mentioned strategies. 
Huang et al. developed a rhodamine based probe for GSH detection with a fast 
detection response that accumulated selectively in the lysosome, allowing it to be used 
over a wide range of pH values (Scheme 3).148 Their sensing strategy is based on 
Michael addition of the nucleophilic thiol unit of GSH to the ,-unsaturated alkene 
fragment of the probe. After Michael addition, formation of an H-bond between the 
rhodamine carbonyl and the N-H group of GSH promotes hydrolysis and ring opening 
of the spirocyclic amide bond to give rhodamine B, which is a well-known and studied 
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fluorophore. Fluorescence studies were performed on a range of amino acids, which 
showed preferential selectivity for detection of GSH. However, the authors failed to 
also perform a RSS and ROS selectivity test to show that no reactivity would occur 
with H2S or other strong oxidants. The probe accumulated selectively in the lysosomes 
of HeLa cells.149, 150  
 
 
Scheme 3: A rhodamine based probe 3.1 for GSH detection in lysosomes. 
 
Wu and co-workers also developed a rhodamine B based system for GSH detection 
based on Michael addition of the thiol unit of GSH to a maleimide moiety, which 
results in ring opening to afford a fluorescent rhodamine B structure 4.2 (Scheme 
4).151-153 Fluorescence studies against other amino acids confirmed its selectivity and 
sensitivity for GSH, although RSS and ROS selectivity tests were not carried out. Cell 
studies in HepG2 and HUVEC cells demonstrated that probe 4.1 could be used for in 
vitro detection of GSH.  
 
 
Scheme 4: Rhodamine B based scaffold with maleimide moieties 4.1 for GSH sensing. 
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Although selective detection of GSH is important, probes for the simultaneous 
detection of multiple biological thiol species (cysteine, homocysteine or H2S) have 
also been developed. Many of these probes employ a dual or tri-channel sensing 
system, whereby reaction with a thiol analyte results in the fluorophore emitting at a 
different emission wavelength. Chen et al. developed a coumarin fluorescent probe 
5.1 that emits at different wavelengths, depending on whether it reacts with GSH or 
H2Sn (Scheme 5).
154 The phenylselenide moiety of the probe is substituted by the thiol 
group of GSH through a SNAr substitution reaction to afford product 5.2 that emits 
green fluorescence. Reaction with H2Sn also results in a SNAr substitution followed by 
intramolecular cyclisation of the second thiol unit to afford an ester group, which 
results in the formation of non-fluorescent 5.4 and the blue fluorescent 5.3. Therefore, 
access to two distinct emission channels enables probe 5.1 to be used for the selective 




Scheme 5: A coumarin based probe 5.1 which can discriminate between GSH and 




In the same manner, Churchill and co-workers have developed two doubly activated 
dual emission fluorescent probes for GSH and cysteine/homocysteine (Scheme 6).155 
The phenylselenium group quenches the fluorescence of the probe due to 
photoinduced electron transfer with the ethyl butanoate group, introduced to improve 
water solubility. The amino group of the GSH undergoes intramolecular reaction with 
the aldehyde group of probes 6.1/6.2 to afford a cyclic iminium species, with the thiol 
unit of the GSH fragment undergoing SNAr displacement of the phenylselenium group 
to give a functionalised probe that exhibits red fluorescence.156 Alternatively, the 
amino and thiol groups of cysteine/homocysteine react with the aldehyde group of the 
probe to afford a 5-membered oxazoline ring, with the amino group of a second 
molecule of cysteine/homocysteine then undergoing an SNAr reaction of the SePh 
group to give a green fluorescent probe. The tandem reaction of S,N substitution-
rearrangement in the case of cysteine/homocysteine in contrast to GSH allows for the 
selective discrimination of the two species. This strategy allows to evaluate different 
thiols with the same probe within different flourescence channels, an effective tool 
used throughout literature.157-160 Both probes 6.1 and 6.2 showed good turn on 
response for GSH and cysteine in solution based studies, affording selective emission 
at two different wavelengths. However, cell studies with A549 cells revealed that 6.2 
showed better turn-on response for GSH when compared to 6.1, whose red 
fluorescence signal output was weak. Hence, only 6.2 was taken forward for further 
in vivo studies, with 6.2 shown to be capable of detecting high levels of GSH in A549 
tumour bearing nude mice. The fluorescence signal of 6.2 in tumour mice was higher 




Scheme 6: Coumarin-based fluorescent probes 6.1 and 6.2 for the simultaneous 
detection of GSH and cysteine/homocysteine exhibit two distinct emission signals: red 
and green fluorescence. 
 
Zhang et al. have designed a lysosome targeted fluorescent probe 7.1, which can 
simultaneously detect H2S, cysteine/homocysteine and GSH.
161 This probe 
incorporates two fluorophores (resorufin and coumarin) and a morpholine unit for 
lysosome targeting. The main site of reaction for all three species is the phenolic ether 
linkage connecting the two fluorophores. Scheme 7 shows the different fluorophore 
species postulated to form, when the probe reacts with H2S, cysteine/homocysteine or 
GSH. Upon reaction with H2S, resorufin is released which emits a red signal, whereas 
the displaced thio-coumarin derivative is non fluorescent. When 7.1 reacts with 
cysteine/homocysteine, resorufin is generated along with a new aza-coumarin (via 
rearrangement of the thio-coumarin intermediate) derivative. This results in the 
generation of red and blue fluorescent signals. Finally, the use of GSH results in a red 
and green fluorescence signal being produced, which are attributed to the formation 
of resorufin and a GSH-coumarin adduct, respectively. Probe 7.1 was shown to exhibit 
distinct signal patterns in HeLa cells: red for H2S, blue-red for cysteine/homocysteine 
and green-red for GSH. This enabled discrimination of lysosomal H2S, 
cysteine/homocysteine and GSH within the cells, with N-ethylmaleimide used as a 




Scheme 7: Proposed mechanisms for the reaction of probe 7.1 with H2S, 
cysteine/homocysteine and GSH. 
 
1.1. Project Aim 
 
The focused literature review reveals the development of selective and sensitive 
fluorescent probes for GSH, with more recent attention directed towards sensing two 
biothiols that are present at the same time. These probes have the potential to 
discriminate between multiple biothiols in the same biological environment and can 
be used as tools to probe their role in biological pathways. Hence, the development of 
a dual fluorescent probe that can discriminate between GSH and other biothiols (H2S, 
cysteine etc.) at the same time was the broader aim of this project. This led in the first 
instance towards the validation of sensing a single biothiol: GSH. 
 
2. Results & Discussion 
 
First, azidorhodamine 8.4 was evaluated as a probe for H2S, since it is known to act as 
both a good reducing agent and nucleophile in a variety of physiological processes 
required to maintain cellular health. Due to its inherent reactivity, H2S can react with 
oxidised thiols162 as well as interacting with a variety of metal centres.163 Developing 
a probe to determine the involvement of H2S as a reactive sulphur species in oxidative 
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stress processes would be beneficial. Azides have previously been reported as 
excellent sensing groups for H2S,
164 which are reduced by H2S to their corresponding 
amines (Scheme 8). A disubstituted azidorhodamine probe (and other mono 
azidorhodamine derivatives) has previously been synthesised by Chang and co-
workers as a H2S probe (Scheme 8).
165 Hence, I was confident that probe 8.4 would 
be a good probe for H2S, whose free amine group could then be functionalised further 
with other sensing groups to allow for the development of a dual analyte probe. 
 
 
Scheme 8: a) Postulated conversion of 8.4 into rhodamine 110 upon reaction with H2S, 
b) Diazidorhodamine made by Chang et al.165 is reduced into rhodamine 110 upon 
reaction with H2S. 
 
Azidorhodamine probe 8.4 has previously been synthesised as an intermediate for 
imaging mRNA.166, 167 Therefore, azidorhodamine 8.4 was easily prepared by 
refluxing 3-aminophenol 9.1 and 3-iodophenol 9.2 at 140 °C in the presence of 
methanesulfonic acid to afford iodorhodamine 9.3 in 48 % yield, which was double 
the 24 % yield previously reported in the literature.167 Subsequently, the iodine group 
of 9.3 was substituted with azide via treatment with NaN3, sodium ascorbate, CuI and 




Scheme 9: Synthesis of azidorhodamine 8.4. 
 
Fluorescence analysis commenced with titration of various concentrations of H2S with 
probe 8.4, whose fluorescence profile was consistent with the formation of rhodamine 
110. Hence, this allowed us to confirm the postulated conversion of azidorhodamine 
into rhodamine 110, with data analysis revealing a LoD of 0.33 μM (Figure 1). 
 
 
Figure 1: a) Dose dependence curve (I/Imax) and b) emission spectrum for probe 8.4 
(500 nM) in the presence of H2S (0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 μM) in PBS buffer 52 
% MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities were measured with λex 
= 472 (bandwith: 20) nm and max λem = 520 nm on a BMG Labtech CLARIOstar® 
plate reader after 30 min. 
 
These positive results led us to perform a RSS and ROS selectivity test to confirm 
8.4’s ability to selectively detect H2S, with relevant (maximum) biological levels for 




Figure 2: Selectivity data for probe 8.4 (500 nM) in the presence of ONOO- (50 µM), 
O2
∙- (500 µM), 1O2 (500 µM) after 5 min. H2O2 (500 µM), ClO
- (500 µM), H2S (10 
µM), GSH (500 µM), cysteine (500 µM), homocysteine (500 µM), S2O3
2- (500 µM), 
SO4
2- (500 µM), and SO3
2- (500 µM) were measured after 30 min. All data was 
obtained in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C at max λem = 520 nm on 
a BMG Labtech CLARIOstar® platereader. 
 
Surprisingly, probe 8.4 showed a significantly higher preference for reaction with 
GSH than H2S, which was unexpected, since the diazido version of 8.4 selectively 
reacts with H2S over GSH.
165 There is one example in the literature where a probe 
containing an azide group had been shown to be capable of selectively detecting GSH 
and cysteine over H2S.
168 This selectivity was achieved through the inherent reactivity 
of the ESIPT probe towards the different types of thiol analytes (Scheme 10), with 
GSH reported to react with an azide group to afford a fluorescent species containing a 




Scheme 10: ESIPT probe developed by Xu et al.168 where the azide group acts as a 
sensing group for GSH and cysteine. 
 
 
Scheme 11: GSH binding to azidorhodamine 8.4 generating fluorescent 11.1. 
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Mass spectrometric analysis revealed that probe 8.4 also reacts with GSH to afford 
fluorescent species 11.1 via the mechanism shown in Scheme 11. The UV spectrum 
of azidorhodamine 8.4 was collected together with and without the presence of GSH 
(Figure 3). The presence of the azide group resulted in no significant absorption peaks 
being observed for 8.4. However, addition of GSH resulted in a new peak appearing 
at 500 nm, which is close to the known maximum absorbance peak for rhodamine 110 
of 492 nm. 
 
 
Figure 3: UV spectrum of azidorhodamine 8.4 in the absence and presence GSH 
(excess) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C measured on a BMG 
Labtech CLARIOstar® plate reader. 
Subsequently, a titration with GSH was carried out with concentrations ranging from 
0.05 mM to 3 mM of GSH (Figure 4) consistent with the biologically relevant levels 
of GSH in cells that range from 0.2 to 10 mM.169 It was noticed that after 3 mM, the 
fluorescence intensity of the azidorhodamine probe 8.4 started to decrease (not 




Figure 4: a) Dose dependence curve (I/Imax) and b) emission spectrum for probe 8.4 
(500 nM) in the presence of GSH (0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 
1, 2, 3 mM) in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence 
intensities were measured for λex = 472 (bandwith: 20) nm and max λem = 520 nm on 
a BMG Labtech CLARIOstar® plate reader. 
 
Given the unusual selectivity of the azide group of this probe 8.4 for GSH, titrations 
were carried out with other relevant sulphur species to ensure no other unusual 
reactivity would occur. Figure 5 illustrates that probe 8.4 shows minimal fluorescence 
upon exposure to other sulphur containing analytes, such as homocysteine, cysteine, 




Figure 5: Titration studies of probe 8.4 with various sulphur species a) homocysteine, 
b) cysteine, c) Na2SO4, d) Na2S2O3 and e) Na2SO3 at concentrations ranging from 1 – 
500 μM in PBS buffer 52 % MeOH : H2O, pH = 7.4 at 25 °C. Fluorescence intensities 
were measured for λex = 472 (bandwith: 20) nm on a BMG Labtech CLARIOstar® 
plate reader. 
 
Additionally, a selectivity study for the reaction of azidorhodamine 8.4 with various 
amino acids was also carried out, with negligible fluorescence being observed towards 
all of the 12 amino acids screened (Figure 6). 
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Figure 6: Selectivity data for probe 8.4 (500 nM) in the presence of GSH (500 µM), 
cysteine (500 µM), homocysteine (500 μM), aspartic acid (500 μM), isoleucine (500 
μM), lysine (500 μM), serine (500 μM), arginine (500 μM), valine (500 μM), histidine 
(500 μM), proline (500 μM), glutamic acid (500 μM), and phenylalanine (500 μM) 
were measured after 30 min. Data was obtained in PBS buffer 52 % MeOH : H2O, pH 
= 7.4 at 25 °C. Fluorescence intensities were measured for λex = 472 (bandwith: 20) 
nm and max λem = 520 nm on a BMG Labtech CLARIOstar® plate reader. 
 
Due the unusal reactivity profile of azidorhodamine 8.4 towards GSH, it was decided 
to evaluate the fluorescent properties of iodorhodamine 9.3 and rhodamine 110 in the 
presence of GSH. Rhodamine 110 is widely used as a fluorescent tool, so the addition 
of ROS and RSS was not expected to result in any change in fluorescence. However, 
exposure of rhodamine 110 to ONOO- and ClO- resulted in its fluorescence being 
quenched (Scheme 12). It is most likely a result of these strong oxidants destroying 
the fluorophore. The amino acid screen test also revealed that all of the amino acids 
tested had no impact on the fluorescent profile of rhodamine 110 (Figure 7). 
 
 




Figure 7: a) Selectivity data for rhodamine 110 (500 nM) in the presence of ONOO- 
(50 µM), O2
∙- (500 µM), 1O2 (500 µM) after 5 min. H2O2 (500 µM), ClO
- (500 µM), 
H2S (10 µM), GSH (500 µM), cysteine (500 µM), homocysteine (500 µM), S2O3
2- 
(500 µM), SO4
2- (500 µM), and SO3
2- (500 µM) were measured after 30 min. b) 
Selectivity data for rhodamine 110 (500 nM) in the presence of GSH (500 µM), 
cysteine (500 µM), homocysteine (500 μM), aspartic acid (500 μM), isoleucine (500 
μM), lysine (500 μM), serine (500 μM), arginine (500 μM), valine (500 μM), histidine 
(500 μM), proline (500 μM), glutamic acid (500 μM), and phenylalanine (500 μM) 
were measured after 30 min. Data was obtained in PBS buffer 52 % MeOH : H2O, pH 
= 7.4 at 25 °C. Fluorescence intensities were measured for λex = 472 (bandwith: 20) 
nm and max λem = 515 nm on a BMG Labtech CLARIOstar® plate reader.  
 
Iodorhodamine 9.3 exhibited significant fluorescence and was shown to react with a 
variety of species, including H2O2, H2S, and GSH (Figure 8). However, none of these 
analytes had a large effect on the fluorescence profile of 9.3. An amino acid screen 
revealed that iodorhodamine 9.3 reacts with GSH and isoleucine preferentially (Figure 
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8). Nevertheless, the changes in fluorescence seen for rhodamine 110 and 
iodorhodamine 9.3 were not as signifcant as observed for azidorhodamine 8.4. 
 
 
Figure 8: a) Selectivity data for iodorhodamine 9.3 (500 nM) in the presence of 
ONOO- (50 µM), O2
∙- (500 µM), 1O2 (500 µM) after 5 min. H2O2 (500 µM), ClO
- (500 
µM), H2S (10 µM), GSH (500 µM), cysteine (500 µM), homocysteine (500 µM), 
S2O3
2- (500 µM), SO4
2- (500 µM), and SO3
2- (500 µM) were measured after 30 min. 
b) Selectivity data for iodorhodamine 9.3 (500 nM) in the presence of  GSH (500 µM), 
cysteine (500 µM), homocysteine (500 μM), aspartic acid (500 μM), isoleucine (500 
μM), lysine (500 μM), serine (500 μM), arginine (500 μM), valine (500 μM), histidine 
(500 μM), proline (500 μM), glutamic acid (500 μM), and phenylalanine (500 μM) 
were measured after 30 min. Data was obtained in PBS buffer 52 % H2O : MeOH, pH 
= 7.4 at 25 °C. Fluorescence intensities were measured for λex = 472 (bandwith: 20) 
nm and max λem = 520 nm on a BMG Labtech CLARIOstar® plate reader. 
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3. Cell Studies 
 
In collaboration with Prof. Juyoon Young and his research group at Ewha Woman’s 
University in Seoul, Korea, probe 8.4 was evaluated in HeLa cells (Figure 9). First 
HeLa cells were treated with N-ethylmaleimide (NEM) which allows to reduce 
celullar thiol levels. Maleimides are commonly used as alkylating agents for thiols.170 
Using NEM allows for proof of concept experiments to study specific detection of 
thiols with probes in vitro. Different conditions with HeLa cells were examined: a) 
probe 8.4 alone, b) NEM + probe 8.4, (c) NEM + Cys + probe 8.4, (d) NEM + Hcy + 
probe 8.4 and (e) NEM + GSH-MEE + probe 8.4. Unfortunately, probe 8.4 showed no 
ability to detect GSH in vitro. Probe 8.4 exhibited inherent fluorescence when the cells 
were untreated as well as when only treated with NEM. No or minimal fluorescence 
should have been observed for these conditions. Upon addition of GSH, the 
fluorescence signal seems to stay the same. An increase of the fluorescence response 
would have been expected, despite inherent fluorescence of the probe 8.4. Gluthatione 
monoethyl ester (GSH-MEE) was used for exogenous addition of GSH since GSH-
MEE is more readily cell permeable than pure GSH. Additionally, exogenous cysteine 
and homocysteine were evaluated in HeLa cells. This should have allowed validation 
of preferential detection of GSH with probe 8.4 over cysteine and homocysteine. 
However, probe 8.4 showed as in all previous conditions no change in fluorescence 
signal. Due to the azide group in probe 8.4, it could potentiall be unstable in a cellular 





Figure 9: HeLa cells were treated with NEM (0.5 mM, 20 min), followed by treatment 
of cysteine (500 μM, 20 min), homocysteine (500 μM, 20 min) or GSH-MEE (500 
μM, 20 min). The probe 8.4 (20 μM) was incubated for 20 min and fluorescence 
images were acquired by confocal microscopy. Legend: (a) probe 8.4, (b) NEM + 
probe 8.4, (c) NEM + Cys + probe 8.4, (d) NEM + Hcy + probe 8.4 and (e) NEM + 
GSH-MEE + probe 8.4. ex = 473 nm, em = 490 – 590 nm. Scale bar: 20 μm. 
Magnification: x60. N = 3. Cell imaging experiments were kindly carried out by 




To conclude, easily prepared azidorhodamine probe 8.4 has been shown to function 
as a selective and sensitive probe for GSH over a range of other amino acids, RSS and 
ROS. GSH reacts with the azide group of azidorhodamine 8.4 to afford a -S-NH-
adduct whose fluorescence can be used to determine the concentration of GSH in 
solution. Unfortunately, HeLa cell studies with 8.4 showed that 8.4 cannot be used as 
a GSH sensing tool in vitro. It was postulated that the labile nature of the azide group 
could generate fluorescent rhodamine 110 readily. Hence, 8.4 cannot be used to gain 
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an understanding of GSH levels in vitro and remains only as an interesting solution 
model. Nevertheless, probe 8.4 has shown that azide groups are not selectively sensing 
H2S when incorporated into an aromatic system. This unique feature opens up new 
possibilities in the design of dual analyte probes and thus, could overcome the inherent 
fluorescent properties in vitro. 
 
5. Future Work 
 
Derivatisation at the free amine position of probe 8.4 could potentially allow for 
further functionalisation to introduce other relevant sensing groups for biothiols or 
ROS, with simultaneous detection of different analytes beneficial to understand their 
essential metabolic roles. Therefore, it is anticipated that synthesis of multicomponent 
probes such as 12.1, 12.2 and 12.3 might allow for cellular studies, as well as drug 
delivery and theranostic applications (Figure 10).  
 
 
Figure 10: Suggested probes 12.1, 12.2, and 12.3 for the simultaneous detection of 
GSH and other biothiols such as H2S, cysteine and homocysteine. 
 
Another possibility would be the inclusion of a boronic ester moiety, illustrated in 
structures 13.1, 13.2 and 13.3 to allow for the detection of ONOO- and GSH at the 
same time (Figure 11). The simultaneous detection of these two analytes could offer 
the opportunity of understanding the interplay between ONOO- and GSH. ONOO- can 
interfere in the GSH/GSSG ratio171, specifically in the mitochondria and hence, 
understanding redox homeostasis pathways would be beneficial. A rhodamine based 
structure such as 13.1 could allow for localisation in the mitochondria whereas the 
rhodol based structures such as in 13.2 and 13.3 might offer better localisation in the 
165 
endoplasmic reticulum.172 This could offer insight and comparison of the interplay of 
ONOO- and GSH in different organelles.173 
 
 



















Chapter 6 – Experimental 
 
General Materials and Methods 
Chemistry 
 
Unless stated otherwise, reagents and solvents were sourced from commercial 
suppliers, specifically: Acros Organics, Fisher Scientific, Fluka Chemie GmbH, 
Fluorochem, Sigma Aldrich and TCI and were used directly as received. Reactions 
requiring inert conditions were performed using dry solvents and under an atmosphere 
of nitrogen. Solvents were dried using an Innovative Technology Inc. PS-400-7 
Solvent Purification System. 
TLC was carried out on commercially available pre-coated aluminium-backed silica 
plates and compounds were visualised under UV light at 254 nm. Column 
chromatography was performed using 60 micron silica purchased from Sigma Aldrich. 
1H NMR and 13C NMR spectra were recorded either in deuterated chloroform, 
acetone, methanol or DMSO at ambient temperature on either a Bruker Avance 250 
(250 MHz), Bruker Avance 300 (300 MHz) or Bruker Avance 500 (500 MHz), with 
proton decoupling for all 13C NMR spectra. Chemical shifts (δ / ppm) are referenced 
against tetramethylsilane as an internal standard and the abbreviations: s, d, t, q, quin, 
sext, m, and br, were used to denote singlet, doublet, triplet, quartet, quintet, sextet, 
multiplet, and broad respectively. Coupling constants (J / Hz) are reported where 
known.  
Initially, analysis by mass spectrometry was conducted either by the EPSRC UK 
national mass spectrometry facility at Swansea University medical school on a 
electrospray ionisation LTQ Orbitrap XL 1 (Thermo Fisher Scientific) or on a 
microTOF electrospray time of flight (ESI-TOF) mass spectrometer (Bruker Dlatonik 
GmbH, Germany) at the University of Bath. More recently, LC-MS analyses were 
performed using an Agilent QTOF 6545 with Jetstream ESI spray source coupled to 
an Agilent 1260 Infinity II Quat pump HPLC with 1260 autosampler, column oven 
compartment and variable wavelength detector (VWD). The MS was operated in 
167 
either positive or negative ionisation mode with the gas temperature at 250 °C, the 
drying gas at 12 L/min and the nebuliser gas at 45 psi (3.10 bar). The sheath gas 
temperature and flow were set to 350 °C and 12 L/min, respectively. The MS was 
calibrated using reference calibrant introduced from the independent ESI reference 
sprayer. The VCap, Fragmentor and Skimmer was set to 3500, 125 and 45 
respectively. 
Fourier Transform Infrared (FTIR) spectra were recorded on an ATR Perkin−Elmer 
FTIR Spectrum 100 spectrometer. The spectra were measured between 4000 − 600 
cm−1. Selected absorption bands are reported in wavenumbers (cm–1), and their relative 
intensities described as s (strong), m (medium), or w (weak). When applicable, peak 




Fluorescence measurements were performed on a BMG Labtech CLARIOstar® plate 
reader using Greiner bio-one microplates, 96-well, PS, flat-bottom (chimney well), 
black. Data were collected via the BMG Labtech Clariostar data analysis software 
package MARS. All solvents used in fluorescence measurements were HPLC or 
fluorescence grade and the water was de-ionised.  
UV-Vis measurements were performed on a Perkin-Elmer Lambda20 
Spectrophotometer, utilising Starna Silica (quartz) cuvette with 10 mm path lengths, 
two faces polished. Data was collected via the Perkin-Elmer UVWinlab software 
package.  
All pH measurements taken for buffer pH adjustments were recorded on a Hanna 
Instrument HI 9321 microprocessor pH meter which was routinely calibrated using 
Fishers standard buffer solutions (pH 4.0 – phthalate, 7.0 – phosphate, and 10.0 – 
borate). 
Phosphate buffered saline (PBS) was freshly prepared from 52 % methanol in water 
with KCl (10 mM), KH2PO4 (2.75 mM) and Na2HPO4 (2.76 mM). The PBS buffer 
was adjusted to pH 7.4/8.2 with 1 M HCl (aq.) as indicated. 
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Stock solutions for a variety of ROS were freshly prepared prior to each experiment: 
Hydrogen peroxide (H2O2) 
Hydrogen peroxide (H2O2) is commercially available whereby the concentration of 
H2O2 was determined through spectrophotometrical analysis with ε = 43.6 cm
−1 M−1 
at 240 nm. 
Peroxynitrite (ONOO-) 
Peroxynitrite (ONOO-) stock solutions were freshly prepared each time prior to usage. 
A solution of 3 M NaOH was cooled to 0 °C to which simultaneously 0.7 M H2O2, 0.6 
M NaNO2 and 0.6 M HCl were added. The ONOO
- solution was analyzed 
spectrophotometrically whereby the concentration of ONOO- was estimated through 
ε = 1670 cm−1 M−1 at 302 nm in 0.1 M NaOH (aq.). 
Hypochlorite (ClOˉ) 
Commercially available NaOCl was analysed spectrophotometrically to determine its 
concentration using ε = 350 cm−1 M−1 at 292 nm. 
Superoxide (O2˙ˉ) 
KO2 (0.0335 g) and 18-crown-6 ether (0.1235 g) were dissolved in DMSO (5 mL) and 
stirred for 5 min to produce a 0.1 M solution of O2˙ˉ.  
Hydroxyl radical (˙OH) 
Iron(II) perchlorate hydrate (0.1274 g) and H2O2 (3.9 µL) were dissolved in H2O (5 
mL) to produce a 0.1 M solution of ˙OH. 
Peroxyl radical (ROO˙) 
2,2′-Azobis(2-methylpropionamidine) dihydrochloride (0.136 g) was dissolved in 
H2O (5 mL) and heated at 37 °C for 30 min to give a 0.1 M solution of ROO˙. 
Singlet oxygen (¹O₂) 
H2O2 (1.3 µL) was added to 4 mL of 0.1 M NaOCl to give a 0.1M solution of ¹O₂. 
Fluorescence titrations of ROS/RNS were carried out at 25 °C in PBS buffer pH 
7.4/8.2. Different concentrations of ROS/RNS were prepared accordingly and 
investigated with the probe at a concentration ranging from 500 nM to 5 μM. 
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1. Chapter 1 




Phenoxazine (2.00 g, 7.38 mmol) was dissolved in chloroform (150 mL). NBS (2.63 
g, 14.76 mmol) was slowly added to the mixture, which was left to stir at RT for 2 h. 
The mixture was quenched with water. After separation of the phases, the organic 
layer was washed with water (3 x 100 mL) and brine (1 x 100 mL), dried over MgSO4, 
filtered and evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 80:20) gave 3,7-
dibromo-10H-phenoxazine (2.00 g, 80 %) as a blue solid. 
 
1H NMR (500 MHz, (CD3)2SO): δ =  6.96 – 6.85 (m, 2 H; ArH), 6.71 – 6.63 (m, 3 H; 
ArH), 6.06 – 5.91 ppm (m, 2 H; ArH); 13C NMR (75.5 MHz, (CD3)2SO): δ = 146.3, 
132.9, 126.4, 122.1, 121.4, 111.3 ppm; m.p. 125 – 128 °C; IR (ATR): 𝜐 = 3393 cm-1 















3,7-dibromo-10H-phenoxazine (2.70 g, 7.92 mmol), bis(pinacolato)diboron (6.04 g, 
23.76 mmol) and KOAc (4.66g, 47.52 mmol) were dissolved in DMF (60 mL), 
degased under argon and treated with PdCl2(dppf) (579 mg, 0.79 mmol). The mixture 
was refluxed at 90 °C for 3 h, and cooled to RT after completion. The solution was 
filtered through celite, diluted with EtOAc, washed with water (3 x 60 mL) and brine 
(3 x 60 mL), dried over MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum 
ether/EtOAc 80:20) gave 3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-
phenoxazine (2.42 g, 70 %) as a dark red solid. 
 
1H NMR (500 MHz, (CD3)2SO): δ = 8.70 (s, 1 H; H–N(1’’)), 7.04 (dd, J = 7.7 Hz, 1.3 
Hz, 2 H; ArH), 6.75 (d, J = 7.7 Hz, 2 H; ArH), 6.43 (d, J = 1.3 Hz, 2 H; ArH), 1.25 
ppm (s, 24 H; H–C(2’’’), H–C(3’’’), H–C(5’’’), H–C(6’’’), H–C(2’’’’), H–C(3’’’’), 
H–C(5’’’’), H–C(6’’’’)); 13C NMR (125.75 MHz, (CD3)2CO): δ = 143.1, 134.8, 131.0, 
120.7, 112.9, 83.3, 24.3 ppm; m.p. 214 – 217 oC; IR (ATR): 𝜐 = 3404 cm-1 (w, N–H); 











1.2.  In vitro Macrophage Assays 
 
Materials 
Unless stated otherwise, reagents and solvents were sourced from commercial 
suppliers, specifically: Biotium, Cayman Chemicals, Fisher Scientific, and Sigma 
Aldrich and were used directly as received. Phosphate buffered saline (PBS) was 
freshly prepared from milli-q water with NaCl (0.14 M), KCl (2.68 mM), Na2HPO4 
(10.14 mM), KH2PO4 (1.76 mM), CaCl2∙2H2O (0.90 mM) and MgCl2∙6H2O (0.49 
mM). The PBS buffer was adjusted to pH 7.4 with 1 M HCl (aq.). 
 
Cell culture 
J774.2 macrophages (ECACC 85011428) were purchased from the European 
collection of authenticated cell cultures. Cells are stored at -196 °C under liquid nitrogen 
until required. Cells are warmed up in a water bath (37 °C) for 2 min. The cell liquid 
was transferred into a falcon tube, to which media (5 mL) was added. The solution was 
centrifuged at 300 RCM for 5 min at 22 °C. After removal of the supernatant, fresh 
media (1 mL) was added and the cells were thrown quickly and incubated at 37 °C, 5 % 
CO2. J774.2 macrophages were grown in culture media consisting of Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with heat inactivated fetal bovine 
serum (FBS) (10 % v/v), and penicillin/streptomycin (1 % v/v). During cell passage 
(every two days), media was removed, new media added and cells were detached with 
a cell scraper and transferred to a new flask according to the protocol provided by the 
European collection of authenticated cell cultures. 
 
Confocal microscopy of J774.2 macrophages 
Fluorescence microscopy images were captured on a Zeiss LSM880 using 8-well 
chambered cover glass with #1.5 high performance cover glass (Cellvis). Images were 
captured at different magnifications with the following parameters: MitoView Green 
ex = 490 nm, em = 523 nm and PR1 ex = 572 nm, em = 583 nm. Lasers 488 nm and 
543 nm with intensities of 3 % and 50 % respectively were used. Processing and analy- 
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sis of confocal microscopy images were performed with Image J. 
 
Fluorescence measurements 
Fluorescence measurements were performed on a BMG Labtech CLARIOstar® plate 
reader with regulated O2 and CO2 gas control using Greiner bio-one microplates, 96- 
well, PS, flat-bottom (chimney well), black. Excitation and emission wavelength were 
set for resorufin presettings (ex = 545 nm, em = 600 nm). All solvents used in 
fluorescence measurements were HPLC or fluorescence grade and the water was of 
milli-q standard. Data collected via the BMG Labtech Clariostar plate reader was 
initially analysed with the data analysis software package MARS from BMG Labtech, 
followed by the GraphPad software Prism. Statistical analysis was performed using 
Prism. All fluorescence experiments were performed in triplicates three times. 
 
Hypoxic cabinet 
An asymmetric Sci-tive Dual (Baker Ruskin) was used for induction of a hypoxia 
environment. The hypoxic cabinet allows for regulation of O2 %, CO2 %, temperature 
and humidity. The hypoxic cabinet was switched on 2 h prior to usage to allow for 
calibration of the system. N2, CO2 and 25 % O2/N2 gases were used to induce the 
desired hypoxic cell culture environment. 
 
Confocal microscopy study 
Cells were plated in a 8-well chambered coverglass at a cell density of 5 x 104 
cells/well in culture media (300 μL/well) and incubated for 16 h. Then, LPS (1 μg/ml) 
and IFN-γ (50 ng/ml) were incubated for 4 h at 37 °C, 5 % CO2. The culture media 
was removed, cells were washed three times with PBS, the probe (15 μM) and 
MitoView Green (200 nM) in a probenecid (1 mM) and Opti-MEM solution were 
added respectively to the cells and incubated for 30 min at 37 °C, 5 % CO2. The media 
solution was removed, cells were washed three times with PBS and subsequently 
dispensed in a solution of probenecid (1 mM) in PBS for confocal microscopy. Where 
specified, SIN-1 (15 μM) was added prior to imaging. 
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Investigation of different cell numbers 
Cells were plated in a clear 96-well plate at a cell density of 1 x 104, 5 x 104, 1 x 105 
cells/well in culture media (200 μL/well) and incubated for 24 h at 37 °C, 5 % CO2. 
The culture media was removed, cells were washed three times with PBS. Images were 
captured using an EVOS FL microscope with an x20 objective. 
 
Cells were plated in a black 96-well plate, the probe (15 μM) in Opti-MEM was added 
to the cells and incubated for 30 min at 37 °C, 5 % CO2. The media solution was 
removed, cells were washed three times with PBS and subsequently dispensed in PBS 
for fluorescence measurements. SIN-1 (15 μM) was added via a computer controlled 
injector after 5 min. Fluorescence intensity recordings were performed for 30 min at 
37 °C. 
 
Investigation of different SIN-1 concentrations 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/ well in 
culture media (200 μL/well) and incubated for 24 h at 37 °C, 5 % CO2. The culture 
media was removed, cells were washed three times with PBS, the probe (15 μM) in 
Opti-MEM was added to the cells and incubated for 30 min at 37 °C, 5 % CO2. The 
media solution was removed, cells were washed three times with PBS and 
subsequently dispensed in PBS for fluorescence measurements. SIN-1 (2, 5, 10, 15, 
20, 40 μM) was added via a computer controlled injector after 5 min. Fluorescence 
intensity recordings were performed for 30 min at 37 °C. 
 
Investigation of different LPS concentrations 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated with LPS (0.1, 1, 100, 1000 ng/ml) for 4 
or 24 h at 37 °C, 5 % CO2. The culture media was removed, cells were washed three 
times with PBS, the probe (15 μM) in Opti-MEM was added to the cells and incubated 
for 30 min at 37 °C, 5 % CO2. The media solution was removed, cells were washed 
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three times with PBS and subsequently dispensed in PBS for fluorescence 
measurements. Fluorescence intensity recordings were performed for 30 min at 37 °C. 
 
Investigation of different PMA concentrations 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h, followed by LPS (100 ng/ml) for 
4 h at 37 °C, 5 % CO2. The culture media was removed, cells were washed three times 
with PBS, the probe (15 μM) in a solution of probenecid (1 mM) in Opti-MEM was 
added to the cells and incubated for 30 min at 37 °C, 5 % CO2. The media solution 
was removed, cells were washed three times with PBS and subsequently dispensed in 
a solution of probenicid (1 mM) in PBS for fluorescence measurements. PMA (5, 10, 
50, 100 nM) was added via a computer controlled injector after 5 min. Fluorescence 
intensity recordings were performed for 30 min at 37 °C. 
 
Investigation of IFN-γ 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h, followed by incubation with LPS 
(100 ng/ml) and IFN-γ (50 ng/ml) for 4 h at 37 °C, 5 % CO2. The culture media was 
removed, cells were washed three times with PBS. The probe (15 μM) in Opti-MEM 
was added to the cells and incubated for 30 min at 37 °C, 5 % CO2. The solutions were 
removed, cells were washed three times with PBS and subsequently dispensed in a 
solution of PBS for fluorescence measurements. Fluorescence intensity recordings 
were performed for 30 min at 37 °C. 
 
Investigation of different O2∙- scavengers 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h, followed by LPS (100 ng/ml) for 
4 h at 37 °C, 5 % CO2. The culture media was removed, cells were washed three times 
with PBS. The scavenger (ebselen (1 mM), uric acid (1 mM), N-acetyl-L-cysteine (1 
mM) and Mn-cpx3 (1 mM)) in Opti-MEM was incubated for 1 h at 37 °C, 5 % CO2. 
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After 30 min of incubation with the scavenger, the probe (15 μM) in Opti-MEM was 
added to the cells and incubated for the remaining 30 min at 37 °C, 5 % CO2. The 
solutions were removed, cells were washed three times with PBS and subsequently 
dispensed in a solution of PBS for fluorescence measurements. Fluorescence intensity 
recordings were performed for 30 min at 37 °C. 
 
Investigation of different ebselen concentrations 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h, followed by LPS (100 ng/ml) for 
4 h at 37 °C, 5 % CO2. The culture media was removed, cells were washed three times 
with PBS. Ebselen (0.1, 0.25, 0.5, 0.75, 1 mM) in Opti-MEM was incubated for 1 h at 
37 °C, 5 % CO2. After 30 min of incubation with ebselen, the probe (15 μM) in Opti-
MEM was added to the cells and incubated for the remaining 30 min at 37 °C, 5 % 
CO2. The solutions were removed, cells were washed three times with PBS and 
subsequently dispensed in a solution of PBS for fluorescence measurements. 
Fluorescence intensity recordings were performed for 30 min at 37 °C. 
 
Investigation of different NO scavengers 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h, followed respectively by LPS 
(100 ng/ml) and NO scavengers (NG-methyl-L-arginine acetate and Nw-nitro-L-
arginine: 0.1, 0.25, 0.5, 0.75, 1, 2 mM) for 4 h at 37 °C, 5 % CO2. The culture media 
was removed, cells were washed three times with PBS. The probe (15 μM) in Opti-
MEM was added to the cells and incubated for 30 min at 37 °C, 5 % CO2. The solutions 
were removed, cells were washed three times with PBS and subsequently dispensed 
in a solution of PBS for fluorescence measurements. Fluorescence intensity recordings 





Investigation of IFN-γ with NOS inhibitors and O2∙- and ONOO- scavengers 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h, followed respectively by LPS 
(100 ng/ml), IFN-γ (50 ng/ml) and NO scavengers (NG-methyl-L-arginine acetate (0.5 
mM) and Nw-nitro-L-arginine (0.5 mM)) incubation for 4 h at 37 °C, 5 % CO2 where 
appropriate. The culture media was removed, cells were washed three times with PBS. 
The scavenger (ebselen (1 mM) and uric acid (1 mM)) in Opti-MEM was incubated 
for 1 h at 37 °C, 5 % CO2 where appropriate. After 30 min of incubation with the 
scavenger, the probe (15 μM) in a solution of probenicid (1 mM) in Opti-MEM was 
added to the cells and incubated for the remaining 30 min at 37 °C, 5 % CO2. The 
solutions were removed, cells were washed three times with PBS and subsequently 
dispensed in a solution of probenecid (1 mM) in PBS for fluorescence measurements. 
Where appropriate, ATP (5 mM) and SIN-1 (15 μM) were added via a computer 
controlled injector after 5 min. Fluorescence intensity recordings were performed for 
30 min at 37 °C. 
 
Investigation of different ATP concentrations 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h, followed by LPS (100 ng/ml) 
incubation for 4 h at 37 °C, 5 % CO2. The culture media was removed, cells were 
washed three times with PBS, the probe (15 μM) in a solution of probenecid (1mM) 
in Opti-MEM was added to the cells and incubated for 30 min at 37 °C, 5 % CO2. The 
media solution was removed, cells were washed three times with PBS and 
subsequently dispensed in a solution of probenecid (1 mM) in PBS for fluorescence 
measurements. ATP (0.1, 0.5, 1, 5 mM) was added via a computer controlled injector 
after 5 min. Fluorescence intensity recordings were performed for 30 min at 37 °C. 
 
Investigation of different P2X7 antagonists 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h, followed by LPS (100 ng/ml) for 
4 h at 37 °C, 5 % CO2. The culture media was removed, cells were washed three times 
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with PBS. P2X7 antagonists (A-438079 (0.1 mM) and CGS15943 (0.1 mM)) and the 
probe (15 μM) in Opti-MEM were added accordingly and incubated for 30 min at 37 
°C, 5 % CO2. ATP (1, 2, 3, 4, 5 mM) was added via a computer controlled injector 
after 5 min. Fluorescence intensity recordings were performed for 30 min at 37 °C. 
 
Investigation of hypoxic vs normoxic environments 
Cells were plated in a black 96-well plate at a cell density of 5 x 104 cells/well in 
culture media (200 μL/well) and incubated for 24 h under normoxic (5 % CO2, 95 % 
air, 37 °C) and hypoxic (hypoxic cabinet settings: 1 % O2, 5% CO2, 37 °C) conditions 
separately. This was followed by incubation of LPS (100 ng/ml) for 4 h under hypoxic 
and normoxic conditions. The culture media was removed, cells were washed three 
times with PBS. The probe (15 μM) in Opti-MEM was added to the cells and incubated 
for 30 min under hypoxic and normic conditions. The solutions were removed, cells 
were washed three times with PBS and subsequently dispensed in a solution of PBS 
for fluorescence measurements. Under hypoxic conditions, the plate reader was 
calibrated to a 1 % O2 environment using N2 gas. SIN-1 (15 μM) was added via a 
computer controlled injector after 10 min. Fluorescence intensity recordings were 
performed for 30 min at 37 °C. 
 
Statistical analysis 
One-way analysis of variance was used for statistical analysis. The Newman-Keuls 
post-test was used for multiple comparisons. The results are expressed as the mean ± 








2. Chapter 2 
2.1. General Methods 
 
Flow infusion analysis was conducted using a Maxis HD quadrupole electrospray 
time-of-flight (ESI-QTOF) mass spectrometer (Bruker Daltonik GmbH, Bremen, 
Germany) in negative-ion mode. The capillary voltage was set to 4500 V, nebulising 
gas at 1 bar, drying gas at 4 L/min. The drying gas temperature was increased from 
200 – 280 °C during the first infusion. For the second infusion the freshly prepared 
sample was run at 280 °C, then increased to 320 °C. Extracted MS spectra represents 
drying gas conditions of 280 °C. The TOF scan range was from 50 – 1000 mass-to-
charge ratio (m/z). Infusion injections were performed by the infusion pump using a 
flow rate of 3 µL/min. The MS instrument was calibrated using a sodium formate 
calibrant solution. The calibrant solution consisted of 3 parts of 1 M NaOH to 97 parts 
of 50 : 50 water : isopropanol with 2 % formic acid. Data processing was performed 

















2.2.  Synthesis  
 
4-(hydroxymethyl)phenyl pivalate (5.2) 
 
NaH–60 % mineral oil (1.70 g, 44.30 mmol) was dissolved in dry THF (200 ml) under 
a N2 atmosphere. The mixture was cooled to 0 °C. 4-(hydroxymethyl)phenol (5.00 g, 
40.30 mmol) was added and stirred at 0 °C until bubbling ceased. The mixture was 
allowed to warm up to RT and stirred at RT for 30 min. Subsequently, the mixture was 
cooled to 0 °C to which pivaloyl chloride (5.43 mL, 44.30 mmol) was added. The 
mixture was stirred for 30 min at 0 °C, warmed up to RT and stirred for a further 2 h. 
Sat. aq. NaHCO3 (50 ml), followed by water (100 ml) were added to the mixture which 
was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed 
with brine (2 x 50 ml), dried over MgSO4, filtered and evaporated in vacuo. This gave 
4-(hydroxymethyl)phenyl pivalate (8.25 g, 98 %) as a colourless oil. 
 
1H NMR (500 MHz, CDCl3): δ = 7.37 (d, J = 8.1 Hz, 2 H; ArH), 7.04 (d, J = 8.5 Hz, 
2 H; ArH), 4.68 (s, 2 H; H–C(7)), 1.36 ppm (s, 9 H; H–C(3’), H–C(4’), H–C(5’)); 13C 
NMR (126 MHz, CDCl3): δ = 177.31, 150.67, 138.38, 128.14, 121.73, 64.92, 39.21, 
27.28 ppm; IR (ATR): 𝜐 = 3346 (w, O–H), 1749 cm-1 (m, C=O); FTMS + p NSI MS: 
m/z (%): 226.1438 (M+NH4
+, calcd for C12H20NO3
+: 226.1438). 
 






4-(bromomethyl)phenyl pivalate (5.3) 
 
Lithium bromide (24.32 g, 0.28 mol) was dissolved in THF (60 mL) and triethylamine 
(10 mL, 0.73 mol) to which 4-(hydroxymethyl)phenyl pivalate (4.38 g, 0.02 mol) 
dissolved in THF (100 mL) was added. The mixture was cooled to 0 °C and 
methanesulfonyl chloride (18.21 g, 0.13 mol) was added dropwise. The solution was 
stirred for 2 h at 0 °C, quenched with water, and allowed to warm up to RT. The 
organic layer was extracted with DCM (3 x 50 mL), washed with sat. aq. NaHCO3 (2 
x 50 mL), dried over MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum 
ether/EtOAc 90:10) gave 4-(bromomethyl)phenyl pivalate (4.14 g, 76 %) as a light 
yellow oil. 
 
1H NMR (300 MHz, CDCl3): δ = 7.42 – 7.37 (m, 2 H; ArH), 7.06 – 7.01 (m, 2 H; 
ArH), 4.49 (s, 2 H; H–C(7)), 1.35 ppm (s, 9 H; H–C(3’), H–C(4’), H–C(5’)); 13C NMR 
(75.5 MHz, CDCl3): δ = 177.07, 151.12, 135.22, 130.29, 122.01, 39.24, 32.95, 27.24 
ppm; IR (ATR): 𝜐 = 1736 cm-1 (m, C=O); HR-ESI-MS: m/z (%): 271.0332 (M+H+, 
calcd for C12H16
79BrO2














4-((10H-phenoxazin-10-yl)methyl)phenyl pivalate (5.5) 
 
Phenoxazine (1.00 g, 5.46 mmol) was dissolved in THF (30 mL). The mixture was 
cooled down to 0 °C and left to stir for 10 min. NaH–60 % mineral oil (0.32 g, 8.19 
mmol) was slowly added. After 10 min, 4-(bromomethyl)phenyl pivalate (2.96 g, 
10.92 mmol) was added slowly. The solution was left to stir at RT for 4 h. The mixture 
was quenched with water (50 mL). After separation of the phases, the aqueous layer 
was extracted with EtOAc (2 x 40 mL). The combined organic layers were washed 
with water (3 x 50 mL), and brine (1 x 50 mL), dried over MgSO4, filtered and 
evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 90:10) gave 4-((10H-
phenoxazin-10-yl)methyl)phenyl pivalate (1.28 g, 63 %) as a purple oil. 
 
1H NMR (300 MHz, CDCl3): δ = 7.45 – 7.35 (m, 2 H; ArH), 7.34 – 7.28 (m, 2 H; 
ArH), 7.10 – 6.98 (m, 4 H; ArH), 6.74 – 6.64 (m, 2 H; ArH), 6.38 – 6.27 (m, 2 H; 
ArH), 4.49 (s, 2 H; H–C(7’’)), 1.35 ppm (s, 9 H; H–C(3’’’), H–C(4’’’), H–C(5’’’)); 
13C NMR (75.5 MHz, CDCl3): δ = 151.13, 150.29, 145.27, 135.22, 133.65, 130.29, 
127.12, 123.87, 121.45, 115.42, 112.35, 58.75, 39.24, 27.25 ppm; IR (ATR): 𝜐 = 1747 
(m, C=O), 1112 cm-1 (s, C–O); HR-ESI-MS: m/z (%): 374.1750 (M+H+, calcd for 
C24H24NO3







4-((3,7-dibromo-10H-phenoxazin-10-yl)methyl)phenyl pivalate (5.6) 
 
4-((10H-phenoxazin-10-yl)methyl)phenyl pivalate (900 mg, 2.41 mmol) was 
dissolved in chloroform (40 mL). NBS (858 mg, 4.82 mmol) was slowly added to the 
mixture, which was left to stir at RT for 1 h. The solution was quenched with water. 
After separation of the phases, the organic layer was washed with water (3 x 50 mL) 
and brine (1 x 50 mL), dried over MgSO4, filtered and evaporated in vacuo. This gave 
4-((3,7-dibromo-10H-phenoxazin-10-yl)methyl)phenyl pivalate (1.21 g, 95 %) as a 
green oil. 
 
1H NMR (300 MHz, CDCl3): δ = 7.38 – 7.31 (m, 2 H; ArH), 7.10 – 6.98 (m, 4 H; 
ArH), 6.87 – 6.75 (m, 2 H; ArH), 6.16 (d, J = 9.0 Hz, 2 H; ArH), 4.70 (s, 2 H; H–
C(7’’)), 1.35 ppm (s, 9 H; H–C(3’’’), H–C(4’’’), H–C(5’’’)); 13C NMR (75.5 MHz, 
CDCl3): δ = 150.42, 145.35, 128.98, 126.85, 126.74, 122.36, 122.26, 121.59, 118.65, 
113.36, 112.95, 65.49, 39.11, 27.14 ppm; IR (ATR): 𝜐 = 1747 (m, C=O), 1109 cm-1 
(s, C–O); FTMS + p NSI MS: m/z (%): 530.9991 (M+H+, calcd for 
C24H22
79Br2NO3
+: 530.9994), 531.9934 (M+H+, calcd for C24H22
79Br81BrNO3
+: 












4-((3,7-dibromo-10H-phenoxazin-10-yl)methyl)phenyl pivalate (2.20 g, 4.14 mmol) 
was dissolved in toluene (60 mL) and cooled to 0 C. DIBAL-H 1M in toluene (12 
mL, 12.42 mmol) was slowly added. The mixture was stirred for 1 h at 0 °C and 
allowed to warm back to RT for 30 min. The mixture was quenched with sat. aq. 
NH4
+Cl- (20 mL), diluted with EtOAc (30 mL), washed with water (3 x 60 mL), dried 
over MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 
90:10) gave 4-((3,7-dibromo-10H-phenoxazin-10-yl)methyl)phenol (937 mg, 54 %) 
as a blue solid. 
 
1H NMR (300 MHz, CDCl3): δ = 7.18 – 7.05 (m, 2 H; ArH), 6.90 – 6.73 (m, 6 H; 
ArH), 6.28 – 6.11 (m, 2 H; ArH)), 4.64 ppm (s, 2 H; H–C(7’’)); 13C NMR (75.5 MHz, 
CDCl3): δ = 154.60, 145.03, 132.36, 126.94, 126.67, 126.39, 118.27, 115.67, 113.01, 
112.52, 48.34 ppm; m.p.: 162 – 165 °C; IR (ATR): 𝜐 = 3381 (w, O–H), 1107 cm-1 (s, 
C–O); TOF MS ASAP: m/z (%): 446.9298 (M+H+, calcd for C19H14
79Br2NO2
+: 
446.9294), 447.9353 (M+H+, calcd for C19H14
79Br81BrNO2
+: 447.9372), 448.9302 
(M+H+, calcd for C19H19
81Br2NO2












4-((3,7-dibromo-10H-phenoxazin-10-yl)methyl)phenol (300 mg, 0.67 mmol), 
bis(pinacolato)diboron (511 mg, 2.01 mmol) and KOAc (395 mg, 4.03 mmol) were 
dissolved in DMF (50 mL), degased under argon and treated with PdCl2(dppf) (49 mg, 
0.07 mmol). The mixture was heated at 90 °C for 6 h, and cooled to RT after 
completion. The solution was filtered through celite, diluted with EtOAc, washed with 
water (3 x 50 mL) and brine (3 x 50 mL), dried over MgSO4, filtered and evaporated 
in vacuo. FC (SiO2; petroleum ether/EtOAc 90:10 – 50:50) gave 4-((3,7-bis(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenoxazin-10-yl)methyl)phenol (193 mg, 
53 %) as a light yellow solid. 
 
1H NMR (300 MHz, (CD3)2CO): δ = 8.34 (s, 1 H; H–O(1’’’)), 7.16 (m, 2 H, ArH), 
6.97 (s, 2 H, ArH), 6.82 (d, J = 8.5 Hz, 2 H, ArH), 6.54 (d, J = 7.9 Hz, 2 H, ArH), 4.85 
(s, 2 H; H–C(7’’)), 1.30 ppm (s, 24 H; H–C(2’’’’), H–C(3’’’’), H–C(5’’’’), H–C(6’’’’), 
H–C(2’’’’’), H–C(3’’’’’), H–C(5’’’’’), H–C(6’’’’’)); 13C NMR (75 MHz, (CD3)2CO): 
δ = 157.9, 145.6, 137.3, 132.4, 128.6, 127.5, 121.7, 116.9, 116.8, 113.5, 84.7, 48.4, 
25.5 ppm; m.p.: 230 – 233 °C; IR (ATR): 𝜐 = 3329 cm-1 (w, O–H); FTMS + p APCI 










(4-carboxybutyl)triphenylphosphonium bromide (670 mg, 1.85 mmol) was dissolved 
in DCM/DMF (10 ml/10 μL). Thionyl chloride (0.7 mL, 9.62 mmol) was added slowly 
to the mixture. The solution was refluxed at 40 °C for 5 h. Solvent was evaporated in 
vacuo giving (5-chloro-5-oxopentyl)triphenylphosphonium (648 mg, 92 %) as an 
orange oil. 
 
1H NMR (300 MHz, CDCl3): δ = 7.88 – 7.58 (m, 15 H; ArH), 3.65 – 3.47 (m, 2 H; H–
C(4)), 3.06 – 3.00 (m, 2 H; H–C(1)), 2.11 – 2.00 (m, 2 H; H–C(3)), 1.88 – 1.64 ppm 
(m, 2 H; H–C(2)); 13C NMR (126.5 MHz, CDCl3): δ = 207.19, 135.38, 133.80, 130.83, 
118.44, 116.99, 25.86, 25.72, 21.48, 21.45 ppm; IR (ATR): 𝜐 = 1727 cm-1 (s, O=C); 

















yl)methyl)phenol (50 mg, 0.09 mmol) was dissolved in DCM (10 mL), cooled to 0 °C, 
to which triethylamine (0.02 mL, 0.18 mmol) and (5-chloro-5-oxopentyl) 
triphenylphosphonium (69 mg, 0.18 mmol) were added. The mixture was allowed to 
warm up to RT and stirred for 24 h. The reaction was quenched with water (30 mL). 
After separation of the phases, the organic layer was washed with water (3 x 20 mL), 
dried over MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 
80:20) gave (5-(4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-
phenoxazin-10-yl)methyl)phenoxy)-5-oxopentyl)triphenylphosphonium (32 mg, 41 
%) as a dark orange oil. 
 
1H NMR (500 MHz, (CD3)2CO): δ = 8.08 – 7.96 (m, 6 H; ArH), 7.94 – 7.86 (m, 3 H; 
ArH), 7.83 – 7.71 (m, 6 H; ArH), 7.57 – 7.51 (m, 2 H; ArH), 7.38 – 7.30 (m, 2 H; 
ArH), 7.09 – 6.80 (m, 4 H; ArH), 6.47 (d, J = 8.7 Hz, 2 H; ArH), 4.90 (s, 2 H; H–
C(7’’)), 4.05 – 3.92 (m, 2 H; H–C(2’’’)), 2.77 – 2.68 (m, 2 H; H–C(5’’’)), 1.96 – 1.84 
(m, 2 H; H–C(3’’’)), 1.36 – 1.30 (m, 2 H; H–C(4’’’)), 1.21 ppm (s, 24 H; H–C(2’’’’’’’), 
H–C(3’’’’’’’), H–C(5’’’’’’’), H–C(6’’’’’’’), H–C(2’’’’’’’’), H–C(3’’’’’’’’), H–
C(5’’’’’’’’), H–C(6’’’’’’’’)); 13C NMR (126 MHz, CDCl3): δ = 201.09, 145.40, 
140.78, 136.18, 132.81, 131.09, 127.28, 127.23, 127.16, 126.77, 118.57, 117.39, 
116.21, 113.47, 113.02, 112.78, 83.79, 83.67, 83.31, 45.91, 25.12, 24.90, 24.64, 24.51 
ppm; IR (ATR): 𝜐 = 1752 cm-1 (m, C=O); FTMS + p NSI MS: m/z (%): 886.4222 




methyl)phenyl carbonochloridate (6.3) 
 
4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenoxazin-10-
yl)methyl)phenol (300 mg, 0.56 mmol) was dissolved in DCM (30 mL) and the 
solution cooled to 0 °C. Triethylamine (0.15 mL, 1.11 mmol) was then added, 
followed by 2-chloroacetyl chloride (0.09 mL, 1.11 mmol). The mixture was allowed 
to warm to RT and stirred for 24 h. The reaction was quenched with water (20 mL) 
and the phases were separated. The organic layer was washed with water (3 x 50 mL), 
dried over MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum ether/ 
EtOAc 80:20) gave 4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-
phenoxazin-10-yl) methyl)phenyl carbonochloridate (41 mg, 12 %) as a dark green 
solid.  
 
1H NMR (300 MHz, CDCl3): δ = 7.24 (d, J = 8.6 Hz, 2 H; ArH), 7.10 – 7.07 (m, 2 H; 
ArH), 7.04 – 7.00 (m, 4 H; ArH), 6.23 (d, J = 7.9 Hz, 2 H; ArH), 4.72 (s, 2 H; H–
C(2’’’), 4.62 (s, 2 H; H–C(7’’)), 1.23 ppm (s, 24 H; H–C(2’’’’’’’), H–C(3’’’’’’’), H–
C(5’’’’’’’), H–C(6’’’’’’’), H–C(2’’’’’’’’), H–C(3’’’’’’’’), H–C(5’’’’’’’’), H–
C(6’’’’’’’’)); 13C NMR (126 MHz, CDCl3): δ = 183.21, 158.19, 145.36, 136.93, 
131.94, 128.66, 127.75, 120.11, 117.33, 116.48, 113.55, 84.07, 62.16, 47.94, 25.25 
ppm; m.p.: 171 – 174 °C; IR (ATR): 𝜐 = 1736 cm-1 (w, C=O); FTMS + p NSI MS: 













yl)methyl)phenyl carbonochloridate (40 mg, 0.07 mmol) was dissolved in acetonitrile 
(10 mL). Pyridine (64 μL, 0.80 mmol) and potassium iodide (22 mg, 0.13 mmol) were 
then added. The mixture was refluxed at 80 °C for 24 h. The solvent was evaporated 
in vacuo. FC (SiO2; petroleum ether/EtOAc 80:20) gave 1-(2-(4-((3,7-bis(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenoxazin-10-yl)methyl)phenoxy)-2-
oxoethyl)pyridin-1-ium (27 mg, 59 %) as a yellow oil. 
 
1H NMR (300 MHz, CDCl3): δ = 8.69 – 8.68 (m, 2 H; ArH), 7.53 – 7.48 (m, 1 H; 
ArH), 7.17 – 7.12 (m, 4 H; ArH), 7.07 – 7.05 (m, 2 H; ArH), 6.81 – 6.78 (m, 2 H; 
ArH), 6.34 – 6.32 (d, J = 7.9 Hz, 2 H; ArH), 6.30 – 6.27 (d, J = 8.0 Hz, 2 H; ArH), 
5.77 (s, 2 H; H–C(2’’’)), 4.72 (s, 2 H; H–C(7’’)), 1.30 ppm (s, 24 H; H–C(2’’’’’’’), 
H–C(3’’’’’’’), H–C(5’’’’’’’), H–C(6’’’’’’’), H–C(2’’’’’’’’), H–C(3’’’’’’’’), H–
C(5’’’’’’’’), H–C(6’’’’’’’’)); 13C NMR (126 MHz, CDCl3): δ = 154.95, 146.56, 
144.89, 136.18, 131.13, 130.67, 130.17, 129.88, 128.35, 127.67, 127.52, 121.11, 
115.98, 111.84, 83.75, 63.76, 48.27, 24.96 ppm; IR (ATR): 𝜐 = 1702 cm-1 (m, C=O); 








pent-4-ynoyl chloride (11.2) 
 
4-Pentynoic acid (300 mg, 3.06 mmol) was dissolved in DCM/DMF (10 ml/10 μL). 
Thionyl chloride (1.16 mL, 15.9 mmol) was added slowly to the mixture. The solution 
was refluxed at 40 °C for 6 h. Solvent was evaporated in vacuo giving pent-4-ynoyl 
chloride (270 mg, 76 %) as a light brown oil. 
 
1H NMR (500 MHz, CDCl3): δ = 3.13 (t, J = 7.1 Hz, 2 H; H–C(4)), 2.57 (td, J = 7.1, 
2.7 Hz, 2 H; H–C(3)), 2.04 ppm (t, J = 2.7 Hz, 1 H; H–C(1)); 13C NMR (126 MHz, 
CDCl3): δ = 172.12, 80.38, 70.26, 45.63, 14.69 ppm; IR (ATR): 𝜐 = 2119 (w, C≡C), 


















yl)methyl)phenyl pent-4-ynoate (10.1) 
 
4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenoxazin-10-
yl)methyl)phenol (200 mg, 0.37 mmol) was dissolved in DCM (40 mL). The solution 
was cooled to 0 °C, followed by the addition of triethylamine (0.1 mL, 0.74 mmol), 
and pent-4-ynoyl chloride (86 mg, 0.74 mmol). The mixture was allowed to warm up 
to RT and stirred for 3 h. The reaction was quenched with water. After separation of 
the phases, the organic layer was washed with water (3 x 30 mL), dried over MgSO4, 
filtered and evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 80:20) gave 4-
((3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenoxazin-10-
yl)methyl)phenyl pent-4-ynoate (107 mg, 47 %) as a dark orange oil. 
 
1H NMR (300 MHz, CDCl3): δ = 7.33 – 7.23 (m, 2 H; ArH), 7.20 – 7.10 (m, 2 H; 
ArH), 7.10 – 7.01 (m, 4 H; ArH), 6.30 (d, J = 7.9 Hz, 2 H; ArH), 4.78 (s, 2 H; H–
C(7’’)), 2.83 – 2.67 (m, 1 H; H–C(5’’’)), 2.63 – 2.48 (m, 2 H; H–C(2’’’)), 2.07 – 1.97 
(m, 2 H; H–C(3’’’)), 1.26 ppm (s, 24 H; H–C(2’’’’), H–C(3’’’’), H–C(5’’’’), H–
C(6’’’’), H–C(2’’’’’), H–C(3’’’’’), H–C(5’’’’’), H–C(6’’’’’)); 13C NMR (126 MHz, 
CDCl3): δ = 170.40, 149.86, 144.84, 135.97, 134.87, 133.47, 131.37, 127.83, 127.21, 
122.18, 121.19, 111.80, 83.77, 83.31, 75.26, 69.59, 33.62, 24.67 ppm; IR (ATR): 𝜐 = 
2161 (w, C≡C), 1280 (m, C–N) 1121 cm-1 (s, C–O); FTMS + p APCI corona MS: m/z 







yl)methyl)phenyl pentanoate (10.2) 
 
4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenoxazin-10-
yl)methyl)phenol (200 mg, 0.37 mmol) was dissolved in DCM (30 mL). The solution 
was cooled to 0 °C. First triethylamine (0.10 ml, 0.74 mmol) was added, followed by 
dropwise addition of valeroyl chloride (0.1 ml, 0.74 mmol). The mixture was stirred 
for 4 h at RT. The reaction was quenched with water, and the phases were separated. 
The organic phase was washed with water (3 x 20 ml), dried over MgSO4, filtered and 
evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 80:20) gave 4-((3,7-
bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenoxazin-10-yl)methyl) 
phenyl pentanoate (72 mg, 31%) as a yellow/orange solid. 
 
1H NMR (500 MHz, CDCl3): δ = 7.28 (d, J = 8.4 Hz, 2 H; ArH), 7.16 (dd, J = 7.9, 1.4 
Hz, 2 H; ArH), 7.07 (d, J = 1.4 Hz, 2 H; ArH), 7.04 (d, J = 8.5 Hz, 2 H; ArH), 6.31 (d, 
J = 8.0 Hz, 2 H; ArH), 4.78 (s, 2 H; H–C(7’’)), 2.54 (t, J = 7.5 Hz, 2 H; H–C(2’’’)), 
1.78 – 1.68 (m, 2 H; H–C(3’’’)), 1.48 – 1.38 (m, 2 H; H–C(4’’’’)), 1.31 (s, 24 H; H–
C(2’’’’), H–C(3’’’’), H–C(5’’’’), H–C(6’’’’), H–C(2’’’’’), H–C(3’’’’’), H–C(5’’’’’), 
H–C(6’’’’’)), 1.01 – 0.94 ppm (m, 3 H; H–C(5’’’)); 13C NMR (126 MHz, CDCl3): δ = 
179.34, 172.42, 150.06, 144.86, 136.00, 133.19, 131.16, 127.16, 122.26, 121.17, 
111.83, 83.76, 48.57, 33.76, 26.89, 24.95, 22.32, 13.82 ppm; m.p. 183 – 186 °C; IR 











yl)methyl)phenol (200 mg, 0.37 mmol) was dissolved in THF (30 mL). NaH – 60 % 
mineral oil (22 mg, 0.56 mmol) was added, followed by dropwise addition of 
propargyl bromide – 80 wt% in toluene (0.09 mL, 0.56 mmol). The mixture was stirred 
at RT for 20 h. The reaction was quenched with MeOH (20 mL), diluted with EtOAc 
(30 mL), washed with water (3 x 60 mL), dried over MgSO4, filtered and evaporated 
in vacuo. FC (SiO2; petroleum ether/EtOAc 80:20) gave 3,7-dibromo-10-(4-(prop-2-
yn-1-yloxy)benzyl)-10H-phenoxazine (110 mg, 51 %) as a dark yellow oil. 
 
1H NMR (300 MHz, CDCl3): δ = 7.20 (d, J = 8.4 Hz, 2 H; ArH), 7.15 (dd, J = 7.9, 1.4 
Hz, 2 H; ArH), 7.06 (d, J = 1.4 Hz, 2 H; ArH), 6.93 (d, J = 8.7 Hz, 2 H; ArH), 6.33 (d, 
J = 8.0 Hz, 2 H; ArH), 4.74 (s, 2 H; H–C(7’’)), 4.66 (d, J = 2.4 Hz, 2 H; H–C(1’’’)), 
2.51 (t, J = 2.3 Hz, 1 H; H–C(3’’’)), 1.26 ppm (s, 24 H; H–C(2’’’’), H–C(3’’’’), H–
C(5’’’’), H–C(6’’’’), H–C(2’’’’’), H–C(3’’’’’), H–C(5’’’’’), H–C(6’’’’’)); 13C NMR 
(126 MHz, (CD3)2CO): δ = 158.03, 145.41, 137.01, 132.17, 129.51, 128.42, 128.38, 
121.56, 121.51, 116.26, 116.23, 113.19, 84.49, 79.92, 48.07, 25.32 ppm; IR (ATR): 𝜐 
= 2160 (w, C≡C), 1346 cm-1 (s, C–O); FTMS + p APCI corona MS: m/z (%): 579.2958 











yl)methyl)phenol (300 mg, 0.55 mmol) was dissolved in THF (30 mL). NaH–60 % 
mineral oil (32 mg, 0.83 mmol) was added, followed by dropwise addition of 
propargyl bromide – 80 wt% in toluene (0.15 mL, 0.83 mmol). The mixture was stirred 
at RT for 20 h. The reaction was quenched with MeOH (20 mL), diluted with EtOAc 
(30 mL), washed with water (3 x 60 mL), dried over MgSO4, filtered and evaporated 
in vacuo. FC (SiO2; petroleum ether/EtOAc 80:20) gave 10-(4-propoxybenzyl)-3,7-
bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-phenoxazine (130 mg, 41 %) as 
a yellow solid. 
 
1H NMR (500 MHz, CDCl3): δ = 7.20 – 7.11 (m, 4 H; ArH), 7.10 – 7.03 (m, 2 H; 
ArH), 6.79 (dd, J = 8.5, 6.1 Hz, 1 H; ArH), 6.70 – 6.64 (m, 1 H; ArH), 6.34 (dd, J = 
7.9, 3.8 Hz, 2 H; ArH), 4.72 (s, 2 H; H–C(7’’)), 4.12 (q, J = 7.2 Hz, 2 H; H–C(1’’’)), 
1.30 (s, 24 H; H–C(2’’’’), H–C(3’’’’), H–C(5’’’’), H–C(6’’’’), H–C(2’’’’’), H–
C(3’’’’’), H–C(5’’’’’), H–C(6’’’’’) ), 1.28 – 1.23 (m, 2 H; H–C(2’’’)) 0.89 – 0.83 ppm 
(m, 3 H; H–C(3’’’)); 13C NMR (126 MHz, CDCl3): δ = 176.69, 171.50, 155.17, 
155.05, 145.57, 144.88, 144.61, 136.82, 136.21, 133.42, 131.27, 131.12, 129.79, 
127.75, 127.49, 127.47, 127.44, 127.25, 123.65, 121.75, 121.11, 115.96, 115.47, 
115.39, 112.51, 111.89, 111.70, 83.85, 83.82, 70.68, 63.23, 24.93, 21.21, 14.33 ppm; 
m.p. 217 – 220 °C; IR (ATR): 𝜐 = 1138 cm-1 (m, C–O–C); HR-ESI-MS: m/z (%): 







yl)methyl)phenyl 4-(4-(bis(2-chloroethyl)amino)phenyl)butanoate (26.1) 
 
Chlorambucil (37 mg, 0.12 mmol) and HATU (49 mg, 0.13 mmol) were dissolved in 
DMF (5 ml) to which 4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-
phenoxazin-10-yl)methyl)phenol (100 mg, 0.18 mmol) and DIPEA (0.06 ml, 0.36 
mmol) in DMF (5 ml) was added. The solution was left to stir at RT for 24 h. After 
completion, the mixture was diluted with EtOAc (15 ml), washed with water (1 x 20 
ml) and brine (3 x 20 ml), dried with MgSO4, filtered and evaporated in vacuo. FC 
(SiO2; petroleum ether/EtOAc 80:20) gave 4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-10-phenoxazin-10-yl)methyl)phenyl 4-(4-(bis(2-chloroethyl) 
amino) phenyl)butanoate (30 mg, 20 %) as an orange solid. 
 
1H NMR (500 MHz, CDCl3): δ = 7.48 – 7.43 (m, 4 H; ArH), 7.34 (dd, J = 7.9, 1.3 Hz, 
2 H; ArH), 7.29 (d, J = 8.2 Hz, 2 H; ArH), 7.20 (d, J = 8.2 Hz, 2 H; ArH), 6.82 (d, J = 
8.3 Hz, 2 H; ArH), 6.50 (d, J = 7.9 Hz, 2 H; ArH), 4.96 (s, 2 H; H–C(7‘‘)), 3.89 (t, J 
= 7.0 Hz, 4 H; H–C(12‘‘‘),H–C(14‘‘‘)), 3.80 (t, J = 7.0 Hz, 4 H; H–C(11‘‘‘), H–
C(13‘‘‘)), 2.83 (t, J = 7.5 Hz, 2 H; H–C(2‘‘‘)), 2.74 (t, J = 7.3 Hz, 2 H; H–C(4‘‘‘)), 
2.21 (p, J = 7.4 Hz, 2 H; H–C(3‘‘‘)), 1.49 ppm (s, 24 H; H–C(2‘‘‘‘), H–C(3‘‘‘‘), H–
C(5‘‘‘‘), H–C(6‘‘‘‘), H–C(2‘‘‘‘‘), H–C(3‘‘‘‘‘), H–C(5‘‘‘‘‘), H–C(6‘‘‘‘‘)); 13C NMR 
(126 MHz, CDCl3): δ = 172.14, 149.99, 144.84, 144.57, 135.97, 133.24, 131.15, 
130.48, 129.90, 127.17, 122.22, 121.18, 112.37, 111.81, 83.74, 53.76, 48.50, 40.66, 
34.07, 33.78, 26.83, 24.95 ppm; m.p.: 105 – 108 °C; IR (ATR): 𝜐 = 1755 (m, C=O), 











Indomethacin (43 mg, 0.12 mmol) and HATU (49 mg, 0.13 mmol) were dissolved in 
DMF (5 ml) to which 4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-10H-
phenoxazin-10-yl)methyl)phenol (100 mg, 0.18 mmol) and DIPEA (0.06 ml, 0.36 
mmol) in DMF (5 ml) was added.The solution was left to stir at RT for 24 h. After 
completion, the mixture was diluted with EtOAc (15 ml), washed with water (1 x 20 
ml) and brine (3 x 20 ml), dried with MgSO4, filtered and evaporated in vacuo. FC 
(SiO2; petroleum ether/EtOAc 80:20) gave 4-((3,7-bis(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-10H-phenoxazin-10-yl)methyl)phenyl 2-(1-(4-chlorobenzoyl)-5-
methoxy-2-methyl-1H-indol-3-yl)acetate (45 mg, 28 %) as a dark orange solid. 
 
1H NMR (500 MHz, CDCl3): δ = 7.67 (dd, J = 8.4, 1.4 Hz, 2 H; ArH), 7.49 – 7.45 (m, 
2 H; ArH), 7.16 – 7.10 (m, 4 H; ArH), 7.08 – 7.03 (m, 4 H; ArH), 6.89 (d, J = 9.1 Hz, 
1 H; ArH), 6.79 – 6.76 (m, 1 H; ArH), 6.71 – 6.67 (m, 1 H; ArH), 6.29 (d, J = 7.9 Hz, 
2 H; ArH), 4.76 (s, 2 H; H–C(7‘‘)), 3.89 (s, 2 H; H–C(2‘‘‘)), 3.83 (s, 3 H; H–C(7‘‘‘)), 
2.44 (s, 3 H; H–C(12‘‘‘)), 1.31 ppm (s, 24 H; H–C(2‘‘‘‘), H–C(3‘‘‘‘), H–C(5‘‘‘‘), H–
C(6‘‘‘‘), H–C(2‘‘‘‘‘), H–C(3‘‘‘‘‘), H–C(5‘‘‘‘‘), H–C(6‘‘‘‘‘)); 13C NMR (126 MHz, 
CDCl3): δ = 169.42, 168.44, 156.28, 149.98, 144.87, 144.83, 139.48, 136.33, 136.19, 
135.93, 131.33, 131.13, 129.28, 127.44, 127.21, 122.07, 121.19, 115.95, 115.16, 
111.86, 111.77, 101.32, 83.78, 83.76, 55.89, 48.44, 30.70, 24.94, 13.56 ppm; m.p.: 
162 – 165 °C; IR (ATR): 𝜐 = 1591 (m, C=O), 1346 cm-1 (s, C–O–C); HR-ESI-MS: 





2.3. In vitro Studies 
 
HeLa cells and RAW264.7 macrophages were obtained from ATCC (the American 
Type Culture Collection). RAW264.7 macrophages and HeLa cells were maintained 
in a Dulbecco’s Modified Eagle’s Medium supplemented with 10 % FBS in a 
humidified atmosphere of 5 % CO2 and 95 % air at 37 ℃ and split when the cells 
reached 90 % confluency. 
 
Cell viability assay 
Cells were plated on 96-well plates in growth medium. After 24 h, cells were treated 
with probes at different concentrations (2.5, 5, 10, 20, and 40 μM) for 24 h. Then, cell 
viability was determined through a standard MTS cell proliferation assay. 
 
Confocal laser scanning microscopy 
Cells cultured in growth medium supplemented with 10 % FBS were plated onto 24-
well microplates. Cells were maintained in a humidified atmosphere of 5 % CO2 and 
95 % air at 37 °C overnight. To detect ONOO- exogenously in HeLa cells and 
RAW264.7 macrophages, the cells were first incubated with the probe (20 μM, 1% 
DMSO in PBS, pH 7.4) for 30 min, followed by incubation with SIN-1 (500 μM) for 
30 min. To quench the exogenously produced ONOO-, the cells were pre-incubated 
with uric acid (100 μM) for 2 h, then SIN-1 (500 μM) for 30 min, and finally the probe 
(20 μM) for 30 min. To simulate endogenous ONOO-, LPS (1 μg/mL) was first 
incubated for 24 h in RAW264.7 macrophages. After washing with PBS, the cells 
were incubated with the probe (20 μM) for 30 min. The cells were washed with PBS 
three times and fixed by 4 % paraformaldehyde for 20 min at RT. After rinsing twice 
with PBS, the cells were stained with Hoechst33342 (5 μg/mL) at 37 °C in a 
humidified atmosphere of 5 % CO2 in air for 5 min. After three rinses with PBS, the 
samples were evaluated on a confocal laser scanning microscopy (Olympus, Japan) 
with ex = 559 nm and em = 580 – 650 nm for probes and ex = 405 nm and em = 470 
– 520 nm for Hoechst33342. 
197 
2.4. In vivo Studies 
 
All animal experiments were approved by the Animal Care and Use Committee of the 
Shanghai Institute of Materia Medica (SIMM), where the experiments were 
conducted. In addition, approval by the Animal Research Ethics Committee of the 
University of Bath was given 
 
In vivo imaging 
Animals were housed in a SPF temperature-controlled room (22 ± 2°C) under a 12 h 
light/dark cycle in the Shanghai Institute of Materia Medica (SIMM) of the Chinese 
Academy of Science. Animals were anesthetized with pentobarbital sodium (50 
mg/kg). At the end of the study, the mice were euthanized with CO2 asphyxiation 
without recovery from the anaesthesia, according to the rules of Animal Care and Use 
Committee of the Shanghai Institute of Materia Medica. Mice were divided into four 
groups and three mice were used in each group from three independent experiments. 
In addition, four mice were used for preliminary experiments to explore conditions. 
 
C57BL/6J mice were divided into two groups; the first group was given an 
intraperitoneal (i.p.) injection of saline (200 μL) as a control group, and the second 
group was injected i.p. with LPS (200 μL, 2 mg/ml in saline, Sigma Aldrich). After 4 
h, animals were anesthetized and abdominal fur was removed using a razor. Then, 
mice were injected i.p. with the probe (100 μL, 200 μM in saline) or saline (100 μL). 
Whole body images were acquired in 30 min by using the IVIS spectrum imaging 













2,4-dihydroxybenzaldehyde (1.00 g, 7.24 mmol) and 4-(bromomethyl)benzene- 
boronic acid pinacol ester (2.20 g, 7.24 mmol) were dissolved in acetonitrile (15 ml) 
to which K2CO3 (1.00 g, 7.24 mmol) and KI (96 mg, 0.58 mmol) were added. The 
solution was refluxed at 80 °C for 2 h. After completion, the mixture was allowed to 
cool to RT, diluted with 1M HCl, extracted with DCM (3 x 10 ml), washed with brine 
(2 x 20 ml), dried over MgSO4, filtered and evaporated in vacuo. Recrystallization in 
ethanol gave 2-hydroxy-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy) benzaldehyde (1.25 g, 49 %) gave a pale orange solid. 
 
1H NMR (500 MHz, CDCl3): δ = 11.44 (s, 1 H; O–H(8)), 9.71 (s, 1 H; H–C(7)), 7.86 
– 7.81 (m, 2 H; ArH), 7.42 (dd, J = 9.7, 8.2 Hz, 3 H; ArH), 6.60 (dd, J = 8.7, 2.4 Hz, 
1 H; ArH), 6.49 (d, J = 2.3 Hz, 1 H; ArH), 5.13 (s, 2 H; H–C(7‘)), 1.35 ppm (s, 9 H; 
H–C(2‘‘), H–C(3‘‘), H–C(5‘‘), H–C(6‘‘)); 13C NMR (126 MHz, CDCl3): δ = 194.54, 
165.97, 164.57, 138.84, 135.44, 135.31, 126.70, 126.55, 115.51, 109.06, 101.89, 
84.06, 70.42, 25.02 ppm; m.p.: 80 – 83 °C; IR (ATR): 𝜐 = 2978 (br. m, H–C=O), 1649 








chromene-3-carboxylic acid (5.5) 
 
2-hydroxy-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)benzalde- 
hyde (1.00 g, 2.82 mmol) and 2,2-dimethyl-1,3-dioxan-4,6-dione (426 mg, 2.96 
mmol) were dissolved in ethanol (15 ml) to which piperidine (6 μl, 0.06 mmol) and 
acetic acid (3.5 μl, 0.06 mmol) were added. The mixture was left to stir first at RT for 
30 min and then refluxed at 78 °C for 3 h. After completion, the solution was cooled 
to RT, the precipitate filtered off and dried in vacuo. This gave 2-oxo-7-((4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-2H-chromene-3-carboxylic acid 
(657 mg, 55 %) as a pale yellow solid. 
 
1H NMR (500 MHz, (CD3)2SO): δ = 8.65 (s, 1 H; H–C(7)), 7.82 (d, J = 8.7 Hz, 1 H; 
ArH), 7.71 (d, J = 7.7 Hz, 2 H; ArH), 7.48 (d, J = 7.8 Hz, 2 H; ArH), 7.16 – 7.03 (m, 
2 H; ArH), 5.30 (s, 2 H; H–C(7‘)), 1.29 ppm (s, 12 H; H–C(2‘‘), H–C(3‘‘), H–C(5‘‘), 
H–C(6‘‘)); 13C NMR (126 MHz, (CD3)2SO): δ = 164.22, 163.17, 157.24, 156.55, 
139.37, 134.62, 131.38, 129.02, 127.04, 113.71, 111.93, 105.47, 104.56, 101.18, 
83.70, 69.85, 24.66 ppm; m.p.: 162 – 165 °C; IR (ATR): 𝜐 = 1746 (m, C=O), 1355 











(4-aminobutyl)triphenylphosphonium bromide (6.2) 
 
(4-bromobutyl)triphenylphosphonium bromide (250 mg, 0.63 mmol) was dissolved in 
an ammonia solution (7M in methanol, 25 ml). The solution was stirred at RT for 72 
h and evaporated in vacuo. This gave (4-aminobutyl)triphenylphosphonium bromide 
as a white solid (158 mg, 76 %). 
 
1H NMR (500 MHz, CDCl3): δ = 8.01 – 7.57 (m, 15 H; ArH), 3.66 (s, 2 H; H–C(4)), 
3.15 (s, 2 H; H–C(1)), 2.27 (s, 2 H; H–C(3)), 1.95 ppm (s, 2 H; H–C(2)); 13C NMR 
(126 MHz, CDCl3): δ = 135.38, 134.13, 134.05, 130.88, 118.45, 117.76, 39.33, 34.51, 
23.17, 22.76 ppm; m.p.: 67 – 69 °C; IR (ATR): 𝜐 = 1587 cm-1 (m, N–H); HR-ESI-MS: 



















Ethylenediamine (0.85 ml, 10.0 mmol) was dissolved in DCM (10 ml) and cooled to 
0 °C. Triethylamine (0.41 ml, 30 mmol) was slowly added, followed by 4-
methylbenzenesulfonyl chloride (1.42 g, 7.5 mmol) dissolved previously in DCM (10 
ml). The solution was allowed to warm up to RT and stirred for 24 h. The solution was 
further diluted with DCM (50 ml), washed with 15 % NaHCO3 (3 x 20 mL) and water 
(3 x 30 mL), dried over MgSO4, filtered and evaporated in vacuo. Recrystallization in 




1H NMR (500 MHz, CDCl3): δ = 7.71 (d, J = 8.3 Hz, 2 H; H–C(2), H–C(4)), 7.31 (d, 
J = 7.9 Hz, 2 H; H–C(1), H–C(5)), 2.98 (s, 2 H; H–C(2’)), 2.85 (s, 2 H; H–C(3’)), 2.40 
ppm (s, 3 H; H–C(7)); 13C NMR (126 MHz, CDCl3): δ = 143.95, 136.60, 130.00, 
129.85, 127.28, 43.14, 21.70 ppm; m.p.: 105 – 107 °C; IR (ATR): 𝜐 = 1596 cm-1 (m, 

















(4-aminobutyl)triphenylphosphonium bromide (80 mg, 0.24 mmol), HATU (95 mg, 
0.25 mmol) and DMAP (15 mg, 0.12 mmol) were dissolved in DMF (5 ml) to which 
2-oxo-7-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-2H-
chromene-3-carboxylic acid (100 mg, 0.24 mmol) and DIPEA (60 μl, 0.36 mmol) in 
DMF (5 ml) was added. The solution was left to stir at RT for 16 h. After completion, 
the mixture was diluted with EtOAc (15 ml), washed with water (3 x 20 ml) and brine 
(3 x 20 ml), dried with MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum 
ether/EtOAc 70:30) gave (4-(2-oxo-7-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)-2H-chromene-3-carboxamido)butyl)triphenylphosphonium (31 mg, 
18 %) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3): δ = 8.48 (s, 1 H; H–C(7)), 8.23 – 8.15 (m, 4 H; ArH), 
7.87 – 7.75 (m,  4 H; ArH), 7.75 – 7.62 (m, 4 H; ArH), 7.41 (dd, J = 8.2, 3.3 Hz, 4 H; 
ArH), 6.97 – 6.82 (m, 2 H; ArH), 6.55 – 6.49 (m, 4 H; ArH), 5.16 (d, J = 6.0 Hz, 2 H; 
H–C(1‘‘)), 3.38 – 3.29 (m, 2 H; H–C(3‘)), 3.00 – 2.82 (m, 2 H; H–C(6‘)), 1.65 (m, 2 
H; H–C(4‘)), 1.44 – 1.35 (m, 2 H; H–C(5‘)), 1.33 ppm (s, 12 H; H–C(2‘‘‘), H–C(3‘‘‘), 
H–C(5‘‘‘), H–C(6‘‘‘)); 13C NMR (126 MHz, CDCl3): δ = 164.21, 162.61, 157.53, 
154.81, 149.02, 148.30, 142.82, 135.32, 135.29, 133.63, 133.60, 133.55, 133.52, 
130.87, 130.80, 130.72, 130.70, 130.62, 129.62, 126.72, 126.69, 114.34, 113.94, 
111.95, 106.76, 101.91, 101.62, 84.02, 70.65, 48.55, 43.20, 39.27, 24.99 ppm; IR 
(ATR): 𝜐 = 1717 (m, C=O), 1358 cm-1 (s, C–O–C); HR-ESI-MS: m/z (%): 738.3135 







2-Morpholinoethylamine (31 mg, 0.24 mmol), HATU (95 mg, 0.25 mmol) and DMAP 
(15 mg, 0.12 mmol) were dissolved in DMF (5 ml) to which 2-oxo-7-((4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-2H-chromene-3-carboxylic acid 
(100 mg, 0.24 mmol) and DIPEA (60 μl, 0.36 mmol) in DMF (5 ml) were added. The 
solution was left to stir at RT for 16 h. After completion, the mixture was diluted with 
EtOAc (15 ml), washed with water (3 x 20 ml) and brine (3 x 20 ml), dried with 
MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 70:30) 
gave N-(2-morpholinoethyl)-2-oxo-7-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)-2H-chromene-3-carboxamide (36 mg, 28 %) as a yellow solid. 
 
1H NMR (500 MHz, CDCl3): δ = 8.16 (s, 1 H; H–C(7)), 7.83 – 7.80 (m, 2 H; ArH), 
7.43 – 7.40 (m, 2 H; ArH), 7.08 (d, J = 8.6 Hz, 1 H; ArH), 6.47 – 6.42 (m, 2 H; ArH), 
5.08 (s, 2 H; H–C(1‘‘)), 3.73 – 3.70 (m, 4 H; H–C(6‘), H–C(7‘)), 3.68 – 3.64 (m, 2 H; 
H–C(3‘)), 2.66 (t, J = 6.7 Hz, 2 H; H–C(4‘)), 2.52 (dd, J = 5.7, 3.7 Hz, 4 H; H–C(5‘), 
H–C(8‘)), 1.34 ppm (s, 12 H; H–C(2‘‘‘), H–C(3‘‘‘), H–C(5‘‘‘), H–C(6‘‘‘)); 13C NMR 
(126 MHz, CDCl3): δ = 166.26, 164.47, 162.96, 139.70, 135.25, 135.19, 135.14, 
132.75, 126.76, 126.69, 112.57, 107.13, 102.56, 83.97, 69.98, 67.10, 59.18, 55.16, 
53.99 ppm; m.p.: 125 – 128 °C; IR (ATR): 𝜐 = 1612 (s, C=O), 1114 cm-1 (s, C–O–C); 












N-(2-aminoethyl)-4-methylbenzenesulfonamide (51 mg, 0.24 mmol), HATU (95 mg, 
0.25 mmol) and DMAP (15 mg, 0.12 mmol) were dissolved in DMF (5 ml) to which 
2-oxo-7-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-2H-
chromene-3-carboxylic acid (100 mg, 0.24 mmol) and DIPEA (60 μl, 0.36 mmol) in 
DMF (5 ml) were added. The solution was left to stir at RT for 16 h. After completion, 
the mixture was diluted with EtOAc (15 ml), washed with water (3 x 20 ml) and brine 
(3 x 20 ml), dried with MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum 
ether/EtOAc 70:30) gave N-(2-((4-methylphenyl)sulfonamido)ethyl)-2-oxo-7-((4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-2H-chromene-3-
carboxamide (35 mg, 24 %) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3): δ = 8.17 (s, 1 H; H–C(7)), 7.82 (dq, J = 5.0, 3.1, 2.6 Hz, 
2 H; ArH), 7.71 – 7.64 (m, 3 H; ArH), 7.45 – 7.37 (m, 2 H; ArH), 7.31 – 7.17 (m, 2 
H; ArH), 6.52 – 6.47 (m, 2 H; ArH), 5.18 – 5.13 (m, 2 H; H–C(1‘‘)), 3.02 (d, J = 1.3 
Hz, 2 H; H–C(3‘)), 2.41 (d, J = 2.8 Hz, 2 H; H–C(4‘)), 2.39 (s, 3 H; H–C(12‘)), 1.33 
ppm (s, 12 H; H–C(2‘‘‘), H–C(3‘‘‘), H–C(5‘‘‘), H–C(6‘‘‘)); 13C NMR (126 MHz, 
CDCl3): δ = 154.65, 149.04, 148.76, 143.50, 136.90, 135.28, 130.88, 130.06, 129.82, 
128.46, 127.14, 126.71, 126.68, 114.35, 114.28, 113.95, 106.74, 101.88, 101.60, 
83.98, 70.78, 43.08, 39.21, 24.98, 21.61 ppm; IR (ATR): 𝜐 = 1720 (m, C=O), 1154 







Tert-butyl (2-aminoethyl)carbamate (10.2) 
 
Ethylenediamine (30 ml, 0.45 mol) was dissolved in chloroform (70 ml) to which di-
tert-butyl dicarbonate (10.00 g, 0.045 mol) in chloroform (50 ml) was very slowly 
added at 0 °C. The solution was left to stir at RT for 24 h. After completion, the mixture 
was poured into water (40 ml). The organic layer was separated and washed with brine 
(2 x 60 ml), dried over MgSO4, and evaporated in vacuo. This gave tert-butyl (2-
aminoethyl)carbamate (6.44 g, 89 %) as a colourless oil. 
 
1H NMR (500 MHz, CDCl3): δ = 4.88 (s, 1 H; H–C(4)), 3.16 (q, J = 6.1 Hz, 2 H; H–
C(2)), 2.79 (td, J = 6.0, 1.3 Hz, 2 H; H–C(3)), 1.47 – 1.41 (m, 9 H; H–C(7), H–C(8), 
H–C(9)), 1.37 ppm (s, 2 H; H–C(1)); 13C NMR (126 MHz, CDCl3): δ = 156.34, 79.37, 
43.56, 31.38, 28.55 ppm; IR (ATR): 𝜐 = 1684 (s, C=O), 1506 cm-1 (s, N–H); HR-ESI-



















Tert-butyl (2-aminoethyl)carbamate (2.88 g, 18 mmol) was dissolved in ethanol (80 
ml) to which 4-bromo-1,8-naphthalic anhydride (5.00 g, 18 mmol) was added. The 
mixture was refluxed at 75 °C for 2 h. After completion, the reaction was cooled to 
RT and the solid was filtered off. The precipitate was washed with cold ethanol and 
dried in vacuo. This gave tert-butyl (2-(6-bromo-1,3-dioxo-1H-benzo[de]isoquinolin-
2(3H)-yl)ethyl)carbamate (6.41 g, 85 %) as a white solid. 
 
1H NMR (300 MHz, CDCl3): δ = 8.67 (dd, J = 7.3, 1.1 Hz, 1 H; ArH), 8.58 (dd, J = 
8.6, 1.1 Hz, 1 H; ArH), 8.43 (d, J = 7.9 Hz, 1 H; ArH), 8.05 (d, J = 7.9 Hz, 1 H; ArH), 
7.86 (dd, J = 8.5, 7.3 Hz, 1 H; ArH), 4.92 (s, 1 H; N–H(3’)), 4.36 (t, J = 5.7 Hz, 2 H; 
H–C(2’)), 3.53 (d, J = 5.9 Hz, 2 H; H–C(1’)), 1.27 ppm (s, 9 H; H–C(6’), H–C(7’), 
H–C(8’)); 13C NMR (126 MHz, CDCl3): δ = 164.16, 156.21, 137.48, 136.12, 134.40, 
133.57, 133.03, 132.40, 131.57, 131.28, 130.81, 130.55, 129.28, 128.68, 128.24, 
84.30, 40.19, 28.35 ppm; m.p. 178 – 181 °C; IR (ATR): 𝜐 = 3368 (w, O=C–N–H), 














carbamate (250 mg, 0.6 mmol) was dissolved in DCM (5 ml) to which trifluroacteic 
acid (0.3 ml, 3.9 mmol) was added. The solution was left to stir at RT for 2 h. After 
completion, solvent and TFA were evaporated in vacuo. This gave 2-(2-aminoethyl)-
6-bromo-1H-benzo[de]isoquinoline-1,3(2H)-dione (185 mg, 96 %) as a pale beige 
solid. 
 
1H NMR (500 MHz, CDCl3): δ = 8.54 (t, J = 8.5 Hz, 2 H; ArH), 8.30 (d, J = 7.8 Hz, 
1 H; ArH), 7.97 (d, J = 7.6 Hz, 1 H; ArH), 7.79 (t, J = 7.8 Hz, 1 H; ArH), 6.90 (s, 2 
H; H2–N(3’)), 4.59 – 4.47 (m, 2 H; H–C(1’)), 3.56 – 3.49 ppm (m, 2 H; H–C(2’)); 
13C 
NMR (126 MHz, (CD3)2SO): δ = 163.60, 163.56, 132.80, 131.61, 131.45, 130.99, 
129.88, 129.21, 128.93, 128.56, 123.08, 122.30, 48.59, 37.58 ppm; m.p.: 193 – 196 
°C; IR (ATR): 𝜐 = 3042 (br. m, N–H2), 1653 cm-1 (s, C=O); HR-ESI-MS: m/z (%): 



















2-(2-aminoethyl)-6-bromo-1H-benzo[de]isoquinoline-1,3(2H)-dione  (76 mg, 0.24 
mmol), HATU (95 mg, 0.25 mmol) and DMAP (15 mg, 0.12 mmol) were dissolved 
in DMF (5 ml) to which 2-oxo-7-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)-2H-chromene-3-carboxylic acid (100 mg, 0.24 mmol) and DIPEA (60 
μl, 0.36 mmol) in DMF (5 ml) were added. The solution was left to stir at RT for 16 
h. After completion, the mixture was diluted with EtOAc (15 ml), washed with water 
(3 x 20 ml) and brine (3 x 20 ml), dried with MgSO4, filtered and evaporated in vacuo. 
FC (SiO2; DCM/MeOH 90:10) gave N-(2-(6-bromo-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)ethyl)-2-oxo-7-((4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzyl)oxy)-2H-chromene-3-carboxamide (44 mg, 25 %) as a 
yellow solid. 
 
1H NMR (500 MHz, CDCl3): δ = 8.53 (s, 1 H; H–C(7)), 7.88 – 7.81 (m, 4 H; ArH), 
7.50 (d, J = 8.7 Hz, 1 H; ArH), 7.44 – 7.40 (m, 4 H; ArH), 6.95 (dd, J = 8.7, 2.4 Hz, 2 
H; ArH), 6.86 (d, J = 2.4 Hz, 1 H; ArH), 5.18 (s, 2 H; H–C(1‘‘)), 2.99 (s, 2 H; H–
C(3‘)), 1.66 (s, 2 H; H–C(4‘)), 1.34 ppm (s, 12 H; H–C(2‘‘‘), H–C(3‘‘‘), H–C(5‘‘‘), 
H–C(6‘‘‘)); 13C NMR (126 MHz, CDCl3): δ = 164.36, 164.25, 157.64, 157.28, 149.58, 
138.40, 135.39, 135.35, 132.78, 131.91, 131.46, 130.96, 129.62, 126.73, 126.71, 
114.48, 113.99, 111.97, 101.64, 84.08, 60.54, 52.88, 25.01, 14.34 ppm; m.p.: 83 – 86 
°C; IR (ATR): 𝜐 = 1743 (m, C=O), 1356 cm-1 (s, C-O-C); HR-ESI-MS: m/z (%): 
725.1486 (M+H+, calcd for C37H33O8N2
81Br11B+: 725.1448). 
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3.2. In vitro Studies 
 
Confocal microscopy 
Fluorescence microscopy images were captured on an Olympus, FLUOVIEW FV10i 
using 35 mm glass base dishes (Iwaki). Images were captured at a magnification of 
x60 with the following parameters: ex = 405 nm, em = 420 – 460 nm. Laser 405 nm 
with an intensity of 50 % was used. Processing and analysis of confocal microscopy 
images were performed with Image J. 
 
Cell culture 
RAW264.7 macrophages were kindly donated by Prof. Masaru Ishii from the 
Graduate School of Medicine, Osaka University. Cells are stored at -196 °C under 
liquid nitrogen until required. Cells are warmed up in a water bath (37 °C) for 2 min. 
The cell liquid was transferred into a falcon tube, to which media (5 mL) was added. 
The solution was centrifuged at 1000 x g for 5 min at 22 °C. After removal of the 
supernatant, fresh media (1 mL) was added and the cells were thrown quickly and 
incubated at 37 °C, 5 % CO2. RAW 264.7 nacrophages were cultured in high-glucose 
Dulbecco’s modified Eagle medium (DMEM) plus Gluta Max-I supplemented with 
10 % FBS, penicillin (100 U/mL) and streptomycin (100 µg/mL) (P/S). The cells were 
incubated at 37 °C in a humidified atmosphere with 5 % CO2. During cell passaging 
(every two days), media was removed, washed with PBS (2 x 4 ml), PET (4 ml) was 
added and incubated for 3 min at 37 °C, 5 % CO2. The solution was mixed and 1 ml 
of cell solution transferred to a new culture dish containing 10 ml of DMEM 
(supplemented with FBS and P/S). 
 
Investigating Cou-mito, Cou-lys and Cou-endo with SIN-1  
Cells were plated in a glass bottom dish at a cell density of 5 x 105 cells in DMEM 
(with FBS, no P/S; 2 ml/dish) and incubated for 18 h. The culture media was removed, 
cells were washed with HBSS (2 x 2 ml), SIN-1 (100 μM) in DMEM (no phenol red, 
no FBS, no P/S) was added and incubated for 30 min / 1 h at 37 °C, 5 % CO2. The 
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culture media was removed, cells were washed with HBSS (2 x 2 ml), the probe (20 
μM) in DMEM (no phenol red, no FBS, no P/S) was added and incubated for 30 min 
at 37 °C, 5 % CO2. This was then directly used for confocal imaging. 
 
Investigate Cou-lys with LPS, IFN-γ and ebselen 
Cells were plated in a glass bottom dish at a cell density of 5 x 105 cells in DMEM 
(with FBS, no P/S; 2 ml/dish) and incubated for 18 h at 37 °C, 5 % CO2. LPS (1 μg/ml) 
and IFN-γ (50 ng/ml) were added and incubated for 4 h at 37 °C, 5 % CO2. The culture 
media was removed, cells were washed with HBSS (2 x 2ml), (where indicated, 
ebselen (50 μM) was incubated for 1 h prior to addition of the probe), the probe (20 
μM) in DMEM (no phenol red, no FBS, no P/S) was added and incubated for 30 min 
at 37 °C, 5 % CO2. This was then directly used for confocal imaging. 
 
Investigating Cou-lys with PMA  
Cells were plated in a glass bottom dish at a cell density of 5 x 105 cells in DMEM 
(with FBS, no P/S; 2 ml/dish) and incubated for 18 h at 37 °C, 5 % CO2. The culture 
media was removed, cells were washed with HBSS (2 x 2 ml), PMA (1 μg/ml) in 
DMEM (no phenol red, no FBS, no P/S) was added and incubated for 1 h respectively 
at 37 °C, 5 % CO2. The culture media was removed, cells were washed with HBSS (2 
x 2 ml), the probe (20 μM) in DMEM (no phenol red, no FBS, no P/S) was added and 















Fluorescein (400 mg, 1.20 mmol) was dissolved in acetonitrile (20 ml) to which 4-
bromomethylphenylboronic acid pinacol ester (1.07 g, 3.6 mmol) and caesium 
carbonate (1.17 g, 3.6 mmol) were added. The solution was refluxed at 80 °C for 18 h 
under N2, then cooled to RT, filtered and rinsed with DCM (50 ml). Solvent was 
evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 80:20) gave 3',6'-bis((4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-3H-spiro[isobenzofuran-
1,9'-xanthen]-3-one (275 mg, 30 %) as an orange solid. 
1H NMR (500 MHz, CD3OD): δ = 8.33 – 8.27 (m, 1 H; ArH), 7.84 – 7.67 (m, 4 H; 
ArH), 7.55 – 7.44 (m, 3 H; ArH), 7.37 – 7.30 (m, 1 H; ArH), 6.98 – 6.89 (m, 3 H; 
ArH), 6.79 – 6.71 (m, 2 H; ArH), 6.57 – 6.49 (m, 2 H; ArH), 6.30 (td, J = 4.5, 2.0 Hz, 
2 H; ArH), 5.34 – 5.20 (m, 4 H; H–C(1’’), H–C(1’’’)), 1.36 ppm (s, 24 H; H–C(9’’), 
H–C(10’’), H–C(12’’), H–C(13’’), H–C(9’’’), H–C(10’’’), H–C(12’’’), H–C(13’’’)); 
13C NMR (126 MHz, CD3OD): δ = 166.67, 165.58, 136.08, 136.06, 135.95, 134.88, 
134.07, 132.41, 131.65, 131.61, 131.26, 128.46, 128.32, 128.05, 127.93, 127.85, 
85.26, 85.19, 68.49, 25.21 ppm; m.p. 252 – 254 °C; IR (ATR): 𝜐 = 1717 (m, C=O), 




In accordance with literature values.141 
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Rhodamine 110 (7.3) 
 
3-aminophenol (3.95 g, 36.62 mol) and phthalic anhydride (2.71 g, 18.31 mmol) were 
dissolved in methansulfonic acid (16 ml). The mixture was refluxed at 140 °C for 24 
h. The solution was allowed to cool down and poured into ice water (60 ml). The pH 
was neutralized with dropwise addition of 10 M NaOH, followed by acidification with 
1 M HCl. The solid was filtered off and dried in vacuo. The solid was resuspended in 
methanol and solvent was evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 
80:20) gave rhodamine 110 (2.12 g, 35 %) as a red solid. 
 
1H NMR (300 MHz, (CD3)2CO): δ = 7.68 – 7.45 (m, 2 H; ArH), 7.16 – 7.03 (m, 3 H; 
ArH), 6.83 (td, J = 7.9, 0.4 Hz, 1 H; ArH), 6.49 (ddd, J = 8.1, 2.4, 1.0 Hz, 2 H; ArH), 
6.20 – 6.02 (m, 2 H; ArH), 2.93 ppm (s, 4 H; H–N(1’’), H–N(1’’’)); 13C NMR (75.5 
MHz, CD3OD): δ = 169.82, 134.86, 134.33, 132.62, 131.45, 130.60, 129.99, 129.98, 
129.21, 128.39, 123.55, 123.09, 117.62, 116.41, 115.71, 114.76, 113.75, 113.04, 
109.68, 96.96 ppm; m.p.: 250 – 252 °C; IR (ATR): 𝜐 = 1722 (s, C=O), 1596 cm-1 (s, 













4-bromobenzaldehyde (300 mg, 1.63 mmol), bis(pinacolato)diboron (828 mg, 3.26 
mmol), KOAc (958 mg, 9.78 mmol) were dissolved in DMF (15 mL), and degased 
under argon for 10 min. PdCl2(dppf) (117 mg, 0.16 mmol) was added to the mixture 
which was refluxed at 90 °C for 24 h. The solution was cooled to RT, filtered through 
celite, diluted with EtOAc (30 ml), washed with water (3 x 30 ml) and brine (3 x 30 
ml), dried over MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum 
ether/EtOAc 80:20) gave 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzaldehyde (258 mg, 68 %) as a dark yellow oil. 
 
1H NMR (500 MHz, CDCl3): δ = 10.05 (s, 1 H; H–C(7)), 7.96 (d, J = 8.0 Hz, 2 H; H–
C(2), H–C(4)), 7.86 (d, J = 8.2 Hz, 2 H; H–C(1), H–C(5)), 1.36 ppm (s, 12 H; H–
C(2’), H–C(3’), H–C(5’), H–C(6’)); 13C NMR (126 MHz, CDCl3): δ = 192.78, 138.27, 
135.36, 128.84, 127.89, 84.48, 24.72 ppm; IR (ATR): 𝜐 = 1703 cm-1 (m, C=O); HR-

















Rhodamine 110 (200 mg, 0.61 mmol) and 4-bromobenzaldehyde (283 mg, 1.22 mmol) 
were dissolved in ethanol/toluene (20 ml, 9:1). A Dean and Stark trap was fitted and 
the solution was refluxed at 77 °C for 24 h. Solvent was evaporated in vacuo and the 
solid was resuspended in methanol (15 ml) to which sodium borohydride (93 mg, 
18.36 mmol) was slowly added. This was left to stir at RT for 2 h and subsequently 
poured into ice water (10 ml). The organic phase was extracted with DCM (3 x 15 ml), 
dried over MgSO4, filtered and evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 
80:20) gave 3',6'-bis((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)amino)-
3H-spiro[isoben-zo furan-1,9'-xanthen]-3-one (124 mg, 27 %) as a red solid. 
 
1H NMR (500 MHz, CD3OD): δ = 7.69 (dd, J = 12.4, 7.7 Hz, 4 H; ArH), 7.63 – 7.53 
(m, 4 H; ArH), 7.49 (d, J = 7.2 Hz, 2 H; ArH), 7.42 (d, J = 7.5 Hz, 2 H; ArH), 7.33 (d, 
J = 7.0 Hz, 4 H; ArH), 6.49 (d, J = 5.3 Hz, 2 H; ArH), 4.70 – 4.47 (m, 4 H; H–C(2’’), 
H–C(2’’’)), 1.32 ppm (s, 24 H; H–C(10’’), H–C(11’’), H–C(13’’), H–C(14’’), H–
C(10’’’), H–C(11’’’), H–C(13’’’), H–C(14’’’)); 13C NMR (126 MHz, CD3OD): δ = 
150.34, 134.48, 134.33, 133.80, 133.02, 132.97, 132.66, 132.09, 132.07, 130.92, 
130.83, 129.73, 129.70, 129.70, 129.65, 129.53, 129.22, 128.40, 128.37, 128.31, 
128.26, 127.40, 127.09, 126.44, 126.20, 125.68, 124.71, 123.30, 123.23, 122.96, 
122.77, 120.73, 111.35, 110.67, 109.78, 108.93, 107.75, 105.39, 74.42, 74.06, 73.98, 
73.23, 73.13, 35.73, 23.80, 23.61 ppm; m.p.: 100 – 102 °C; IR (ATR): 𝜐 = 1610 cm-1 







3-aminophenol (2.00 g, 18.30 mmol), resorcinol (2.01 g, 18.30 mmol) and phthalic 
anhydride (2.71 g, 18.30 mmol) were dissolved in methansulfonic acid (16 ml). The 
mixture was refluxed at 140 °C for 24 h. The solution was allowed to cool down and 
poured into ice water. The pH was neutralised with dropwise addition of 10M NaOH, 
followed by acidification with 1M HCl. The solid was filtered off and dried in vacuo. 
The solid was resuspended in methanol and solvent was evaporated in vacuo. FC 
(SiO2; petroleum ether/EtOAc 80:20) gave rhodol (1.97 g, 33 %) as an orange/red 
solid. 
 
1H NMR (500 MHz, CD3OD): δ = 8.00 (d, J = 7.6 Hz, 1 H; ArH), 7.77 – 7.71 (m, 2 
H; ArH), 7.68 (t, J = 7.5 Hz, 1 H; ArH), 7.56 (dd, J = 5.6, 3.3 Hz, 1 H; ArH), 7.19 (d, 
J = 7.5 Hz, 1 H; ArH), 6.71 (d, J = 2.2 Hz, 2 H; ArH), 6.61 – 6.52 ppm (m, 2 H; ArH); 
13C NMR (126 MHz, CD3OD): δ = 171.38, 161.66, 154.30, 136.37, 135.68, 132.01, 
131.98, 131.06, 130.23, 129.85, 128.28, 126.07, 125.55, 124.45, 113.84, 111.61, 
103.50 ppm; m.p.: 190 – 192 °C; IR (ATR): 𝜐 = 2814 (br. m, O–H), 1702 (m, C=O), 












yl)benzoic acid (5.3) 
 
Rhodol (800 mg, 2.4 mmol) was dissolved in acetonitrile (40 ml) to which 4-
bromomethylphenylboronic acid pinacol ester (1.43 g, 4.8 mmol) followed by caesium 
carbonate (1.56 g, 4.8 mmol) were added. The solution was refluxed at 80 °C for 18 h 
under N2, then cooled to RT, filtered and rinsed with DCM (50 ml). Solvent was 
evaporated in vacuo. FC (SiO2; petroleum ether/EtOAc 80:20) gave 3',6'-bis((4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)-3H-spiro[isobenzofuran-
1,9'-xanthen]-3-one (600 mg, 33 %) as an orange solid. 
 
1H NMR (500 MHz, CDCl3): δ = 8.28 (dd, J = 7.8, 1.4 Hz, 1 H; ArH), 7.88 – 7.85 
(m, 2 H; ArH), 7.80 (dd, J = 7.9, 5.0 Hz, 2 H; ArH), 7.71 (td, J = 7.5, 1.5 Hz, 2 H; 
ArH), 7.65 (dd, J = 7.8, 1.5 Hz, 3 H; ArH), 7.49 – 7.44 (m, 2 H; ArH), 7.37 (dt, J = 
8.2, 0.7 Hz, 1 H; ArH), 6.95 – 6.91 (m, 2 H; ArH), 6.82 (dd, J = 7.8, 2.5 Hz, 3 H; 
ArH), 5.26 – 5.14 (m, 3 H; H–C(1’’’), H–C(7)), 4.72  (s, 2 H; H–C(1’’)), 1.34 ppm 
(s, 24 H; H–C(9’’), H–C(10’’), H–C(12’’), H–C(13’’), H–C(9’’’), H–C(10’’’), H–
C(12’’’), H–C(13’’’); 13C NMR (126 MHz, CDCl3): δ = 179.74, 165.13, 158.69, 
155.65, 135.22, 135.04, 135.03, 132.69, 131.43, 130.44, 128.85, 127.33, 126.68, 
126.04, 125.66, 121.04, 108.87, 107.51, 105.35, 101.37, 83.93, 67.46, 65.31, 60.38, 
24.85 ppm; m.p. 102 – 104 °C; IR (ATR): 𝜐 = 1722 (m, C=O), 1596 cm-1 (s, N–H); 





4.2. In vitro Studies 
 
HeLa cells were purchased from the Korean Cell Line Bank (Seoul, Korea). HeLa 
cells were cultured in MEM (Minimum Essential Media, Welgene, Korea) 
supplemented with 10 % FBS (Hyclone, USA), penicillin (100 U/ml) and 





Cells were seeded in 35-mm glass bottomed dishes at a density of 3 x 10
5
 cells/dish in 
culture media and incubated overnight at 37 ℃, 5 % CO
2
. Cells were washed with 
PBS (Welgene), incubated with 0, 50, 100 μM of ONOO- (Cayman, USA) for 20 min, 
washed with PBS, treated with the probe (200 nM or 500 nM) for 20 min and washed 
with PBS. For fluorescence cell imaging, confocal laser microscopy (FV1200, 
Olympus, Japan) and FV10-ASW 4.0 software were used. Cells were excited by a 473 
nm diode laser and detected with BA 490 – 590 nm emission filter with the following 


















3-aminophenol (1.00 g, 9.17 mmol), 3-iodophenol (2.02 g, 9.17 mmol) and phthalic 
anhydride (1.36 g, 9.17 mmol) were dissolved in methansulfonic acid (8 ml). The 
mixture was refluxed at 140 °C for 24 h. The solution was allowed to cool down and 
poured into ice water. The pH was neutralised with dropwise addition of 10 M NaOH, 
followed by acidification with 1 M HCl. The solid was filtered off and dried in vacuo. 
The solid was resuspended in MeOH and solvent was evaporated in vacuo. FC (SiO2; 
petroleum ether/EtOAc 80:20) gave 3'-amino-6'-iodo-3H-spiro[isobenzofuran-1,9'-
xanthen]-3-one (1.92 g, 48 %) as a red solid. 
 
1H NMR (500 MHz, (CD3)2SO): δ= 8.04 (d, J = 7.60 Hz, 1 H; ArH), 7.81 (d, J = 1.7 
Hz, 2 H; ArH), 7.75 (t, J = 7.5 Hz, 2 H; ArH), 7.50 (dd, J = 8.3, 1.7 Hz, 2 H; ArH), 
7.35 (dt, J = 7.6, 1.0 Hz, 1 H; ArH), 6.62 ppm (d, J = 8.3 Hz, 2 H; ArH); 13C NMR 
(126 MHz, (CD3)2SO): δ = 168.83, 161.11, 152.58, 150.77, 138.76, 136.53, 133.83, 
131.09, 130.07, 127.85, 125.96, 125.52, 125.49, 124.46, 118.77, 116.16, 104.81, 
97.40, 83.67, 81.08 ppm; m.p.: 267 – 269 °C; IR (ATR): 𝜐 = 1746 (s, C=O), 1588 cm-









3'-amino-6'-iodo-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one (500 mg, 1.13 mmol), 
sodium azide (147 mg, 2.26 mmol) and sodium ascorbate (11 mg, 0.06 mmol) were 
dissolved in DMSO/H2O (6/1.2 ml). The solution was degased under N2. Copper 
iodide (44 mg, 0.23 mmol) and N’N-dimethylethylenediamine (19 μl, 0.17 mmol) 
wered added. The mixture was left to stir at RT for 24 h. The solution was diluted with 
brine (20 ml), extracted with EtOAc (3 x 10 ml), washed with brine (3 x 15 ml), dried 
over MgSO4, filtered and evaporeted in vacuo. FC (SiO2; petroleum ether/EtOAc 
60:40) gave 3'-amino-6'-azido-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one (240 mg, 
60 %) as a pink solid. 
 
1H NMR (500 MHz, CDCl3): δ = 8.04 (d, J = 7.60 Hz, 1 H; ArH), 7.81 (d, J = 1.7 Hz, 
2 H; ArH), 7.75 (t, J = 7.5 Hz, 2 H; ArH), 7.50 (dd, J = 8.3, 1.7 Hz, 2 H; ArH), 7.35 
(dt, J = 7.6, 1.0 Hz, 1 H; ArH), 6.62 ppm (d, J = 8.3 Hz, 2 H; ArH); 13C NMR (126 
MHz, CDCl3): δ = 150.98, 135.57, 133.44, 130.34, 129.30, 126.48, 125.88, 125.59, 
123.79, 118.80, 95.71 ppm; m.p.: 285 – 288 °C; IR (ATR): 𝜐 = 1746 (s, C=O), 1588 
cm-1 (s, N–H); HR-ESI-MS: m/z (%): 357.1027 (M+H+, calcd for C20H13N4O3
+: 
357.0982). 









For the RSS and amino acid selectivity studies, 5 mM stock solutions in water were 
prepared from commercially available reagents and salts: GSH, H2S, NaS2O3, Na2SO4, 
Na2SO3, cysteine, homocysteine, aspartic acid, isoleucine, lysine, serine, arginine, 
valine, histidine, proline, glutamic acid, and phenylalanine.  
 
5.3.  In vitro Studies 
 
HeLa cells were purchased from the Korean Cell Line Bank (Seoul, Korea). HeLa 
cells were cultured in MEM (Minimum Essential Media, Welgene, Korea) 
supplemented with 10 % FBS (Hyclone, USA), penicillin (100 U/ml) and 
streptomycin (100 U/ml) (Welgene). Cells were subcultured every 3 days and kept at 




Cells were seeded in 35-mm glass bottomed dishes at a density of 3 x 105 cells/dish in 
culture media and incubated overnight at 37 ℃, 5 % CO2. HeLa cells were washed 
with PBS (Welgene) treated with N-ethylmaleimide (0.5 mM) for 20 min, washed with 
PBS and then treated either with cysteine (500 μM), homocysteine (500 μM), or GSH-
MEE (500 μM) for 20 min, washed with PBS, stained with the probe (20 μM) for 20 
min, and washed with PBS. For fluorescence cell imaging, confocal laser microscopy 
(FV1200, Olympus, Japan) and FV10-ASW 4.0 software were used. Cells were 
excited by a 473 nm diode laser and detected with BA 490 – 590 nm emission filter 
with the following conditions: objective lens magnification: x60, laser transmissivity 
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